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CHAPTER 1
General introduction
In part adapted after:
Hereditary tubular transport disorders: implications for renal handling 
of Ca2+ and Mg2+
By Henrik Dim ke1, Joost G. Hoenderop1, René J. B indels1.
''Departm ent of Physiology, Radboud University Nijmegen Medical Centre, the Netherlands.
Clin Sci (Lond). 118:1-18, 2010.

M aintenance of serum electrolytes (such as Na+, Cl", Ca2+, and Mg2+) is essential for many 
physiological processes, such as blood pressure control, in tracellu lar signaling, neural 
excitability, and bone formation. The kidney plays a central role in contro lling the excretion of 
electrolytes in response to conditions of deprivation or excess of these ions (1-5). Transepithelial 
(i.e. net result of paracellu lar and transcellular) transport of divalents across the epithelia differs 
in the various nephron segments. Transport of Na+ or Cl" is often transcellular, but these ions are 
in some nephron segm ents partially transported via the paracellu lar route. Secondary active 
transport of Na+ occurs in the proximal tubule (PT), th ick ascending limb (TAL), distal convoluted 
tubule (DCT), connecting tubule (CNT) and associated collecting ducts (CD). Likewise, 
transcellular Cl" transport is found predom inantly in the TAL, DCT, CNT, and CDs. In addition, 
the PT and TAL reabsorb Mg2+ and Ca2+ in a paracellular manner, while active transcellu lar 
transport occurs in the DCT and CNT, respectively (Figure 1).
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Figure 1. Schem atic model of the renal electrolyte reabsorptive capacity. (A) Renal Na+ 
reabsorption in individual nephron segments within the kidney. (B) Renal Mg2+ reabsorption in individual 
nephron segments. (C) Renal Ca2+ reabsorption in individual nephron. PT, proximal tubules: TAL, thick 
ascending limb of the loop of Henle; DCT, distal convoluted tubule; CNT, connecting tubule; CD, collecting 
duct.
General introduction to the distal convolution
The distal convolution is an anatomical structure com prising the DCT, CNT, and the initial CD (6). 
The structure is a main site in the active reabsorption of Na+, Cl", Ca2+, and Mg2+ from  the filtrate.
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As these segm ents represent one of the final structures in the kidney where electrolyte 
reabsorption occurs, it plays a key role in fine-tuning the final urinary excretion of these ions. As 
such, the structure serves as an im portant determ inant of the system ic concentration of 
electrolytes, by am ending the urinary excretion. Several species differences can be noted in the 
com position and borders of the individual nephron segm ents of the distal convolution, particularly 
between rabbit in comparison to man, mice, and rat (6-8). W hile the transition between the 
different nephron segm ents ends abruptly in the rabbit, the borders between these segm ents are 
more interm ingled in the other species (6-8). The cellular composition in rabbit has well-defined 
DC T cells, with the subsequent appearance of CNT principal-like cells blended with acid or base 
secreting intercalated cells (6-8). The CN T cells are then substituted with CD  principal cells 
towards the end of the distal convolutions. An im portant difference between CN T and CD  cells is 
the higher transport capacity of the CNT (9). In species other than rabbit, an additional nephron 
segm ent exists, the so-called DCT2 segm ent where the thiazide-sensitive NaCl cotransporter 
(NCC) and the am iloride-sensitive epithelial Na+ channel (ENaC) are coexpressed (will be 
discussed below) (7, 10). Lumen negative transepithelia l voltage increases from approximately 
-5 mV in the early convolution till values approxim ating -40 mV or more towards the end of the 
late convolution (11-15). However, som e variability in the measured voltages have been reported 
(11).
Electrolyte transport pathways in the DCT
NaCl transport in the DCT
The DCT reclaims som e 5-10% of Na+ from the renal ultrafiltrate (11). It is, therefore not 
surprising that disorders, which disturb transport processes in this segment, affect the renal 
reabsorptive capacity for NaCl and thereby influence system ic blood pressure. The tubular fluid 
to plasma ratio of Na+ declines progressively along the length of the DCT, emphasizing the role 
of this segm ent in dilution of the luminal fluid (16). Detailed physiological m easurem ents using
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m icropuncture have shown that vectorial Na+ transport in the DCT is load dependent, thus an 
increased Na+ delivery increases Na+ reabsorption in this nephron segm ent (3, 4). The 
mechanism that amends the reabsorptive capacity of the DCT to changes in Na+ load is entirely 
sensitive to thiazide diuretics (17). The majority of NaCl reclaim ed by the DCT, is taken up via 
the thiazide-sensitive cotransporter, NCC (18) (Figure 2). NCC was originally cloned from  the 
urinary b ladder of the w inter flounder, Pseudopleuronectes americanus (19). The cotransporter 
takes up Na+ and Cl- in the stoichem ical relationship 1:1. In the mammalian kidney, the 
cotransporter localizes to apical membrane domains of the DCT cell (20-22). The driving force 
for NaCl transport across the apical membrane, is provided by the basolaterally located Na+, 
K +-ATPase (23). Inwardly transported Cl- exits the cell v ia the CLC-Kb channel located in the 
basolateral membrane of the DCT (24) (Figure 2).
Mg2+ transport in the DCT
Detailed physiological m easurem ents suggest tha t the distal convolutions are responsible for 
reabsorbing 5-6% of the filtered Mg2+ (25, 26). These values were determ ined by subtracting the 
delivery of ions to the distal sites and the final urine. S im ilar experim ents reported that between 
early and late distal collections, approxim ately 8% of the filtered load is reabsorbed (27). Based 
on their early and late distal m icropuncture data, Brunette and colleagues suggested that 
reabsorption of Mg2+ is localized in the early portion, rather than along the whole distal 
convolution, thus predom inantly in the DCT. The early distal convolution constitutes a high 
resistance epithelium  with a lumen negative voltage of approxim ately -5 mV (12, 13, 28). 
Moreover, the transepithelial movem ent of Mg2+ appears to be unidirectional. These 
observations support the presence of active transcellu lar Mg2+ transport in this segm ent (29). 
This is further corroborated by the observation tha t the cellu lar Mg2+ concentration in the DCT 
ranges between 0.2-1.0 mM (30, 31), while the concentration of the lumen is m aintained around 
0.2-0.7 mM (1). Under these conditions, uptake of Mg2+ across the apical membrane would be
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dictated largely by the negative intracellular membrane potential found in the DCT cell (32, 33). 
In addition, distal reabsorption of Mg2+ appears to be load dependent, as increasing delivery 
augm ents reabsorption (29, 34). Cellular influx of Mg2+ likely occurs through the Transient 
Receptor Potential Melastin 6 channel (TRPM6), a channel selective fo r divalent cations (35) 
(Figure 2). TRPM6 is structurally s im ilar to other TRP channels with 6 transm em brane segments. 
Only shared with TRPM 7 is the unique a-kinase domain fused to the C-termini (36). It is worth 
noting that current debate questions whether TRPM6 functions as a hom o-tetram er or as a 
heterom er with TRPM7 (35, 37-42). Thus the exact m olecular com position of the Mg2+ influx 
pathway in transporting epithelia remains to be determ ined. TRPM6 mRNA expression is 
restricted to the kidney, lung, and intestine (43, 44). Im m unohistochemical localization of the 
channel has been reported, where TRPM6 is restricted to the apical membrane domains of the 
DCT cell (35). Intracellular carrier proteins and basolateral excursion mechanisms are yet to be 
identified (Figure 2).
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Figure 2. Schem atic model o f the cellular com position o f renal ion transport proteins  
within the distal convoluted tubule (DCT). NCC, thiazide-sensitive NaCl cotransporter; CLC-Kb, Cl- 
channel Kb; TRPM6, transient receptor potential melastatin 6 Mg2+ channel; EGFR, epidermal growth 
factor receptor. Na+, K+-ATPase consisting of a, p, and y subunits.
Electrolyte transport pathways in the DCT2/CNT
NaCl transport in the CNT
The CNT segm ent is com posed of several cell types, the Na+ transporting CNT cell (sim ilar to the
14
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CD principal cells), as well as acid/base secreting intercalated cells (3). Vectorial Na+ transport in 
the CNT and CD is mediated via the epithelial Na+ channel, ENaC. ENaC is located in the apical 
plasma membrane of the CNT and CCD cells (45, 46) (Figure 3). The channel is com posed of 
three subunits term ed a, p, and y (47). As in the DCT, transepithelia l Na+ transport is driven by 
the basolateral Na+, K+-ATPase (23, 48). In addition, these segm ents play an im portant role in K+ 
homeostasis, and Na+ reabsorption is here functionally coupled with K+ secretion. The apically 
located renal outer m edulla K+ channel (ROMK1) is responsible for the secretion of K+ (49-51) 
(Figure 3). The CNT and CD cells also possess the aquaporin 2 water channel (AQP2), which 
plays a key role in vasopressin-m ediated water reabsorption (52) (Figure 3).
(  TRPV5^  i
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Figure 3. Schem atic model o f the cellular com position o f renal ion and w ater transport 
proteins within the connecting tubule (CNT)/collecting duct (CD) cell. AQP2-3, Aquaporin 
2-3; ENaC, epithelial Na+ channel; ROMK, renal outer medullary K+ channel; TRPV5, transient receptor 
potential vanilloid 5 Ca2+ channel. Na+, K+-ATPase consisting of a, p, and y subunits.
Ca2+ transport in the DCT2/CNT
Detailed m icropuncture studies have estimated tha t approxim ately 3-7% of the filtered Ca2+ is 
reclaimed between the early or late sites in the distal convolution and the final urine in the rat (26, 
53, 54). However, the absence of direct determ inations of delivery in juxtam edullary nephrons 
may only provide rough estimates. It is unclear whether these punctures represent the whole
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Ca2+-transporting segm ent in the distal convolutions. Approxim ately 2% of the filtered load is 
reabsorbed between early and late distal collections in the sam e nephron, while the amount 
doubles in the presence of parathyroid hormone (PTH) (27). Ca2+ reabsorption is essentially 
thought to be active, as it occurs in the presence of lower intraluminal Ca2+ concentrations and 
lumen negative transepithelia l voltages (54). The transient receptor potential vanillo id 5 channel 
(TRPV5) provides the main apical entry step for Ca2+ in the distal convolutions. TRPV5 was 
originally cloned from  primary cultures of rabbit renal CNT/CCD tubules (55). The channel 
localizes primarily to the CNT in the rabbit (7, 56). In other rodents, expression of TRPV5 is also 
found in the DCT2 segment, in addition to the CNT and the initial CD (7, 8, 57, 58) (Figure 3). In 
mouse, TRPV5 is highly expressed in apical membrane domains of particularly the late distal 
convoluted tubule (DCT2), with a gradual decrease along CNT and initial CD (2, 8), suggesting 
that TRPV5-m ediated Ca2+ uptake predom inates in the DCT2 segment. The channel co-localizes 
with the Ca2+-binding protein calbindin-D28K and the basolateral extrusion proteins, the plasma 
m embrane ATPase 1b (PMCA1b) and the Na+/Ca2+ exchanger type 1 (NCX1) (Figure 3). 
Transgenic mice lacking TRPV5 show augm ented renal Ca2+ loss and m icropuncture studies 
effectively dem onstrate that Ca2+ reabsorption in the distal convolutions is disturbed (59). 
Several studies have shown TRPV5 as an essential constituent in transcellu lar Ca2+ reabsorption 
and it is, therefore, surprising that no m onogenic disorders or polym orphism s have been 
identified thus far (60).
Hormonal regulation o f electrolyte transport in the distal convolution
Aldosterone
Aldosterone is an im portant hormone involved in blood pressure m aintenance and K+ secretion. 
The distal convolution is sensitive to the hormone, which augm ents transport in these segments, 
resulting in many of the system ic changes observed contributed to aldosterone excess. Thus, 
when m ineralocorticoids or glucocorticoids are infused in the rat, the am ount of tritium -labeled
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m etolazone binding sites (indirect m easurem ent of NCC transporters) increases (61, 62). Later 
studies revealed tha t an increase in NCC protein abundance occurs after application of 
aldosterone (21). A ldosterone is also the key regulator of ENaC. Adm inistration of the hormone 
increases the expression of a-EN aC as well as targets the heterom eric complex to the 
m embrane (45, 63-65). This increase in vectorial Na+ transport in the CNT/CD segm ents allows 
the secretion of K+. In addition, aldosterone has been shown to stim ulate the expression of 
ROM K mRNA (66).
Angiotensin II
Upon intravascular volum e depletion, the juxtaglom eru lar apparatus secretes renin. The release 
of renin from the juxtaglom eru lar cells ultim ately results in increased Angiotensin II production. 
Angiotensin II has multiple functions, acting i) as a powerful vasoconstrictor, ii) causing Na+ 
retention v ia  direct effects on the renal epithelial cells, and iii) increases aldosterone release from  
the adrenal cortex. These processes serve to restore extracellular volum e and arterial pressure. 
Angiotensin II has been shown to act within the distal convolution both acute and chronically. As 
such, Candesartan, an angiotensin receptor type 1 antagonist, has been shown to reduce the 
expression of NCC (67). Chronic adm inistration of angiotensin II also increases the abundance 
of ENaC (68). Angiotensin II acutely provokes trafficking of NCC to the apical membrane of the 
DCT (69). Furthermore, Angiotensin II has been shown to increase the activity of NCC via a 
W ith-No-Lysine (W NK) 4 dependent mechanism, augm enting phosphorylation of the N-terminal 
domain in the transporter (70). In addition, acute application of Angiotensin II stimulates 
am iloride-sensitiv Na+ transport in the distal convolution, suggesting activation of ENaC channels 
(71). The effects of Angiotensin II w ithin the distal convolution all serves to restore extracellular 
volum e loss and hence arterial pressure.
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Vasopressin
Vasopressin (antidiuretic hormone) is secreted from  the posterior lobe of the pituitary in 
response to changes in serum osm olality and extracellular fluid volume. The hormone acts by 
constricting blood vessels, and stim ulating water reabsorption in the kidney. Increased renal 
water reabsorption is achieved by m odulating CNT/CD water permeability, increasing medullary 
urea transport, and stim ulating the furosem ide-sensitive Na+, K+, Cl- cotransporter (NKCC2) in 
the TAL. In addition to these effects, vasopressin also acts within the distal convolution to 
increase Na+ transport. In the DCT, vasopressin acutely activates NCC via phosphorylation of its 
N-terminal domain (72). The underlying physiological explanation fo r this observation remains 
obscure, but may be related to vasopressin 's role in extracellu lar fluid balance. Chronic 
stim ulation of the vasopressin receptor type 2 reduces Na+ excretion in healthy humans (73). 
This can be explained by an increased expression of the p- and y- subunits of ENaC in the CNT 
and CD (74). In addition, vasopressin also acutely stim ulates the insertion of ENaC channels into 
the apical membrane of the cell (75, 76).
Parathyroid hormone (PTH)
PTH  is released from  the parathyroid glands in response to changes in the system ic Ca2+ 
concentration. The organ detects very small changes in the serum Ca2+ via the Ca2+-sensing 
receptor (CaSR), and responds by releasing PTH when serum Ca2+ is low and vice versa. PTH 
acts on several organs, including the kidney, intestine, and bone to increase Ca2+ (re-) 
absorption and release. The distal convolution is also a target of PTH (77), here the hormone 
stim ulates Ca2+ transport on multiple levels. Parathyroidectom y causes hypocalcem ia due to a 
reduction in circulating PTH concentrations. In rats, this procedure decreases the renal 
abundance of the Ca2+-transport proteins TRPV5, calbindin-D28K, and NCX1 (78). Using primary 
isolated rabbit CNT/cortical CD (CCD) cultures, it has been shown that PTH application 
stim ulates transepithelia l Ca2+ transport (79). It was subsequently delineated tha t PTH stim ulates
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TRPV5 activity via a protein kinase A signaling cascade, which phosphorylates the channel, 
increasing open probability and hence Ca2+ reabsorption (80).
1.25-dihydroxyvitamin D3
1.25-dihydroxyvitamin D3 is a key regulator of Ca2+ handling. The hormone undergoes several 
conversion steps, including the final 1 a-hydroxylation in the kidney, which leads to biologically 
active 1,25-dihydroxyvitamin D3 (81). Dietary Ca2+ and PTH both regulate 1a-hydroxylase activity 
in the kidney. The main effect of 1,25-dihydroxyvitamin D3 is in the intestine, but the hormone 
also modulates Ca2+ transport in the distal convolution. 1,25-dihydroxyvitamin D3 stimulates 
transepithelial Ca2+ transport in rabbit primary CNT/CCD cultures (79). In line with this 
observation, is the increased expression of TRPV5 in the presence of 1,25-dihydroxyvitamin D3 
(57). Calbindin D28K expression is also regulated by 1,25-dihydroxyvitamin D3.
Estrogen and gender
Gender-associated differences can be noted in the urinary excretion of Na+ and can be related to 
the actions of sex hormones on the kidney. As such, estrogen is known to reduce the urinary Na+ 
excretion (82). In line with this, is the apparent higher abundance of NCC in the distal convolution 
of female rats, compared to that of males (83). The effects of estrogen on renal Na+ excretion, 
may be related to its actions on the renin-angiotensin-aldosterone system (84). Removal of 
testosterone from males also increases the expression of NCC, suggesting an opposing 
relationship between the two hormones.
Several studies have reported gender differences in the urinary Ca2+ excretion, with 
greater urinary Ca2+ losses occurring in males (85, 86). Estrogens have been shown to increase 
the renal reabsorption of Ca2+, which would explain the observed gender differences (87). This 
augmentation in Ca2+ reabsorption has subsequently shown to coincide with an increase in the 
abundance of TRPV5 (87). Whether testosterone plays opposing roles to that of estrogen
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remains unclear.
Estrogens also affect renal Mg2+ handling, as urinary Mg2+ losses in postmenopausal 
women is significantly decreased after estrogen replacement (88, 89). Lack of estrogens also 
reduce the abundance of TRPM6 in rats, while re-supplementation normalizes the expression, in 
line with the renal effects of estrogen (43).
Calcitonin (CT)
CT is synthesized by the C cells of the thyroid gland and is secreted in response to increases in 
the systemic Ca2+ concentration (90). This is largely achieved by inhibiting osteoclast-mediated 
bone resorption. In the kidney, CT stimulates the reabsorption of Ca2+ (91-94). This is in part 
achieved by increasing the reabsorption of Ca2+ in the thick ascending limb (91-93). However, 
additional actions of CT on the distal convolution have also been reported, where the hormone 
stimulates the vectorial movement of Ca2+ (94).
Transport defects affecting electrolyte handling in the distal convolution
Gitelman’s syndrome
Gitelman's syndrome is a salt-losing disorder characterized by hypokalemic metabolic alkalosis, 
hypomagnesemia, and hypocalciuria (95). Renin activity and aldosterone concentrations are 
elevated, but only marginally in comparison to Bartter's patients. The disorder is autosomal 
recessive and is caused by mutations in the gene encoding the thiazide-sensitive NaCl 
transporter NCC (Slc12a3) (96). The Gitelman phenotype is mimicked by chronic thiazide 
treatment, a potent blocker of NCC (97, 98). The loss of NaCl from the DCT leads to a 
compensatory increase in Na+ reabsorption segments distal to the DCT. This compensation is 
largely responsible for the hypokalemia observed in Gitelman patients. Mice with a targeted 
deletion of NCC show no mean arterial pressure variation when maintained on a normal diet.
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However, when reducing dietary NaCl content, NCC deficient mice develop hypotension (99).
The hypocalciuric effect of NCC gene deletion or chronic thiazide administration is likely 
due to hypovolemia, although some reports have suggested an additional direct effect on Ca2+ 
reabsorption in the distal convolutions (100, 101). Volume contraction causes secondary 
increases in proximal tubular Na+ transport, and thus facilitates paracellular hyperabsorption of 
Ca2+. This is supported by several observations. Micropuncture studies in mice with genetic 
ablation of the NCC gene, showed a reduced delivery of Na+ and Ca2+ to the late PT, consistent 
with increased Na+ and Ca2+ reabsorption in the PT. In addition, these micropuncture 
experiments indicate that Ca2+ reabsorptive rates were similar in the distal convolutions in the 
wild-type and NCC deficient mice, further confirming that the effect is proximal (102). In wild-type 
mice administered thiazide diuretics, similar observations were made using micropuncture 
studies, suggesting that the hypocalciuric effect localizes to the PT (103). Furthermore, 
thiazide-induced hypocalciuria can still be observed in TRPV5 deficient mice, which effectively 
lack Ca2+ transport in the distal convolutions (103). This nicely confirms that the mechanism by 
which hypocalciuria develops after thiazide usage and likely also in Gitelman's syndrome is 
independent of distal Ca2+ reabsorption.
Hypomagnesemia is a consistent feature of Gitelman's syndrome. The phenotypic 
characteristic is likely the result of a decreased abundance of TRPM6, leading to renal Mg2+ 
wasting. However, the mechanism that decreases renal TRPM6 expression in Gitelman's 
syndrome remains incompletely understood. Mice deficient in NCC as well as rats given 
thiazides show severe atrophy of the DCT (i.e. the fractional volume of the early DCT is 
drastically reduced) (102, 104). In addition, NCC-deficient mice show a decreased expression of 
TRPM6, which localizes intrarenally solely within the DCT (103). Interestingly, in contrast to 
previous results, administration of lower doses of thiazides, produce no changes in the 
morphology of the DCT, while expression of TRPM6 remains decreased (103). Aldosteronism, a 
recurring feature of Gitelman's syndrome, has been implicated in renal Mg2+ wasting (105-107).
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Similarly, lack of aldosterone can be associated with hypermagnesemia (105, 106). 
Spironolactone, a mineralocorticoid receptor antagonist has been shown to consistently reduce 
urinary Mg2+ excretion in a number of patient groups (105, 106, 108). In patients with Gitelman's 
syndrome, spironolactone treatment increases serum Mg2+ concentration and reduces the 
fractional tubular excretion of Mg2+ (108). Thus, these studies suggest that the apparent 
aldosterone excess observed in Gitelman's syndrome might be an underlying cause. Conversely, 
chronic infusion of aldosterone does not change the renal mRNA abundance of TRPM6 in mice 
(107). Moreover, marked hyperaldosteronism is observed in antenatal Bartter's patients, while 
less than 20% of these individuals display hypomagnesemia. The positive effect of 
spironolactone on Mg2+ balance deserves further research. Currently, the absence of NCC in 
DCT has been shown to induce hypocalciuria via changes in PT reabsorption and 
hypomagnesemia by reducing TRPM6 expression.
Pseudohypoaldosteronism type II (PHAII)
The WNK kinase family consists of serine-threonine kinases with a characteristic displacement 
of a catalytic lysine residue, necessary for ATP binding (109, 110). The recent identification of 
the WNK family members as multifunctional proteins required for ambient blood pressure 
maintenance and renal electrolyte handling has progressively broadened the knowledge of how 
these processes are regulated (111, 112). PHAII, also known as Gordon syndrome, is an 
autosomal dominant disorder associated with hypertension, an augmented renal reabsorption of 
NaCl, and impaired secretion of K+ and H+ (112, 113). The genetic defects in PHAII are due to 
loss-of-function mutations in WNK4 as well as activating mutations in WNK1 caused by intronic 
deletions in the gene (112). Several studies have now shown that WNK1 and WNK4 play 
important roles in modulating electrolyte transport pathways in the distal convolutions (114-117). 
WNK4 functions primarily by inhibiting thiazide-sensitive transport, by removing NCC from the 
membrane into lysosomal compartments (114, 118, 119). In addition, the inhibitory actions of
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WNK1 on WNK4 influence membrane abundance and hence activity of the transporter (114, 
117). WNK4 also inhibits ENaC (120), while both WNKs impair K+ secretion via ROMK (115, 116, 
121).
In addition to the often hypertensive phenotype, hypercalciuria and nephrolithiasis have 
been reported in PHAII patients (122, 123). Accordingly, individuals carrying a WNK4 Q565E 
PHAII mutation, present with hypercalciuria and a decreased bone mineral density. Conversely, 
affected members with activating WNK1 mutations, present with normocalciuria (124). It is 
interesting to note that no apparent change is observed in serum Mg2+ concentrations or renal 
Mg2+ handling of PHAII patients (124-126). The mechanism by which dysfunctional WNK4 
stimulates calciuria in PHAII is unclear, but may occur via several mechanisms: i) Secondary to 
volume expansion, a condition that is predicted to reduce proximal tubule Na+ reabsorption, 
resulting in decreased electrochemical driving force for Ca2+ uptake across the PT epithelia (103,
127, 128). As the majority of Ca2+ reabsorption occurs in the proximal tubule, volume expansion 
might be the largest contributor to the hypercalciuria in PHAII. Even so, individuals carrying the 
WNK1 deletion have normocalciuria, in the presence of elevated blood pressure (and likely an 
expanded ECV); ii) Alternatively, the hypercalciuric phenotype in PHAII may be due to impaired 
interactions between WNK4 and renal Ca2+ transport proteins (129). In line with this, it has been 
reported that WNK4 directly activates Ca2+ transport by increasing surface expression TRPV5 in 
the Xenopus oocyte expression system (129). However, the WNK4 PHAII mutants showed a 
similar activating effect on TRPV5. Using lentivirus-induced gene delivery to primary rabbit 
CNT/CD cells, we found that cells infected with WNK4 and the WNK4 Q565E mutant, both 
decreased transepithelial Ca2+ transport (Dimke, Hoenderop, and Bindels, unpublished 
observations). Consequently, the exact etiology behind the hypercalcemia in PHAII needs further 
clarification. It is interesting to note, that while PHA II is considered as a mirror image of 
Gitelman's syndrome, no changes in serum Mg2+ have been observed in these individuals.
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Hypomagnesemia with secondary hypocalcemia (HSH)
TRPM6 was originally identified as the causative gene of the autosomal recessive disorder 
known as HSH (44, 130). Individuals suffering from HSH present in early infancy with symptoms 
related to neuromuscular excitability, such as muscle spasms, tetany, and generalized 
convulsions (131). These symptoms likely occur as a consequence of a severe fall in plasma 
Mg2+ and Ca2+ concentrations. Symptoms can be reduced by high dose Mg2+ administration. 
Interestingly, this Mg2+ supplementation normalizes the plasma Ca2+ concentration, while plasma 
Mg2+ remains subnormal (132). A patient with HSH displayed failure to effectively absorb Mg2+ 
from low intraluminal intestinal Mg2+ concentrations (133). However, the HSH patient had a 
positive Ca2+ balance, excluding a common defect in Mg2+ and Ca2+ transport mechanisms. 
These data support a role for TRPM6 in saturable active Mg2+ transport, serving as an apical 
entry mechanism for Mg2+ in the enterocyte. Although the hypomagnesemia in HSH appears to 
be primarily the result of mal-absorption of Mg2+ in the intestine, there is also a serious, although 
not well studied renal Mg2+ leak. HSH patients have been reported to display either normal renal 
Mg2+ conservation (132-134), or show an additional renal Mg2+ leak (44, 130, 135). However, 
when patients with HSH were administered an intravenous Mg2+ load, renal wasting was clearly 
noticeable (130). Thus, these individuals waste urinary Mg2+ at a lower plasma concentration, 
than normal individuals do. Agus previously described that maintaining a fractional Mg2+ 
excretion above 2% in the presence of hypomagnesemia should be considered a renal leak in 
itself (136). This is corroborated by a report showing an inappropriately high fractional excretion 
given severe hypomagnesemia in HSH patients (44).
Isolated autosomal recessive hypomagnesemia (IRH)
This rare form of hypomagnesemia was initially described in two siblings who presented with low 
serum Mg2+ concentrations and an inappropriately high fractional excretion of Mg2+. In addition, 
these individuals suffered from psychomotor retardation during their youth and are presently
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suffering from moderate mental retardation and epileptic seizures (137, 138). Thus, these 
observations indicated a potential defect largely related to the renal Mg2+ transport, similar to that 
observed for Mg2+ loaded patients with HSH. Interestingly, there were no observable secondary 
changes in the handling of Ca2+ (137), which may to some extend explain why these patients are 
devoid of tetany. Detailed homozygosity mapping approaches and direct sequencing revealed 
that these sisters had a mutation in the pro-epidermal growth factor (EGF) gene, causing a 
defect in the routing of the EGF precursor to the basolateral plasma membrane (138). This 
mutation resulted in impaired autocrine/paracrine secretion of EGF to the interstitium, thereby 
inhibiting the activation of basolateral EGF receptors (EGFR) in the DCT. Subsequent patch 
clamp analysis and classical biochemical experiments showed that application of EGF activates 
TRPM6 and shuttles it from endomembrane compartments to the membrane (138, 139). 
Interestingly, inhibition of the EGFR by monoclonal antibodies targeting the EGFR (Cetuximab) 
causes pronounced hypomagnesemia in colorectal cancer patients (138, 140). Unlike patients 
with impaired sorting of the EGF protein, cetuximab treatment produces secondary 
hypocalcemia in patients with moderate to severe hypomagnesemia (grade 2 or higher), likely 
resulting from impaired PTH secretion (140). Similarly, patients with severe hypomagnesemia 
did show signs of fatigue and cramps. The syndrome of IRH and related inhibition of the EGFR 
by cetuximab diverges from HSH in several of the phenotypic characteristics, suggesting 
additional effects of EGF on Mg2+ handling. Incubation of TRPM6 expressing cells with 
cetuximab completely abolishes the EGF-induced increases in channel currents. Unlike TRPM6, 
current literature suggests that TRPM7 is not activated by EGF and thus appears an unlikely 
target (139). Whether other transporters are involved in conferring hypomagnesemia in IRH 
remains to be defined. Taken together, these results indicate that EGF is a novel magnesiotropic 
factor acting primarily to increase renal Mg2+ reabsorption.
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Chapter 1 
Aims of the thesis
This thesis aims to understand the physiological implications of regulating transport within the 
distal convolution of the kidney. Dissecting the molecular mechanisms responsible for 
transepithelial electrolyte transport in these nephron segments, allows us to extrapolate how 
these processes may impact overall electrolyte homeostasis.
NCC plays a key role in renal salt reabsorption and thereby the maintenance of 
systemic blood pressure. A better understanding of the regulation of NaCl transport by NCC may 
ultimately increase our understanding of how blood pressure is maintained and the etiology 
underlying primary hypertension. In an effort to understand how NCC is regulated, we performed 
pull-down experiments using the N-terminal domain as bait and subsequently screened binding 
partners from mouse kidney by mass spectrometry. In chapter 2 we describe the identification of 
Y-adducin, a novel regulator of NCC that functions by interacting with the phosphorylatable 
N-terminal domain of the cotransporter.
Monoclonal antibodies such as Cetuximab targeting the extracellular EGFR domain 
have been implicated in the regulation of epithelial Mg2+ transport. While mostly patients with 
colorectal cancer are treated with Cetuximab, numerous patient groups suffering from cancer 
receive the EGFR tyrosine kinase inhibitor, Erlotinib. To better understand the role of EGFR 
blockade in cancer patients and its relevance for managing hypomagnesemia, chapter 3 details 
the effects of the EGFR inhibitor Erlotinib on renal and systemic Mg2+ handling.
Regulation of systemic Ca2+ balance is of major importance for the maintenance of 
many physiological processes such as neuromuscular stability, bone formation etc. Thus, 
understanding how hormones and molecular factors regulate TRPV5 may help elucidate how 
serum Ca2+ is maintained and how it is perturbed in pathophysiological conditions. As such, the 
overall contribution of androgens to gender differences in renal handling of Ca2+ and hence 
overall Ca2+ balance remains unclear. Therefore, chapter 4 investigates the effect of 
testosterone on the expression of renal Ca2+ transport proteins and the urinary Ca2+ excretion.
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Similarly, chapter 5 delineates the potential role of TRPV5 in the calcitonin-stimulated Ca2+ 
reabsorption. Tissue transglutaminase is a Ca2+ dependent enzyme involved in covalent 
crosslinking of proteins and is regulated by TRPV channels, however it remains unclear whether 
TRPV5 could be regulated as well. Chapter 6 shows that tissue transglutaminase functions as a 
novel molecular inhibitor of TRPV5.
Hypercalciuria is the most common abnormality found in individuals with Ca2+ stone 
formation. As Ca2+ transport is an integral part of the distal convolution, dysregulation thereof 
may cause kidney stone disease (nephrolithiasis). Nephrolithiasis is a global health problem that 
affects approximately 10% of the population by the seventh decade of life. Utilizing a 
W-ethyl-W-nitrosourea mouse mutagenesis resource to identify new genetic models of 
hypercalciuria, chapter 7 characterized a novel mouse model with an autosomal dominant 
serine 682 proline missense mutation in TRPV5 resulting in hypercalciuria and tubulointerstitial 
nephritis.
Chapter 8 summarizes the findings made within the frame of this thesis and provides a 
detailed discussion pertaining to these observations, by placing them in the context of the current 
knowledge regarding the distal convolution and renal electrolyte handling.
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A bstract
Hypertension is projected to affect more than 1 billion individuals worldwide. Primary 
hypertension remains a major risk factor for the development of cardiovascular and chronic 
kidney diseases. The thiazide-sensitive NaCl cotransporter (NCC) plays a key role in renal salt 
reabsorption and thereby the maintenance of systemic blood pressure. This study was designed 
to further elucidate the molecular mechanisms governing the regulation of NCC. Pull down 
experiments coupled to mass spectrometry identified y-adducin as a novel interactor of the 
transporter. y-Adducin co-localized with NCC to the distal convoluted tubule and stimulated NCC 
activity in a dose-dependent manner. The stimulatory effect of y-adducin occurs upstream from 
the With-No-Lysine Kinase 4. The binding site of y-adducin mapped to the amino (N)-terminus of 
NCC encompassing three previously reported phosphorylation sites. Furthermore, competition 
with the N-terminal domain of NCC abolished the stimulatory effect of y-adducin on the 
transporter. y-Adducin was unable to increase NCC activity when these phosphorylation sites 
were made constitutively inactive or active. In addition, y-adducin bound only to the 
dephosphorylated N-terminal of NCC. Taken together, our observations suggest that y-adducin 
functions as a novel dynamic regulator of NCC, likely by amending the phosphorylation state of 
the transporter and consequently its activity.
In troduction
Hypertension is a highly prevalent clinical condition and has been estimated to affect as many as
1.56 billion individuals in the year 2025 (1). Primary hypertension is a key contributor to 
cardiovascular complications. As such, hypertension has been estimated to account for a large 
fraction of strokes and ischaemic heart disease on a global scale (2). The National Vital Statistics 
Report lists heart disease as the primary cause of death, affecting more than 20 million people in 
the U.S. alone (3). In addition, elevated blood pressure is a leading cause in the development of
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chronic renal failure (4). Kidney disease remains both a cause and a consequence of 
hypertension (3, 4). According to the Guytonian model, the kidney plays an essential role in 
chronic blood pressure maintenance by adjusting blood volume in response to changes in 
systemic pressure (5). Such modifications are achieved in part by amending the urinary 
excretion of NaCl. Consequently, defects in genes encoding renal salt transporters often lead to 
hypo- or hypertensive phenotypes (6).
The Joint National Committee for the detection, evaluation, and treatment of high blood 
pressure recommends thiazides as the first line treatment of uncomplicated stage I hypertension, 
or combined with other antihypertensive agents for patients with stage II hypertension (7). 
Thiazides act by blocking NaCl reabsorption in the distal convoluted tubule (DCT), which 
reclaims 5-10% of Na+ from the renal ultrafiltrate (8). It is, therefore, not surprising that disorders 
disturbing transport processes in this segment, affect the renal reabsorptive capacity for NaCl 
and, thereby, influence systemic blood pressure. The thiazide-sensitive NaCl transporter (NCC) 
is responsible for the majority of inward Na+ transport in the DCT. In line with this, renal NaCl 
wasting and secondary hypokalemic metabolic alkalosis can be observed in Gitelman patients 
(OMIM 263800) that carry a defect in the SLC12A3 gene encoding NCC (9, 10). In addition, 
blockage of NCC with thiazide diuretics leads to a Gitelman-like phenotype (8). Conversely, 
pseudohypoaldosteronism type II (PHAII, Gordon syndrome, OMIM 145260) augments renal 
reabsorption of NaCl and can, thereby, increase systemic blood pressure (11, 12). PHAII results 
from mutations in the With-No-Lysine (WNK) kinases 1 and 4, which play an instrumental role in 
regulating electrolyte transport pathways in the distal part of the nephron, for instance, by 
modifying the activity of NCC (12-15).
A better understanding of the regulation of NaCl transport by NCC may ultimately 
increase our understanding of how blood pressure is maintained and the etiology underlying 
primary hypertension. During the last decade, research within this field has greatly expanded our 
knowledge about how NaCl transport via NCC is controlled. The cotransporter contains several
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phosphorylation sites in its amino (N)-terminal domain, a feature that is well conserved among 
several members of the SLC12 family (16-19). Phosphorylation of these residues are critically 
important for the activation of NCC in response to chloride (Cl')-depletion (16). Serine/threonine 
kinases of the STE20 family (such as the Ste20-related proline-alanine-rich kinase (SPAK) and 
oxidative stress response 1 (OSR1)) have been shown to play an important role in modulating 
the phosphorylation state of NCC (20). In addition, kinases in the WNK family as well as the 
serum- and glucocorticoid-inducible kinase 1 (SGK1) have been shown to interact within this 
network, thereby changing the activity of SPAK and OSR1, and potentially altering the 
phosphorylation state of the transporter (21-24). As shown in detail by Yang, Ellison and 
co-workers, trafficking of the NCC transporter is particularly affected by the concerted action of 
the WNK kinases (WNK1, WNK3, and WNK4) (14, 25). Genetically modified mice strains largely 
support these observations and solidify the important role of NCC regulation in blood pressure 
maintenance (13, 26-30). However, the molecular mechanisms governing NCC phosphorylation 
and trafficking have yet to be fully elucidated.
The aim of the present study was to identify novel interactors of NCC, which could be 
involved in modulating its function. As the N-terminal domain has been shown to play an 
important role in activation of the transporter, pull down experiments were performed with this 
domain of NCC in mouse kidney lysates and subsequently coupled with mass spectrometry. This 
study describes the identification of y-adducin, as a novel auxiliary factor interacting with NCC. 
Adducins were originally identified as heteromeric membrane skeletal proteins implicated in the 
binding of spectrin to actin (31). y-Adducin was selected as an interesting candidate gene based 
on the previous involvement of this protein family in primary hypertension in both humans and 
rats (32-34). Here, we delineated the molecular basis by which y-adducin stimulates the activity 
of NCC.
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Results
y-Adducin stimulates the activity of the thiazide-sensitive cotransporter NCC 
Mass spectrometry identified y-adducin as a potential binding partner to the N-terminal 
cytoplasmic terminal domain of NCC. The interaction was confirmed by pull down experiments in 
Human Embryonic Kidney (HEK) 293 cells transiently transfected with glutathione S-transferase 
(GST)-conjugated terminal domains of NCC and hemagglutinin (HA)-tagged y-adducin. The 
resulting cell lysates were incubated with glutathione-coupled Sepharose beads to precipitate 
GST-bound complexes. Strong binding was seen by y-adducin towards the N-terminal domain of 
NCC (Figure 1A). Immunohistochemical stainings showed that y-adducin co-localizes to DCT 
tubules that also express NCC (Figure 1B). Here, y-adducin localized to cytoplasmic and 
(baso)-lateral domains of the cell. y-Adducin was not restricted to the DCT, as expression was 
also found in the proximal tubule and thick ascending limb as reported previously (35). DCT 
fragments were isolated from mice expressing enhanced green fluorescent protein (eGFP) after 
the parvalbumin promoter (36). The restricted renal expression of this protein to the DCT allowed 
fluorescence-based sorting of the segment using a Complex Object Parametric Analyzer and 
Sorter (COPAS) (37). Thus, this method permits evaluation of whether the abundance of 
y-adducin is enriched in the DCT in comparison to other tubules in the renal cortex. In line with 
the more ubiquitous expression of the protein, the relative enrichment of y-adducin mRNA in the 
DCT remained, while that for NCC was markedly enriched (Figure 1C). To estimate the 
functional effect of y-adducin on the transport capacity of NCC, 22Na+ uptake studies were 
performed using the Xenopus laevis oocyte system. Oocytes injected with cRNA encoding NCC 
showed a significant thiazide-sensitive 22Na+ uptake compared to water-injected oocytes. 
Co-injection with increasing amounts of y-adducin cRNA stimulated NCC activity in a 
dose-dependent manner (Figure 1D). In addition, no difference in the expression level of 
HA-NCC could be detected between oocytes injected without or with increasing concentrations 
of HA-tagged y-adducin in the presence of HA-NCC. A dose-dependent increase was observed
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in the abundance of the HA-tagged y-adducin. Injection of small interference (si) RNA against 
endogenous Xenopus laevis y-adducin, in oocytes pre-injected with NCC, resulted in a 
significant decrease in thiazide-sensitive 22Na+ uptake (Figure 2).
Figure 1. y-Adducin  b inds s trong ly  to  the N-term inus o f NCC and stim u la tes the ac tiv ity  
o f the cotransporter. (A) GST-pull down assay in HEK293 cells transiently transfected with either the 
GST-tagged N- or C-terminal of NCC or GST alone, all in combination with y-adducin, was used to 
evaluate binding of y-adducin to NCC. CP denotes co-precipitate and IB represents the protein 
immunoblotted against. (B) y-Adducin co-localizes with NCC to the DCT. Representative 
immunohistochemical images are shown as obtained by confocal laser-microscopy. Sections were 
incubated with specific antibodies against NCC and y-adducin and stained using Alexa-conjugated 
secondary antibodies. (C) y-Adducin mRNA is expressed in the DCT as well as in other nephron 
segments. Semi-quantitative real-time PCR was used to determine the abundance of NCC and y-adducin 
mRNA extracted from fluorescently sorted DCT tubules and the kidney cortex (CTX). (D) Effect of 
y-adducin upon NCC function. y-Adducin stimulated NCC activity in a dose-dependent manner. 22Na+ 
uptakes in Xenopus laevis oocytes microinjected with water, 5 ng of HA-tagged human NCC cRNA alone, 
or in combination with increasing amounts of HA-tagged y-adducin cRNA. The experiment was performed 
in the absence (open bars) or presence (closed bars) of 0.1 mM thiazide. Data is presented as means ± 
SEM. *p < 0.05 is statistically significant as compared to NCC injected oocytes. Western blots were used 
to quantify the expression of NCC and y-adducin in groups of oocytes injected as described above. Data is 
presented as means ± SEM.
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Figure 2. E ffect o f siRNA against endogenous Xenopus laevis  y-adducin on 22Na+ uptakes 
in oocytes in jected w ith  NCC. Oocytes were injected with 5 ng of NCC cRNA in the presence or 
absence of 10 ng of y-adducin cRNA. 1 ng of double-stranded siRNA was injected 24 hrs prior to the 22Na+ 
uptake. Closed bars denote the presence of 0.1 mM thiazide. *p < 0.05 is considered statistically 
significant from the group injected with NCC.__________________________________________________
y-Adducin abrogates the inhibitory effect of WNK4.
To investigate whether y-adducin affects NCC activity via the same signaling cascade as WNK4, 
the effect of WNK4 on y-adducin-stimulated Na+ transport was evaluated. WNK4 has been 
shown to reduce NCC activity by directing the protein to the lysosomal compartment (14, 38). In 
line with this, WNK4 was able to inhibit NCC-dependent 22Na+ uptake (Figure 3A). Importantly, 
the stimulatory effect of y-adducin was also observed in the presence of WNK4 (Figure 3A). 
Moreover, injections of increasing concentrations of y-adducin completely reverted the inhibitory 
effect of WNK4 on NCC-mediated 22Na+ uptake (Figure 3B). Furthermore, the effect of y-adducin 
abrogated the WNK4-dependent reduction in NCC activity, as the stimulatory effect of y-adducin 
was still present when increasing amounts of WNK4 cRNA were injected (Figure 3C).
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Figure 3. y -Adducin reverts the in h ib ito ry  effect o f WNK4. (A) WNK4 did not inhibit 
Y-adducin-stimulated NCC activity. Xenopus laevis oocytes were injected with 5 ng of NCC cRNA, in the 
presence or absence of 10 ng y-adducin as well as 10 ng of WNK4. cRNA. (B) WNK4 did not revert the 
stimulatory effect of y-adducin. 22Na+ uptakes in oocytes co-injected with 5 ng of NCC cRNA, 10 ng of 
y-adducin cRNA, and with increasing amounts of WNK4 cRNA (from 20 ng to 60 ng). (C) Increasing 
amounts of y-adducin reverted the inhibitory effect of WNK4 on NCC. 22Na+ uptakes in oocytes co-injected 
with 5 ng of NCC cRNA, 10 ng of WNK4 cRNA, and with increasing amounts of y-adducin cRNA (from 20 
ng to 40 ng). Closed bars denote the presence of 0.1 mM thiazide. *p < 0.05 is statistically significant from 
NCC injected oocytes. #p < 0.05 is statistically significant from the group co-injected with WNK4 and NCC.
y-adducin stimulates NCC activity independent of membrane trafficking
The stimulatory effect of y-adducin on NCC may be explained by increased trafficking of the 
transporter to the plasma membrane or by changes in the intrinsic activity of the transporter. To 
evaluate whether the membrane abundance of NCC increases in the presence of y-adducin, cell 
surface expression of eGFP-NCC was determined by confocal laser scanning microscopy. The 
intensity of the eGFP signal at the plasma membrane as well as the 22Na+ uptake rates 
correlated dose-dependently with the amount of injected eGFP-NCC cRNA (Figure 4, A and B). 
Thus, this method was used to determine semi-quantitatively the presence of NCC at the plasma 
membrane. Co-injection of y-adducin significantly increased eGFP-NCC-dependent 22Na+ uptake, 
while the auxiliary protein y-adducin did not significantly affect the plasma membrane expression 
of eGFP-NCC (Figure 4, C and D).
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Figure 4. The e ffect o f y-adducin occurs independent o f NCC tra ffick ing  to  the oocyte 
membrane. (A) 22Na+ uptakes in Xenopus laevis oocytes injected with 1-10 ng of GFP-NCC cRNA. (B) 
Corresponding GFP fluorescence at the membrane of oocytes injected with 1-10 ng of GFP-NCC cRNA. 
(C) Effect of thiazide-sensitive 22Na+ uptake (left) and quantification of the GFP fluorescence in the 
membrane (right) of Xenopus laevis oocytes injected with 10 ng of GFP-NCC cRNA, in the presence or 
absence of 10 ng of y-adducin cRNA. (D) Representative images of GFP fluorescence at the oocyte 
membrane after injected with increasing amounts of GFP-NCC cRNA as well as the group co-injected with 
10 ng of y-adducin cRNA using confocal laser scanning microscopy. *p < 0.05 is statistically significant.
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Figure 5. Role o f hypo-osm otic  C l'-depletion on y-adducin stim ula ted NCC activ ity .
Oocytes were injected with 5 ng of NCC cRNA, in the presence or absence of 10 ng of Y-adducin cRNA 
and incubated for 16 hrs in iso- (200 mOsm) and hypo-osmotic (170 mOsm) Cl--free solutions. Closed bars 
represent the addition of 0.1 mM thiazide. *p < 0.05 is statistically significant from the NCC injected group 
kept in hypo-osmotic media.
y-adducin stimulates NCC activity in hypo-osmotic C l-depleted conditions 
Hypotonicity has previously been shown to increase the activity of NCC. The effect of 
hypotonicity could be replicated in our experiments, resulting in an increase in NCC activity. In 
addition, during hypotonic conditions y-adducin was still able to increase transporter activity 
(Figure 5).
The stimulatory effect o f Y-adducin depends on the N-terminal phosphorylation sites in NCC 
To delineate whether y-adducin affects NCC function by its interaction with the N-terminus of 
NCC, competition assays were performed in which NCC and y-adducin were co-injected together 
with increasing amounts of the N-terminus of NCC. During these conditions, injection of the NCC 
N-terminus abolished the stimulatory effect of y-adducin on NCC activity (Figure 6A). The binding 
site of y-adducin in the N-terminus of NCC was subsequently mapped by pull down analysis. For
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determination of the binding site, a series of fragments from the N-terminal domain of NCC were 
generated as depicted in figure 6B, with the 1-135 representing the full-length N-tail. All 
N-terminal fragments were fused to GST to allow precipitation using glutathione-coupled 
Sepharose beads. N-terminal deletion fragments of NCC were expressed transiently in HEK293 
cells together with y-adducin. GST-pull down experiments revealed that y-adducin only binds the 
N-terminus when the 1-80 fragment is present, albeit at a lower affinity than to the full length 
N-tail (Figure 6, C and D). As this region encompasses the three phosphorylation-sites of NCC 
(Thr55, Thr60, Ser73 in human NCC), which previously have been shown necessary for activation 
of the protein in response to Cl"-depletion (16), the role of y-adducin on the phosphorylation of 
NCC was evaluated. y-Adducin was co-injected with triple phosphorylation-site NCC mutants 
(converted to alanines (A) or aspartates (D) to mimic either the constitutively inactive or active 
sites, respectively) and 22Na+ uptakes were performed. The stimulatory effect of y-adducin on 
NCC-mediated Na+ transport was lost when the three phosphorylation sites were converted into 
constitutively active sites (D) (Figure 6E), suggesting an important role of y-adducin in 
modulating the phosphorylation of NCC. Similarly, when the N-terminal phosphorylation sites 
were converted to inactive phosphorylation sites (A), NCC-dependent 22Na+ transport dropped 
markedly in line with previously published data (Figure 6E) (16). Also in this experimental setting, 
when the phosphorylation sites were made constitutively inactive, y-adducin had no effect on 
NCC-mediated 22Na+ transport.
These data suggest that the stimulatory effect of y-adducin is critically dependent on the 
phosphorylation sites in the N-terminal domain of NCC. To further elucidate the relationship 
between y-adducin and NCC, pull down experiments were performed to determine whether 
binding of y-adducin to the N-tail of NCC was dependent on the phosphorylation status of this 
domain. Thus, GST-pull downs were performed using the N-terminus of NCC as well as the 
N-terminal constitutively inactive or active phosphorylation forms (Figure 6F). Binding of 
y-adducin was found to the N-terminus of wild-type NCC and the constitutively inactive form,
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while no binding was observed to the constitutive active phosphorylation form of NCC.
D iscussion
NCC is of crucial importance for the reabsorption of NaCl by the kidney, thus influencing arterial 
pressure. Here, we report the identification of y-adducin, a novel auxiliary protein interacting with 
the N-terminal domain of NCC. Our study is the first to delineate the stimulatory action of 
y-adducin on the thiazide-sensitive NaCl cotransporter and highlights that the effect of y-adducin 
is critically dependent on the phosphorylation status of NCC. These observations are based on 
the following data: i) the identified protein y-adducin binds strongly to the N-terminal domain of 
NCC and markedly stimulates the activity of the transporter; ii) the stimulatory actions of 
y-adducin occur in the regulatory cascade prior to the WNK4-dependent lysosomal shuttling of 
NCC; iii) competition with increasing amounts of the N-terminal part of NCC completely reverts 
the stimulatory action of y-adducin on thiazide-sensitive 22Na+ transport; iv) the y-adducin binding 
site is mapped to the exact region encompassing three phosphorylation sites that previously 
have been shown to affect the activity of the cotransporter; v) NCC forms lacking 
phosphorylatable sites in the N-terminus do not exhibit increased 22Na+ transport rates when 
co-injected with y-adducin; vi) y-adducin dissociates from NCC when the phospho-residues are 
converted to aspartates, mimicking a constitutively active phosphorylated state.
y-Adducin was originally cloned from rat kidney (39). The protein exhibits homology with 
the previously identified a- and p-adducin family members. Adducins are heteromeric membrane 
skeletal proteins originally implicated in spectrin-actin binding (31). y-Adducin contains a 
N-terminal globular head domain, a so-called neck domain, and a protease sensitive C-terminal 
domain. The protein shows a wide tissue distribution, but with a robust expression in kidney (39). 
In addition, y-adducin contains several sites that are necessary for its regulation by calmodulin, 
protein kinase A, and protein kinase C (40). The adducins form heteromeric proteins composed
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Figure 6. Phosphoryla tion o f the N-term inal dom ain o f NCC is essentia l fo r the 
s tim u la to ry  e ffect o f y-adducin on NCC activ ity . (A) The ability of the NCC N-terminal domain to 
inhibit y-adducin-stimulated transport of the cotransporter as evaluated by 22Na+ uptakes. Oocytes were 
co-injected with 5 ng of NCC cRNA, 10 ng of y-adducin cRNA, and increasing amounts of the N-terminal 
domain of NCC (from 2.5 ng to 10 ng). *p < 0.05 is statistically significant from all other groups. (B) 
Schematic drawing representing the GST fusion proteins containing different portions of the N-terminal tail 
of NCC. These were generated to map the binding site of y-adducin to NCC. Black domains represent the 
N-terminal phosphorylation sites, while gray denotes the SPAK binding site. (C) GST-pull down assay in 
HEK293 cells. Deletion fragments of the NCC N-terminal domain (aa 1-135; 1-80; 1-40) coupled to GST 
were generated to determine the HA-y-adducin binding site within the cotransporter. (D) GST-pull down 
assay repeated, but the N-terminus was truncated from the opposite end (aa 1-135; 40-135; 80-135; 
112-135). Note y-adducin binds only in the presence of the full-length terminus or the 1-80 fragment. (E) 
The effect of y-adducin requires phosphorylatable NCC sites. 22Na+ uptakes were performed in oocytes 
injected with 5 ng of NCC cRNA, 5 ng of constitutively inactive (NCC TM(A); T55A, T60A, S73A), or 5 ng of 
the constitutively active (NCC TM(D); T55D, T60D, S73D) NCC phospho-mutants, in the presence or 
absence of 10 ng of y-adducin cRNA. (F) GST-pull down assay in HEK293 cells. Co-precipitation of 
HA-tagged y-adducin with the native GST-N-terminus, and the GST-N-terminus containing constitutively 
inactive and active phosphorylation sites. CP denotes co-precipitate and IB indicates the protein which 
was immunoblotted against. The 22Na+ uptake experiments were performed in the presence (closed bars) 
or absence (open bars) of 0.1 mM thiazide. *p < 0.05 is statistically significant from NCC injected oocytes. 
NS, not statistically significant.
of either a-and p-subunits or a- and y-subunits. As the p-subunit has a restricted expression and 
is primarily found in brain and hemopoietic tissues, it has been suggested that the a- and 
y-subunit functions as heteromers in tissues where the p-subunit is absent (39). It is interesting to 
note that while y-adducin localizes to the DCT with NCC, a-adducin which is also expressed in 
the kidney seems absent from the distal part of the nephron (35). This may suggest that 
y-adducin has a unique function in DCT where it could function as a homomer. Mutations in rat a- 
and p-adducin identified in the Milan hypertensive rat strain (MHS) have been shown to alter the 
activity of the Na+, K+-ATPase in vitro (41). In contrast, little is known about the function of 
y-adducin in terms of renal NaCl transport processes. Our data suggest that y-adducin plays an 
important role in regulating epithelial electrolyte transport in the DCT
y-Adducin is able to completely revert the inhibitory effect of WNK4 on NCC. 
Consequently, our observation infers that y-adducin protects against the inhibitory actions of 
WNK4, either by affecting processes occurring before lysosomal removal of the protein or by 
directly blocking the WNK4-dependent inhibitory action on NCC. As no changes in the 
membrane localization of NCC were observed after co-injection of y-adducin, one may conclude
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that y-adducin controls processes preceding lysosomal shuttling of NCC. The functional effect of 
phosphorylation of the thiazide-sensitive NCC transporter has not been fully delineated. Previous 
studies have reported that when the N-terminal phosphorylation sites in NCC are converted to 
alanines mimicking inactive phosphorylation sites, the activity of the transporter is markedly 
decreased. This occurs even though the membrane abundance remains unaffected, suggesting 
that the intrinsic activity is inhibited (16). Similarly, when the transporter is incubated at hypotonic 
low Cl- conditions, which noticeably increases its phosphorylation level, NCC increases its 
activity, again independent of trafficking to the oocyte membrane (16). In line with this finding is 
the observation that the Thr96 and Thr101-phosphorylated form of the related family member, the 
rat furosemide-sensitive Na+, K+, 2Cl--cotransporter (NKCC2) (corresponding to Thr55, Thr60 
phospho-form of human NCC), is found exclusively at the membrane as evaluated by electron 
microscopy (42). Similarly to NCC in oocytes, when the phosphorylation level of NKCC2 is 
increased by growth hormone, no change in trafficking of the transporter can be observed (16, 
42). Consequently, the y-adducin-stimulated NCC activity needs to be explained by an intrinsic 
change in transporter activity, as the amount of transporters in the membrane remains 
unchanged. Such changes could ensue, for instance, if affinity constants for Na+ or Cl- will shift, 
to such a degree that the maximal velocity is altered. Thus, the data obtained in our study as well 
as the previous literature strongly imply a link between the phosphorylation state and the intrinsic 
activity of the transporter.
We found that the effect of y-adducin is entirely dependent on the phosphorylation sites of 
NCC. The sequence of y-adducin does not suggest that the protein is a kinase. Furthermore, 
there is no experimental evidence showing that y-adducin or other members of the family 
possesses kinase activity. The most likely explanation is that y-adducin associates with kinases 
involved in the phosphorylation of the transporter, thereby anchoring them to the 
dephosphorylated N-terminal of the transporter. The STE20 family of kinases, comprising 
members such as SPAK and OSR1, has been shown to increase the phosphorylation state of
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NCC in vitro and in vivo (20, 29). In addition, WNK1, via SPAK and OSR1, has previously been 
shown to be responsible for increasing the transport activity and phosphorylation level of NCC 
during hypotonic Cl--depleted conditions (20). Moreover, WNK4 plays an important role in 
stimulating the NCC phosphorylation via SPAK and OSR1 in response to angiotensin 
II-mediated receptor activation (43). The phosphorylation state of NCC is also markedly 
enhanced by dietary NaCl restriction, an effect that appears aldosterone-dependent and is lost in 
transgenic animals with a PHAII mutation in WNK4 (44). Consequently, phosphorylation of the 
N-terminal domain in NCC seems to be a common final pathway by which several stimuli 
converge to regulate the activity of the transporter. Here, we report that y-adducin may function 
as an important component in the phosphorylation cascade of NCC.
Based on the data generated in our study, a schematic model predicting the functional 
role of y-adducin was generated. As depicted in Figure 7, y-adducin may stimulate NCC activity 
by anchoring a kinase, likely SPAK or OSR1 to the dephosphorylated transporter (step 1). 
Subsequently, the kinase increases the phosphorylation level of NCC, thereby stimulating the 
activity of the transporter (step 2). After the kinase-mediated phosphorylation event, y-adducin 
dissociates from NCC and may also facilitate the release of the associated kinase (step 3). 
Dephosphorylation of the transporter reduces the activity of NCC to its basal state. However, this 
event also allows for the binding of y-adducin to the N-terminal again, and the cycle can be 
repeated (step 4). Thus, these speculations infer a dynamic model in which y-adducin binding 
and dissociation to NCC is directly correlated with the dephosphorylation and phosphorylation of 
the transporter, respectively.
The adducin gene family has previously been implicated in arterial hypertension. A 
G460W polymorphism in the a-adducin gene showed linkage to primary hypertension in certain 
patient groups (32). One intronic single nucleotide polymorphism (SNP) has currently been 
described in the y-adducin gene (A/G; rs3731566), which correlates with peripheral and central 
pulse pressures (due to increases in systolic pressure), changes in the urinary Na+/K+ ratio, and
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Figure 7. Proposed model fo r  the regulation of NCC ac tiv ity  via phosphory la tion  by 
Y -adducin. Step 1) y-Adducin binds to the dephosphorylated N-tail of NCC and may thereby facilitate the 
binding of a kinase to the transporter. Step 2) Upon binding, the kinase can phosphorylate NCC, which 
leads to an increase in the activity of the transporter. Step 3) The phosphorylation of the N-terminal domain 
in NCC causes y-adducin to dissociate from the transporter and may also promote the release of the 
associated kinase. Step 4) After dephosphorylation of the N-tail of NCC, y-adducin can again bind and the 
cycle can be repeated.___________________________________________________________________
urinary aldosterone excretion, but only in individuals that also harbor the G460W polymorphism 
in a-adducin (45). These observations suggest that y-adducin can affect blood pressure, 
however in order to be visible clinically, arterial pressure needs to be perturbed by the G460W 
polymorphism in a-adducin. Moreover, mutations in the rat a-adducin gene (F316Y) accounts for 
some of the blood pressure difference in crossings between the MHS strain and normotensive
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controls (33). Conversely, rat p-adducin (Q526R) and rat y-adducin (Q572K) have not been 
directly associated with the hypertensive phenotype, while they were shown to interact 
epistatically with the a-adducin gene (34). Blood pressure changes remain to be determined in 
mice with a targeted deletion of the a-adducin gene, however, these mice show severe growth 
retardation and many develop hydrocephaly (46). In addition, mice lacking p-adducin which is 
highly expressed in brain and hematopoietic tissues develop hypertension (47). Systolic blood 
pressure and pulse rate remain stable in mice lacking y-adducin, which can be expected since 
also mice with a targeted deletion of NCC show no mean arterial pressure variation when 
maintained on a diet with normal dietary NaCl. However, when NCC-deficient mice were given a 
reduced dietary NaCl content, they developed hypotension (48). Whether similar dietary 
restrictions are needed in order to provoke hypotension in the y-adducin-deficient mice remains 
to be established.
In conclusion, we identified y-adducin as a novel regulator of NCC and showed that the 
stimulatory action of y-adducin is intimately linked with the N-terminal phosphorylation sites in the 
cotransporter. Based on our data, y-adducin may contribute importantly to the regulation of NCC 
and hence blood pressure maintenance. Our findings will aid in the understanding of the complex 
cascade regulating NCC activity. Importantly, the observations made in our study may help 
elucidate the molecular events underlying the formation of primary hypertension.
Materials and Methods
Constructs
HA-tagged human NCC in pT7Ts has been previously described (49). The human y-adducin 
clone was obtained from Imclone systems (New York, USA), subcloned into a 
pCI-NEO-IRES-GFP vector and further subcloned into pT7Ts. GST-conjugated N- and C- 
terminal fragments of NCC were subcloned by PCR to pGEX-6p-2 for E. Coli protein production
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and further subcloned into pEBG vectors for expression of GST-fused proteins in HEK293 cells. 
GST-fused proteins containing different portions of the N-terminal domain of NCC were 
constructed according to the schematic drawing in figure 6B. These constructs inserted in pEBG 
vectors were generated either by PCR subcloning or truncated by stop codons using the 
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, US). In addition, the 
N-terminal domain of NCC (amino acids 1-135) for the competition assay was generated by 
insertion of a stop codon by site directed mutagenesis in the full length NCC in pT7Ts. The triple 
phospho sites (Thr55, Thr60, Ser73) in NCC mimicking constitutively inactive (converted to 
alanines) or active (converted to aspartates) phospho-proteins were generated by site directed 
mutagenesis in pT7Ts vectors. Similarly, the N-termini with modified phosphorylation sites were 
further subcloned by PCR into pEBG for GST-pull down analysis. A Myc-tag was inserted in front 
of WNK4 by subcloning and the complete insert was placed into a pT7Ts vector using the 
gateway system (Invitrogen, Breda, the Netherlands). For generation of eGFP-NCC in pT7Ts, 
hNCC was subcloned by PCR from hNCC pT7Ts and constructed behind eGFP in a pCB7 
vector. The complete insert was thereafter subcloned into pT7Ts. All inserts were verified by 
direct sequencing.
GST-pull down and Mass-spectrometry
The intracellular N- and C-terminal domains of NCC coupled to GST were produced in E. Coli 
BL21 cells. The bacteria were lysed and the GST-NCC terminal fusion domains were purified on 
glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech). C57BL/6 mice were killed 
under 1.5% v/v isofluorane anesthesia (Nicholas Piramal Limited, London, United Kingdom) and 
the kidneys were homogenized in lysis buffer (20 mM Tris/HCl, 140 mM NaCl, 1 mM CaCl2, 0.2% 
(v/v) Triton-X-100, 0.2% (v/v) NP-40, pH 7.4) containing protease inhibitors (0.10 mg/ml 
leupeptin, 0.05 mg/ml pepstatin-A, 1 mM phenylmethylsulfonyl fluoride, and 5 mg/ml aprotinin). 
The precipitated GST-terminal proteins were incubated overnight at 4°C with mouse kidney
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lysates. After extensive washing, the precipitates were placed on a SDS-PAGE gel and analyzed 
by the Nijmegen Proteomics Facility (Radboud University Nijmegen Medical Centre, The 
Netherlands, http://www.proteomicsnijmegen.nl/). Proteins were in-gel digested with trypsin. 
After extraction from the gel, peptides were analyzed using nano-flow liquid chromatography 
coupled to a linear ion trap fourier-transform mass spectrometer (LTQ FT, Thermo Fisher 
Scientific). Peptide and protein identifications were extracted from the data by means of the 
search program Mascot using the NCBI database 20080103 containing Mus musculus taxonomy 
with addition of known contaminant proteins such as trypsin and human keratins.
Precipitation of GST-coupled fusion domains of NCC with HA-tagged y-adducin in 
HEK293 cells was done as described in detail previously (50).
COPAS sorting and semi-quantitative Real-Time PCR Analysis
Transgene mice expressing eGFP after the parvalbumin promoter have been described 
previously (36). The animals were anesthetized by an intraperitoneal injection of Hellabrunn 
mixture (ketamine 0.05 mg/g bodyweight and xylazine 0.02 mg/g bodyweight), and perfused 
transcardially with digestion solution (1 mg/ml collagenase A (#1088793, Roche Diagnostics, 
Mannheim, Germany) and 1 mg/ml hyaluronidase (#H3884, Sigma Aldrich, Zwijndrecht, the 
Netherlands) in KREBS (145 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 mM NaH2 PO4 , 2.5 mM 
CaCl2, 1.8 mM MgSO4, 5 mM glucose, pH 7.3). The animal ethics board of Radboud University 
Nijmegen approved all experimental procedures. The kidney cortex was finely minced and 
incubated in digestion solution for 22 min at 37°C, subsequently sieved through a series of 
meshes and finally collected on a 40 ^m filter. Fluorescently labeled DCT tubules were isolated 
from transgenic animals, using a COPAS sorter as described in detail previously (37). The 
GFP-positive fraction consists of DCT fragments. The remainder was saved and denoted whole 
kidney tubules. Tubule RNA was extracted using TriZol Total RNA Isolation Reagent (Life 
Technologies BRL, Breda, The Netherlands), and processed into cDNA. The cDNA was mixed
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with Power SYBR® green PCR mastermix (Applied Biosystems, Foster City, CA, USA) and exon
overlapping primers against y-adducin (5'-CACATCCACACCCTTGCCAC-3';
5'-CCTGGTAGTCATAGTAGGCGAC-3'), NCC (5'-CTTCGGCCACT GGCATTCT G-3';
5'-GATGGCAAGGTAGGAGATGG-3'), and the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 5'- AACATCAAATGGGGTGA-3'; 5'- 
GGTTCACACCCATCACAA-3').
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In vitro cRNA translation
pT7Ts plasmid vectors were linearized by restriction digestion at the 3'-end of the insert. The 
plasmids were transcribed in vitro using the mMESSAGE mMACHINE® T7 Kit (Ambion, Austin, 
TX, USA) to generate cRNA. The integrity of the product was confirmed on 1% (w/v) agarose, 
37% (v/v) formaldehyde gels. RNA concentrations were determined spectrophotometrically at 
260 nm. The cRNA aliquots were stored at -80°C.
Evaluation o f NCC function
All animal experiments described below received the approval from the animal ethics board of 
Radboud University Nijmegen. Isolation and 22Na+ uptakes in oocytes were done as described 
previously (51, 52), with minor modifications. Briefly, Xenopus laevis oocytes were surgically 
collected after decapitation, manually separated, and incubated in collagenase A (1 mg/ml). 
Incubations were done in Ca2+-free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 
mM HEPES/NaOH, pH 7.4, 50 mg/l gentamicin). The following day, stage V and VI oocytes were 
selected and injected with the appropriate cRNAs in a final volume of 50 nl/oocyte. The oocytes 
were subsequently incubated in Ca2+-containing ND96 including 1.8 mM CaCl2 for 2-3 days at 
16°C. 16 hrs prior to the uptake, oocytes were placed in Cl"-depleted media (96 mM 
Na-isethionate, 2 mM K-gluconate, 1.8 mM Ca-gluconate, 1 mM Mg(NO3")2, 5 mM HEPES/NaOH, 
pH 7.4, 50 mg/dl gentamicin, ~200 mOsm) or hypotonic Cl"-depleted media (same as above but
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with 79.7 mM Na-isethionate, —170 mOsm). Before the uptake, oocytes were preincubated in 1 
mM ouabain, 0.1 mM amiloride, and 0.1 mM bumetanide in the presence or absence of 0.1 mM 
thiazide in Cl'-depleted media. 22Na+ uptake (1 |iCi 22Na+/ml, Perkin Elmer) was done in K+-free 
isotonic uptake buffer (40 mM NaCl, 56 mM NMDG-Cl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM 
HEPES/NaOH, pH 7.4) for 1 hr. Oocytes were washed 5 times at the end of the 22Na+ 
incubation with ice-cold uptake medium, transferred to scintillation vials, and lysed in 10% 
(w/v) Na+-dodecyl sulfate. Radioactivity was counted in a liquid scintillation counter.
Evaluation o f total expression of NCC and y-adducin in the oocyte
HA-NCC was detected in total membrane isolates, while HA-y-adducin was detected in the 
remaining cytosolic fraction. As described in detail previously (49), membrane preparations and 
total lysates were prepared, blotted onto membranes, and detected using an enhanced 
chemiluminescence system (Pierce, Rockford, IL).
Quantification of eGFP-NCC in the oocyte membrane
Oocytes were injected with 1, 5, or 10 ng of eGFP-NCC cRNA as well as 10 ng eGFP-NCC 
cRNA in the presence of 10 ng of y-adducin. cRNA. Images were acquired on an Olympus 
FV1000 laser-scanning microscope (Center Valley, PA, USA) using a 20X objective. Background 
subtraction and semi-quantitative determination of eGFP-NCC abundance at the plasma 
membrane was done using Image J (image processing program, NIH, USA)
SiRNA against Xenopus laevis y-adducin
To confirm endogenous expression of y-adducin in Xenopus laevis oocytes, primers designed 
against y-adducin in Xenopus Tropicalis were used to amplify a fragment by RT-PCR (TaKaRa 
Taq™, Shiga, Japan) from oocyte cDNA. The fragment was extracted from the gel and 
sequenced. Sequence similarity was identical to the previously published mRNA of hypothetical
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protein LOC432146 from Xenopus laevis. siRNA was designed using double stranded 
oligo-probes against the following sequence of endogenous Xenopus laevis y-adducin, 
5'-AATGACCCCGGCTACATCCGC.-3'. Oocytes were injected with 5 ng of HA-NCC siRNA as 
described above. siRNAs were injected 24 hrs prior to the uptake.
Immunohistochemistry
Kidneys from C57BL/6 mice were immersion fixated in 1% (w/v) 
periodate-lysine-paraformaldehyde fixative. 10 |im cryosections were prepared and co-stained 
with anti-y-adducin antibodies (1:25, rabbit, H-60, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) and NCC (1:100, guinea pig; generously provided by Jan Loffing, Switzerland). Images 
were acquired on an Olympus FV1000 laser-scanning microscope (Center Valley, PA, USA).
Statistical analysis.
All results obtained in oocytes were the average of at least 3 independent experiments, each 
containing a minimum of 10 oocytes per group. Overall statistical between groups was 
determined by one-way ANOVA. In case of significance, multiple comparisons between groups 
were performed by Bonferroni post hoc tests. Values are presented as means ± SEM. p < 0.05 
is considered statistically significant.
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Abstract
A mutation in pro-EGF causes isolated hypomagnesemia. Further, monoclonal antibodies 
targeting the extracellular EGFR domain have been implicated in the regulation of epithelial Mg2+ 
transport. However, the effect of the widely used EGFR tyrosine kinase inhibitor, Erlotinib, on 
Mg2+ homeostasis remains unknown. To investigate the potential role of Erlotinib on Mg2+ 
handling, C57BL/6 mice were given intraperitoneal injections for 23 days. In Erlotinib-injected 
mice, a small but significant decrease in serum Mg2+ concentrations was observed at day 16 and
23, while the fractional excretion of Mg2+ remained unchanged after 23 days. Semi-quantitative 
immunohistochemical evaluation did not reveal detectable changes in renal Transient Receptor 
Potential Melastatin 6 (TRPM6) protein expression. The effect of Erlotinib on TRPM6 was 
investigated in human embryonic kidney (HEK) 293 cells. Patch clamp analysis in TRPM6 
expressing cells demonstrated that Erlotinib inhibited EGF-induced changes in TRPM6 current 
density at a concentration of 30 |iM. At lower concentrations (0.3 |iM), Erlotinib failed to inhibit 
EGF-mediated TRPM6 stimulation. Likewise, EGF-induced tyrosine phosphorylation of its 
receptor was only blocked by 30 |iM of Erlotinib. In addition, 30 |iM Erlotinib inhibited 
EGF-stimulated increases in the mobile fraction of endomembrane TRPM6 channels. In this 
mouse model, Erlotinib does influence Mg2+ handling. However, the effect on the systemic Mg2+ 
concentration seems less potent than that observed with antibody-based EGFR inhibitors in vivo. 
Currently, clinical data detailing the effect of Erlotinib on Mg2+ handling is lacking. Based on the 
doses given to cancer patients it is unlikely that Erlotinib severely affects serum Mg2+ 
concentrations in these individuals.
Introduction
Overall maintenance of serum Mg2+ concentration is essential for many cellular processes, 
including adequate function of neurological and cardiovascular systems. The Transient Receptor
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Potential Melastatin subtype 6 (TRPM6) was originally identified as the causative gene for the 
rare autosomal recessive disorder; hypomagnesemia with secondary hypocalcemia (1, 2). 
TRPM6, which is expressed in kidney and colon (1, 3, 4), constitutes the gatekeeper and 
postulated rate-limiting entry step for active Mg2+ (re-) absorption.
The effect of EGF on TRPM6 has been firmly established. Application of EGF readily 
increases TRPM6 current density (5, 6). Additional evidence suggests that EGF provokes 
trafficking of the channel to the plasma membrane, via activation of the Rho GTPase, Rac1 (5). 
These discoveries were prompted by the observations that anti-cancer treatments with 
monoclonal antibodies (Cetuximab), targeting an extracellular epitope on the epidermal growth 
factor receptor (EGFR), causes hypomagnesemia in patients with colorectal cancer. In addition, 
genetic linkage and sequence analysis implicated the pro-EGF gene in isolated recessive renal 
hypomagnesemia (6-8). The observed decline in serum Mg2+ is accompanied by renal Mg2+ 
wasting, as these patients maintain an inappropriately high fractional Mg2+ excretion (6).
While mostly patients with colorectal cancer are treated with monoclonal EGFR inhibitors, 
numerous patient groups suffering from cancer receive tyrosine kinase inhibitors, such as 
Erlotinib or Gefitinib. These include individuals being treated for non-small cell lung cancer as 
well as pancreatic cancer (9). Erlotinib has been grouped with platinum compounds in most trials, 
a combination that may potentiate the effects on serum Mg2+ concentrations (10). At present, 
there are no published clinical reports detailing the potential effect of tyrosine kinase inhibitors on 
systemic and renal Mg2+ handling. Given the pronounced effect of Cetuximab on Mg2+ 
homeostasis, we sought to ascertain whether Erlotinib alters Mg2+ handling. Thus Mg2+ 
homeostasis and TRPM6 expression levels were investigated in wild-type mice receiving 
Erlotinib for 23 days, and the effect of Erlotinib on current density and mobility of TRPM6 was 
studied in human embryonic kidney (HEK) 293 cells transiently overexpressing the channel.
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Erlotinib reduces serum Mg2+ concentration in C57BI/6 mice
C57BL/6 mice were injected intraperitoneally with a high dose of Erlotinib or vehicle for 23 day (2 
mg/mouse/day) (n=9 per group). Blood samples were obtained at day 16, by puncturing a 
vascular bundle in the sub-mandibular area. Serum Mg2+ concentration showed a significant 
decline in the Erlotinib-injected group (p<0.05) (Figure 1A), while no difference was detected in 
serum Ca2+ concentration between groups (Figure 1B).
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Figure 1. Effect of Erlotinib on serum Mg2+ and Ca2+ concentrations. (A-B) Changes in serum 
Mg2+ and Ca2+ concentrations after 16 days, in mice receiving daily injections with Erlotinib or vehicle. 
(C-D) Effect of Erlotinib or vehicle on serum Mg2+ and Ca2+ concentrations after 23 days. Values are 
presented as means ± SEM (n = 9). *p<0.05 is considered statistically significant.
Upon sacrifice after 23 days of Erlotinib injections, similar results were found, namely a 
slight but significant decline in the serum Mg2+ concentration in the Erlotinib-injected group (p< 
0.05) (Figure 1C). Erlotinib did not affect the systemic Ca2+ concentration at day 23 (Figure 1D).
No difference was observed in the urinary excretion of Mg2+, (Figure 2A) and the urinary 
Ca2+ excretion (Figure 2B) after 23 days of Erlotinib administration. The glomerular filtration rate
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remained within normal limits (Figure 2C). Importantly, no change in the fractional excretion of 
Mg2+ was observed in mice receiving Erlotinib (Figure 2D). The fractional excretion of Ca2+ 
remained unchanged after chronic administration of Erlotinib (Figure 2E). These results suggest 
that Erlotinib-treated mice waste Mg2+, as serum Mg2+ is decreased while a compensatory 
reduction in the fractional Mg2+ excretion is absent.
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Figure 2. Functional data after 23 days of Erlotinib injections. (A-B) Daily urinary excretion of 
Mg2+ and Ca2+ in mice injected with Erlotinib for 23 days. (C) Creatinine clearance (estimated glomerular 
filtration rate) in Erlotinib- and vehicle- injected mice as well as (D-E) the corresponding fractional 
excretions of Mg2+ (FEMg) and Ca2+ (FECa). Values are presented as means ± SEM (n = 9). *p<0.05 is 
considered statistically significant.
Renal TRPM6 protein expression is unchanged in Erlotinib-injected mice
As mice injected with Erlotinib develop a modest reduction in serum Mg2+, without appropriate 
compensation by the kidney, a possible effect could be on the expression level of TRPM6. 
Therefore, TRPM6 mRNA abundance was determined in the Erlotinib-and vehicle-injected mice. 
Chronic administration of Erlotinib caused a significant 0.67 fold decrease in the mRNA 
expression of TRPM6 (p<0.05, n=9) (Figure 3A). TRPM6 protein abundance was determined by 
semi-quantification of fluorescence, from anti-TRPM6 immunolabeled kidney sections. However, 
using this method no change in TRPM6 fluorescence was found (p=0.99, n=9) (Figure 3B). As
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TRPM6 is abundantly expressed in colon, the main site for active Mg2+ absorption in the intestine, 
the effect of Erlotinib on colonic TRPM6 mRNA expression was investigated. No change in the 
abundance of colonic TRPM6 was observed between Erlotinib- and vehicle- injected mice 
(Figure 3C).
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Figure 3. Effect of Erlotinib on mRNA and protein abundance of TRPM6. (A)
Semi-quantitative real-time PCR was used to determine the abundance of TRPM6 mRNA extracted from 
kidney. (B) Histogram depicting TRPM6 protein abundance determined by computerized analysis of 
immunohistochemical images. Representative immunohistochemical pictures of TRPM6 in vehicle- and 
Erlotinib- injected mice. (C) Semi-quantitative real-time PCR determination of TRPM6 mRNA expression in 
colon. Data is presented as means ± SEM. *p<0.05 is considered statistically significant.
Renal EGFR expression is increased in mice injected with Erlotinib
To investigate whether changes in the renal EGF system were apparent after chronic
administration of Erlotinib, renal mRNA expression of EGF and the EGFR was determined. A 1.6
fold increase in the mRNA abundance of the EGFR receptor was observed in Erlotinib-injected
mice (p<0.05, n=9) (Figure 4A). Additionally, no change in renal mRNA expression of EGF was
observed after injection of Erlotinib (n=9) (Figure 4B). To evaluate changes in the secretion of
EGF after administration of Erlotinib, the urinary excretion of EGF was measured in the
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experimental groups. No differences were observed in the total urinary excretion of EGF 
between vehicle- and Erlotinib-injected animals (Figure 4C). In addition, no changes were 
detected when the values were corrected for the urinary creatinine excretion (Figure 4D). As the 
colonic EGF system may be affected in a similar way, as observed in the kidney, the abundance 
of the EGFR and the EGF mRNA was investigated in samples extracted from colon. However, 
no differences in the colonic expression of the EGFR (n=9) (Figure 4E) and EGF (n=9) (Figure 
4F) were detectable between vehicle- and Erlotinib-injected animals.
Supraphysiological concentrations of Erlotinib are necessary to inhibit TRPM6 channel activity 
HEK293 cells expressing TRPM6 were subjected to whole cell patch-clamp analysis. Using this 
technique a TRPM6 specific outward current was detectable. Pretreatment with Erlotinib alone 
did not significantly affect channel currents from controls. Application of EGF (10 nM) 
significantly increased channel activity compared to control (p<0.05) (Figure 5A-C). Pretreatment 
with Erlotinib (30 |iM) completely prevented the EGF-induced increase in TRPM6 current density 
(p<0.05). However, at lower Erlotinib concentrations (0.3 |iM), Erlotinib did not significantly inhibit 
EGF-stimulated TRPM6 channel currents (Figure 5A-C). Tyrosine phosphorylation of the 
immunoprecipitated EGFR was evaluated under the same experimental conditions as 
aforementioned (Figure 5D). In the presence of EGF, tyrosine phosphorylation of the 
immunoprecipitated receptor was markedly increased. Preincubation of HEK293 cells with 
Erlotinib (30 |iM) blunted the EGF-induced EGFR tyrosine phosphorylation. However, incubation 
with 0.3 |iM of Erlotinib was not sufficient to effectively block EGFR phosphorylation. Cells 
incubated in the absence of EGF showed no detectable tyrosine phosphorylation of the EGFR.
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Figure 4. Erlotinib modulates EGFR mRNA expression. (A-B) Semi-quantitative determination of 
the mRNA abundance of EGFR and EGF in kidney of vehicle and Erlotinib-injected mice. (C-D) 
Measurements of urinary EGF excretion as well as the urinary EGF/creatinine ratio. (E-F) Colonic mRNA 
abundance of EGFR and EGF. Data is presented as means ± SEM. *p<0.05 is considered statistically 
significant.
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Figure 5. EGFR blockade by Erlotinib can prevent EGF-induced changes in TRPM6 
current density. (A) Time course of the current development (pA/pF) at +80 mV of TRPMG (■) 
transfected HEK293 cells, pretreated with EGF (• )  and Erlotinib 30 |jM (A) or 0.3 |jM (T). (B) Current 
recorded after 200 sec stimulation by a voltage ramp between -100 and +100 mV of TRPMG transfected 
HEK293 cells (1), pretreated with EGF (2) or Erlotinib (3) alone, or pretreated with EGF and Erlotinib 30 
jM  (4) / 0.3 jM  (5). (C) Histogram summarizing the current density (pA/pF) at +80 of TRPMG transfected 
HEK293 cells pretreated with EGF and/or Erlotinib as indicated. * indicates p<0.01 compared to TRPMG 
current (n=12-2G cells). # indicates p<0.05 compared to TRPMG pretreated with EGF (n=12-2G cells). (D) 
The immunoprecipitated EGFR was placed on Western blots for the detection of tyrosine phosphorylation 
(pTyr) as well as the EGFR itself. In addition, alpha-tubulin was detected in whole cell lysates as a control 
for total expression.
Erlotinib inhibits EGF-stimulated mobility o f endomembrane TRPM6
Fluorescence recovery after photobleaching (FRAP) was used to estimate the mobility and 
mobile fraction of GFP-tagged TRPM6 channels in HEK293 cells. The electrophysiological 
properties of GFP-TRPM6 have previously been shown be display comparable currents to that of 
wild-type TRPM6 in the presence or absence of EGF (5). In line with this, an increase in the 
maximal recovery was found after EGF application (p<0.05) (Figure 6 D-E). Pretreatment with 
Erlotinib (at 30 ^M) prevented the EGF-stimulated increase in the mobile fraction of TRPM6 
channels (p<0.05) (Figure 6 D-E).
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Figure 6. Erlotinib inhibits EGF-stimulated changes in the mobile fraction of TRPM6. (A)
Fluorescence recovery kinetics as a function of time, measured in HEK293 cells transiently transfected 
with GFP-TRPM6. Cells were pre-incubated with Erlotinib (30 |jM, 30 min) alone (A) or prior to EGF 
application (10 nM, 30-60 min, A), and compared to control (■) or EGF-treated cells (□). (B) Histogram 
representing the maximal recovery of fluorescence (estimated mobile fraction) in HEK293 cells expressing 
GFP-TRPM6 with or without application of Erlotinib, EGF, or both. Data is presented as means ± SEM (n = 
9). *p<0.05 is considered statistically significant from control. #p<0.05 statistically significant from 
EGF-treated.
Discussion
The current study shows Erlotinib is capable of affecting TRPM6 regulation and thereby altering 
Mg2+ handling. This conclusion is based on; 1) mice receiving supraphysiological doses of 
Erlotinib for 23 days develop a decrease in their serum Mg2+ concentration. 2) Erlotinib-injected 
mice fail to reduce the fractional renal excretion of Mg2+ in response to a decreased serum Mg2+ 
concentration. 3) Whole-cell patch clamp analysis in HEK293 cells shows that Erlotinib 
significantly inhibited EGF-stimulated TRPM6 channel activity.
Administration of 92 mg/kg Erlotinib (~2.3 mg/ 25 g mouse) intraperitoneally yielded a 
plasma concentration of approximately 40 |iM after 1 hr in mice (11). A virtually identical dose 
was employed in our mice study (2 mg/mouse/day), thus we can expect similar plasma 
concentrations of Erlotinib. HEK293 cells received dosages in the same range (30 |iM of 
Erlotinib). Given the moderate effects of Erlotinib in vivo, application of the compound could still 
block EGF-stimulated TRPM6 currents and routing in HEK293 cells. This can possibly be
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explained by the bioavailability of the compound. It has been estimated that 92-95% of the 
administered Erlotinib is bound to plasma proteins (12), thus the estimated free concentration in 
our mouse model would approximate 2-3 |iM, a dose that likely would impose less inhibition on 
EGF-stimulated TRPM6 activity in vitro. Individuals receiving a single standard dose of Erlotinib 
(150 mg) show a maximal plasma concentration amounting to 2.65 ± 2.02 |iM (1.14 |ig/ml) of the 
compound (12, 13), representing a ~10 times lower circulating concentration than the mouse 
model. Given that the free circulating concentration of Erlotinib is likely to be around 0.3 |iM in 
human patients, we tested whether this concentration would be able to block the effect of EGF 
on TRPM6 currents. However, we could not detect any significant differences from 
EGF-stimulated cells. Evaluating EGF-induced tyrosine phosphorylation of its receptor 
substantiated these data. At Erlotinib concentrations of 30 |iM, we were unable to detect any 
phosphorylation of the EGFR. At lower concentrations (0.3 |iM), resembling the free 
concentration found in humans receiving standard doses of Erlotinib, EGFR phosphorylation was 
still present after application of EGF. Previous studies show that Erlotinib inhibits 
ligand-stimulated tyrosine autophosphorylation of the EGFR, with an IC50 of approximately 20 nM 
in cells. However, concentrations of at least a few hundred nM of Erlotinib are necessary to 
block more than 90% of the ligand-induced autophosphorylation (14, 15). The results obtained in 
this study fits well with the previous observations. Taken together, these data indicate that 
Erlotinib treatment in human patients is unlikely to induce severe hypomagnesemia as observed 
with EGFR-directed antibodies. However, it remains unclear whether the cellular concentration 
of Erlotinib, namely that obtained in the DCT, is similar to what is observed in plasma. Similarly, 
the bioavailability of monoclonal antibodies may explain why colorectal cancer patients receiving 
Cetuximab show a pronounced decrease in serum Mg2+ concentrations; to such a degree that 
hypomagnesemia develops.
We also find that inhibition of Mg2+ transport by Erlotinib is likely to occur via inhibition of 
TRPM6 routing, by preventing EGF-mediated changes in the mobile fraction of TRPM6 proteins.
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After application of Erlotinib, the EGF-stimulated fraction of TRPM6 channels becomes 
unresponsive. As previously shown, EGF does not only increase the mobile fraction, but also 
increases the plasma membrane expression of the channel, suggesting that EGF exerts its effect 
by redistributing TRPM6 from storage vesicles to the membrane (5). In the experimental animal, 
where physiological levels of EGF are present, blockade of the EGFR would be expected to 
retain a bigger fraction of TRPM6 channels in endomembrane compartments, thereby preventing 
plasma membrane trafficking and hence reduce Mg2+ influx. This hypothesis would also explain 
renal Mg2+ wasting, without concomitant changes in renal TRPM6 protein expression.
EGFR inhibition by Erlotinib influences Mg2+ handling, by decreasing serum Mg2+ content, 
without providing a compensatory decrease in the fractional renal Mg2+ excretion. These data are 
in good agreement with those obtained from patients receiving Cetuximab, although less 
pronounced (6, 7). Thus, the kidney is not able to effectively compensate for the reduction in 
serum Mg2+ concentration. Accordingly, the data insofar support tubular Mg2+ wasting, as a 
potential source of reducing serum Mg2+ concentration or at least in keeping serum Mg2+ lowered. 
Systemic and renal Ca2+ homeostasis remained unaffected during administration of Erlotinib, 
suggesting that EGF does not directly affect Ca2+ handling. Thus the changes in renal Mg2+ 
handling correlate well with impaired distal tubular transport, where Mg2+ transport is 
mechanistically separated from that of Ca2+. Also, the lack of secondary changes in Ca2+, which 
often accompany perturbations in Mg2+ homeostasis, may be explained by the modest decline in 
serum Mg2+ concentration observed in Erlotinib-injected animals. This is confirmed in patients 
treated with Cetuximab, as the appearance of hypocalcaemia was limited to individuals 
presenting with at least grade 2 hypomagnesemia (serum Mg2+ between 0.5 to 0.4 mM) (7). The 
underlying cause of the secondary hypocalcemia during severe hypomagnesemia remains 
incompletely understood, although impaired release of PTH from the parathyroid gland and 
desensitization of bone to PTH is likely implicated (16, 17).
Despite a significant decrease in renal TRPM6 mRNA abundance, semi-quantitative
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comparison of TRPM6 immunofluorescence could not detect a difference in protein expression. 
These findings may be explained by the observation that TRPM6 is retained in endomembrane 
vesicles, leading to a decreased degradation of the protein. In such an event, mRNA expression 
would be expected reduced, as the protein is retained in the cell. In fact, in vitro findings in this 
study support this observation, i.e. impaired mobility of TRPM6 after EGF-stimulation in the 
presence of Erlotinib.
No change was observed in colonic TRPM6 mRNA abundance. Due to difficulties 
detecting TRPM6 immunohistochemically in the colon, it is not possible to confirm whether 
TRPM6 protein abundance remains unchanged. Moreover, it cannot be excluded whether 
Erlotinib inhibits EGF-stimulated TRPM6 trafficking in the colon, as we observe in HEK293 cells. 
However, it is currently not possible to effectively estimate Mg2+ uptake in the intact animal using 
tracers, due to the very short half-life of the radioactive 28Mg2+ isotope. In addition, one would 
expect an increased TRPM6 expression in the colon during conditions of lowered serum Mg2+, 
an effect that is not observed here and elsewhere (3). It is currently unclear how colonic Mg2+ 
absorption is regulated. An increase was found in the renal EGFR mRNA expression, while in 
the colon no such change could be detected. This response may indicate that particularly in 
kidney, the EGF axis is affected after Erlotinib treatment. Additionally, the EGF mRNA 
abundance remained unchanged in both organs. Measurements of EGF in the urine supported 
these findings, suggesting that EGF secretion is not altered in response to Erlotinib.
The current study is to our knowledge the first to delineate the effects of Erlotinib on Mg2+ 
handling in vivo. Taken together, these findings suggest that Erlotinib can inhibit EGF-stimulated 
TRPM6 activity and consequently impair Mg2+ reabsorption in the kidney. Additionally, it provides 
an explanation about why hypomagnesemia has not been correlated with Erlotinib treatment in 
patients undergoing chemotherapy, as has been observed with Cetuximab. However, it should 
be noted that Erlotinib has the potential to modulate renal and systemic Mg2+ handling in vivo. 
Therefore, caution should be given when treating individuals prone to developing
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hypomagnesemia, and patients receiving combinational treatment with Mg2+ lowering 
compounds.
Materials and methods
Experimental protocol
C57BL/6 mice (10 weeks old, n=18) received intraperitoneal injections with Erlotinib or vehicle 
for 23 days. The animals were kept in a light- and temperature-controlled room with ad libitum 
access to food and water. Erlotinib (Tarceva®, generously provided by Roche Diagnostics 
GmbH, Penzberg, Germany) was dissolved in 10% dimethylsulfoxide (DMSO) v/v in saline with
0.1% Pluronic P105 v/v as previously described (11). The compound was delivered once daily at 
a dose of 2 mg/mouse/day. Controls received an identical vehicle solution. At day 16, blood was 
obtained by puncturing the vascular bundle located rear of the jawbone. During the last 24 hrs of 
the experimental period, mice were placed in metabolic cages and subsequently sacrificed under
1.5% v/v isofluorane anesthesia (Nicholas Piramal Limited, London, United Kingdom). Blood was 
withdrawn by perforating the orbital vessels and serum was extracted afterwards. Additionally, 
organs were dissected out and immediately frozen in liquid nitrogen. One half kidney was 
processed for immunohistochemistry by immersion fixation in 2% w/v 
periodate-lysine-paraformaldehyde (PLP), followed by overnight incubation in 15% w/v sucrose. 
The animal ethics board of Radboud University Nijmegen approved all experimental procedures.
Analytical procedures
Serum and urinary Mg2+ and Ca2+ concentrations were measured using a colorimetric assay kit 
according to the manufacturer's protocol (Roche Diagnostics, Almere, the Netherlands). Urinary 
mouse EGF was measured by an Enzyme-linked immunosorbent assay (R&D DuoSet® ELISA, 
DY2028, R&D systems Europe Ltd., United Kingdom). The wells were coated with anti-mouse
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EGF overnight, blocked with BSA (1 hour, room temperature) and washed with 
phosphate-buffered saline with 0.05% (v/v) Tween 20 (PBS-T). Urine samples and recombinant 
mouse EGF, used as standard (diluted in 0.5% (w/v) BSA), were added (2 hours, room 
temperature). After washing in PBS-T, biotinylated goat anti-mouse EGF was added, followed by 
horseradish peroxidase-conjugated streptavidin. Color was developed with OPD 
(o-Phenylenediamine) and stopped with H2SO4 (end concentration 0.33 M). Absorbance was 
measured at 492 nm (Varioskan, Thermo electron corporation, Waltham, USA); data were 
analyzed using SkanIt Software for Varioskan (Thermo electron corporation, Waltham, USA). 
Detection range of the ELISA was between 2-577 pg/ml.
Semi-quantitative Real-Time PCR Analysis
Tissue RNA was extracted using TriZol Total RNA Isolation Reagent (Life Technologies BRL, 
Breda, The Netherlands). After DNase treatment (Promega, Madison, WI), 1.5 |jg of RNA was 
reverse transcribed by Molony-Murine Leukemia Virus-Reverse Transcriptase (Invitrogen) as 
described previously (18). The cDNA was mixed with Power SYBR® green PCR mastermix 
(Applied Biosystems, Foster City, CA, USA) and primers against TRPM6 
(5'-AAAGCCATGCGAGTTATCAGC-3'; 5'-CTT CACAAT GAAAACCT GCCC-3'), EGFR (5'- 
CAGAACTGGGCTTAGGGAAC-3'; 5'-GGACGATGTCCCTCCACTG-3'), EGF (5'- 
GAGAATCTACTGGACAGACAGTGG-3'; 5'-CTCGAGATTCTCTCCTGGATG-3') or the 
housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT; 
5'-TTATCAGACTGAAGAGCTACTGTAATGATC-3';
5'-TTACCAGTGTCAATTATATCTTCAACAATC-3'). The mRNA expression levels were 
quantified using a single color real-time PCR detection system (MyiQ™, Biorad, Veenendaal, the 
Netherlands). Data analysis was carried out using the Relative Expression Software Tool 
(REST©(19)).
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Immunohistochemistry
7 |im PLP fixed cryosections were prepared and stained with anti-TRPM6 (guinea pig antiserum), 
as described previously (4). Photographs of TRPM6 staining in kidney cortex were taken trough 
a 25x objective on a Zeiss fluorescence microscope (Sliedrecht, The Netherlands) equipped with 
a digital photo camera (Nikon DMX1200). Semi-quantitative determination of TRPM6 protein 
expression was done using Image J (image processing program, NIH, USA), similar to previous 
publications (20).
Cell culture and transfection
Cells were maintained and transfected using Lipofectamine 2000 (Invitrogen-Life Technologies, 
Breda, The Netherlands) as previously described (21). Briefly, HEK293T cells were transiently 
transfected with a N-terminal HA-tagged TRPM6 in the pCINeo/IRES-GFP vector for patch 
clamp analysis (4). HEK293 cells were transfected with TRPM6 N-terminally conjugated to 
Green Fluorescent Protein (GFP) in the pCINeo vector for FRAP analysis (5). Experiments were 
performed 48-72 h post-transfection. Cells were preincubated at 37°C in the presence or 
absence Erlotinib (30 |iM or 0.3 |iM) for 60 minutes. Cells were also incubated with or without 
EGF (10 nM) for 30 minutes.
Electrophysiology
Electrophysiological recordings were made as previously described (4, 5). Briefly, whole-cell 
currents were determined in the tight seal whole-cell configuration using a patch clamp amplifier 
controlled by Patchmaster software (HEKA, Lambrecht, Germany). Cells were kept in an 
extracellular bath solution (150 mM NaCl, 10 mM HEPES/NaOH, 1 mM CaCl2, pH 7.4). Electrode 
resistances were between 2-4 MQ after filling with standard pipette solution (150 mM NaCl, 10 
mM EDTA and 10 mM HEPES/NaOH, pH 7.2). Capacitance and access resistances were 
continuously monitored using the automatic capacitance compensation of the Patchmaster
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software. A linear voltage ramp protocol from -100 to +100 mV (within 450 ms) was applied every 
2 s from a holding potential of 0 mV. Extracting the current amplitudes at +80 and -80 mV from 
individual ramp current records assessed the temporal development of membrane currents. 
Current densities presented were determined by normalizing the current amplitude to the cell 
membrane capacitance. All experiments were performed at room temperature. The analysis and 
display of patch clamp data were performed using Igor Pro software (WaveMetrics, Lake 
Oswego, USA).
Western blotting and immunoprecipitation
HEK293T cells were incubated with EGF and Erlotinib as described above. Immunoprecipitation 
and western blotting was performed as previously described (22). Briefly, cells were incubated in 
lysis buffer (150 mM NaCl, 25 mM Tris/HCL pH=7.5, 1% Brij97 (Polyethylene Glycol Monooleyl 
Ether), 5 mM EDTA/NaOH pH=8.0, 1 mM Na3VO4, 1 mM NaF, 1 mM phenylmethylsulfonyl 
fluoride, 1 |jg/ml leupeptin, 1 |jg/ml aprotinin, 1 |jg/ml pepstatin) and spun down at 1000 g for 10 
min at 4°C. Lysates were incubated overnight with anti-EGFR directed mouse antibodies 
(sc-120, Santa Cruz Biotechnology, CA, UAS) coupled to protein A-Sepharose beads. 
Immunoprecipitates were run on SDS-PAGE gels and blotted onto membranes for detection of 
tyrosine phosphorylation (4G10, Millipore, MA, USA) and EGFR abundance (sc-03, Santa Cruz 
Biotechnology). Alpha-tubulin was detected in whole cell lysates and used as a housekeeping 
control (T6199, Sigma Aldrich, Zwijndrecht, the Netherlands).
Fluorescence recovery after photobleaching (FRAP)
The experiments were performed essentially as described previously (5). GFP-TRPM6 
expressing HEK293 cells were plated onto glass Petri dish chambers (0.17 mm thick Wilco Wells, 
USA) and mounted on a confocal laser-scanning microscope (Zeiss LSM 510). Cells were kept 
in a standard solution (130 mM NaCl, 20 mM HEPES/Tris, 5 mM KCl, 5 mM glucose, 1 mM
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CaCl2, 1 mM MgCl2, pH 7.4). After defining two regions of interest (ROI) and subsequent 
recording two base-line fluorescence measurements, irreversible photobleaching of one ROI 
was initiated. Following photobleaching, fluorescence of both ROI's was measured over a 4 min 
period. Recovery in fluorescence was calculated from baseline measurements. The unbleached 
ROI was used to correct for photobleaching induced by image acquisition. The FRAP data was 
fitted by nonlinear regression analysis using previously published equations (23). Between 14-16 
cells were measured in each experimental condition.
Statistical analysis
Values are presented as means ± SEM. Comparisons between two groups were made using an 
unpaired t-test. Statistical significance was determined by ANOVA in the patch clamp and FRAP 
experiments. p<0.05 is considered statistically significant.
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A bstract
Gender differences in renal handling of Ca2+ have previously been reported. However, the 
overall contribution of androgens to these differences remains uncertain. The aim of this study 
was to determine whether testosterone affects active renal Ca2+ reabsorption by regulating the 
Ca2+ transport proteins Transient Receptor Potential Vanilloid-subtype 5 (TRPV5), calbindin-D28K, 
the plasma membrane Ca2+-ATPase, and the Na+/Ca2+ exchanger. Male mice, compared to 
females, had a higher urinary Ca2+ excretion accompanied by reduced renal expression of Ca2+ 
transporters. In addition, androgen deficient bilaterally orchidectomized (ORX) mice excreted 
less Ca2+ in their urine than sham-operated controls. ORX-induced hypocalciuria was normalized 
after testosterone replacement. Consistently, androgen deficiency resulted in augmentation of 
both renal mRNA and protein abundance of TRPV5 and calbindin-D28K, which in turn was 
suppressed by testosterone treatment. Importantly, no significant differences in serum estrogen, 
parathyroid hormone or 1,25-dihydroxyvitamin D3 levels were observed between control, ORX 
and testosterone-supplemented ORX mice. Moreover, incubation of primary rabbit connecting 
tubules and cortical collecting duct cells with the non-aromatizable androgen, 
dihydrotestosterone, reduced transcellular Ca2+ transport. In conclusion, this study demonstrates 
that sex differences in renal Ca2+ handling are in part mediated by the inhibitory actions of 
androgens on TRPV5-mediated active renal Ca2+ transport.
In troduction
Several studies have reported sex differences in the urinary Ca2+ excretion, showing a greater 
urinary Ca2+ loss in males than in females (1, 2). In addition, estrogens have been shown to 
increase the renal reabsorption of Ca2+, which is in good agreement with the observed gender 
differences (3). Presently, it remains unclear whether androgens play an opposing role to 
estrogens in modulating renal Ca2+ reabsorption. The androgen receptor (AR) is expressed in
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renal epithelial cells (4), and a growing body of evidence points to sex differences in various 
functional characteristics of mammalian kidneys; for example, a higher glomerular filtration rate 
in the male rat kidney (possibly due to higher renal plasma flow and lower vascular resistance) 
(reviewed in (5)). However, the role of androgens in regulating renal Ca2+ handling remains 
poorly characterized.
In the kidney, Ca2+ re-enters the blood by passive paracellular as well as active 
transcellular reabsorption. The active Ca2+ reabsorptive component is restricted to the distal 
convoluted tubules (DCT) and the connecting tubules (CNT) (6-9). Here, Ca2+ enters the 
epithelial cell via the Ca2+-selective ion channel Transient Receptor Potential Vanilloid-subtype 5 
(TRPV5). Subsequently, Ca2+ is bound to calbindin-D28K that transports Ca2+ from the apical to 
the basolateral side where the Na+/Ca2+-exchanger (NCX1) and the plasma membrane 
Ca2+-ATPase (PMCA1b) extrude Ca2+ into the peritubular lumen (6).
Active renal Ca2+ reabsorption is critical in determining the final urinary Ca2+ excretion, 
and has been demonstrated to be regulated by calciotropic hormones, including parathyroid 
hormone (PTH) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (6, 10, 11). Estrogen has also been 
shown to affect active renal Ca2+ transport, although sex hormones are usually not considered as 
calciotropic factors (6, 12).
The present study aims to determine whether androgens contribute to the gender 
differences in renal Ca2+ handling by regulating the expression of Ca2+ transport proteins TRPV5, 
calbindin-D28K, NCX1 and PMCA1b. Because changes in systemic androgen concentrations also 
affect bone mineralization via a long-term process (13), we evaluated the short-term effects of 
androgen deficiency in orchidectomized (ORX) mice and of testosterone resupplementation 
(ORX+T), on the expression of the renal Ca2+ transporters. In addition, to exclude possible 
effects of androgens on bone turnover, non-aromatizable dihydrotestosterone (DHT) was applied 
to an isolated cell system of primary renal connecting tubule (CNT) / cortical collecting duct cells 
(CCD).
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Gender differences in urinary Ca2+ excretion
To investigate whether sex differences could be noted in renal and intestinal Ca2+ handling, 24 h 
urinary Ca2+ excretion and intestinal absorption was determined in age-matched male and
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Figure 1. Mice sex d ifferences in urinary Ca2+ excretion. (A) 24 h urine Ca2+ excretion and 
C a /C r  ratio were determined in both female and male mice. Data are presented as means ± 
S.E.M. Cr, creatinine. * p < 0.05 male vs. female mice. n = 8 samples per group. (B) Intestinal 
45Ca2+ absorption into serum of male (♦ )  and female (■ ) mice after oral gavage. n = 5 animals 
per group.
female mice. Body weight (26.7 ± 0.8 in male vs. 25.4 ± 1.8 g in female) and diuresis (1.3 ± 0.5 in 
male vs. 1.1 ± 0.3 ml/24 h in female) was not significantly different between sexes. Male mice 
demonstrated a significant higher 24 h urinary Ca2+ excretion (4.1 ± 0.3 vs. 3.3 ± 0.2 pmol/day) 
and Ca2+/Cr ratio (0.23 ± 0.03 vs. 0.18 ± 0.02), in comparison to females (Figure 1A). Male and
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female mice consumed similar amounts of food (3.30 ± 0.02 g vs. 3.24 ± 0.03 g, respectively) 
and hence ingested comparable amounts of Ca2+ (33.0 ± 0.2 mg vs. 32.4 ± 0.3 mg, respectively). 
In addition, intestinal radioactive Ca2+ tracer uptakes were performed in male and female mice. 
Intestinal Ca2+ absorption was determined by an in vivo absorption assay, measuring serum 
levels of radioactive 45Ca2+ at several time points after oral gavage. The intestinal absorption of 
Ca2+ was similar in both males and females (Figure 1B).
Sex differences in renal expression of Ca2+ transporters
The increased urinary Ca2+ excretion and Ca2+/Cr ratio in male mice, was paralleled by a 
significant decline in the renal mRNA expression of TRPV5, calbindin-D28K, NCX1 and PCM Alb 
(Figure 2A,B). For calbindin-D28K abundance, this was confirmed by immunoblotting (Figure 3A). 
Densitometrical analysis of the immunoblots showed significantly less calbindin-D28K protein 
expression in male than in female mice (Figure 3B). Similarly, computerized analysis of 
immunohistochemical images revealed a significant decrease in TRPV5 and calbindin-D28K 
abundance in male mice as compared to female mice (Figure 4).
Localization of the androgen receptor in mouse kidney
Binding of the steroid hormone to the androgen receptor (AR) may regulate the expression of 
renal Ca2+ transporters. To investigate whether the AR is localized in TRPV5-expressing cells, 
immunohistochemical labeling of TRPV5 and the AR was performed using mouse kidney 
sections. As depicted in Figure 5, TRPV5 and the AR are co-expressed in DCT/CNT cells.
Effects o f ORX and testosterone treatment on serum and urine parameters
To specifically address the effects of androgens on renal Ca2+ handling, urinary Ca2+ excretion
was measured in sham-operated, ORX mice, and in ORX+T. Importantly, the body weight of
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Figure 2. Mice sex d ifferences in the expression o f renal Ca2 transporte rs. (A) renal 
mRNA expression of TRPV5 and calbindin-D28K were determined by real-time quantitative 
RT-PCR analysis, expressed as the ratio of HPRT, and depicted as percentage of female mice. 
(B) Similarly, mRNA expression of PM CAlb and NCX1 was determined in kidney RNA isolates 
from male and female mice. mRNA expression was corrected for endogenous HPRT.
mice between sham-operated, ORX and ORX+T groups was not different (27.1 ± 0.7, 26.1 ± 0.9, 
and 26.9 ± 0.9 g, respectively). ORX significantly decreased urinary excretion of Ca2+ (4.4 ± 0.3 
(sham-operated) vs. 2.3 ± 0.2 (ORX) pmol/day) and the Ca2+/creatinine (Cr) ratio (0.28 ± 0.05 
(sham-operated) vs. 0.16 ± 0.03 (ORX)) (Figure 6). A change in renal transport was apparent, as 
the fractional Ca2+ excretion was significantly reduced (0.94 ± 0.12 (sham- operated) vs. 0.49 ±
0.04 (ORX) %). Testosterone supplementation of ORX mice restored renal Ca2+ excretion (4.3 ±
0.3 pmol/day) and the Ca2+/Cr ratio (0.25 ± 0.03) to values comparable with the sham-operated 
mice. Table 1 summarizes the effects of ORX and testosterone replacement
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Figure 3. Mice sex d ifferences in the expression o f renal Ca2+ transporte rs. (A)
Immunoblots of protein samples (10 pg each) from homogenates of kidney tissues were labeled 
with antibodies against calbindin-D28K or p-actin. (B) Expression of calbindin-D28K protein was 
quantified by computer-assisted densitometry analysis and presented as the ratio to p-actin 
expression levels, in relative percentages compared with female mice. Data are presented as 
means ± S.E.M. * p < 0.05 male vs. female mice. n = 6 samples per group.
Sham ORX ORX+T
Ca2+ (mM) 2.8 ± 0.1 2.6 ± 0.1 2.5 ± 0.1
Testosterone (ng/dl) 499 ± 129 59 ± 11 a 1005 ± 291ab
Estrogen (pg/ml) 63 ± 16 36 ± 12 50 ± 10
PTH (pg/ml) 23.9 ± 6.5 20.7 ± 5.5 25.4 ± 7.4
1,25(OH)2Ü3 (pmol/ml) 156 ± 19 130 ± 11 143 ± 17
Table 1. Effect o f testosterone on serum  Ca2+ and ca lc io trop ic  horm ones. Serum 
concentrations of Ca2+ and calciotropic hormones in sham-operated mice and ORX mice with 
or without testosterone replacement (Sustanon 250, 250 mg/kg/week subcutaneously, 2 
weeks). PTH, parathyroid hormone; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3. a p < 0.05 vs. 
sham-operated mice; b p < 0.05 vs. ORX mice. n = 8 samples per parameter.
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therapy on systemic Ca2+ handling, calciotropic hormones, and sex hormones. Serum 
testosterone levels were effectively reduced in untreated ORX mice, whereas supplementation 
with Sustanon 250 resulted in significantly higher serum testosterone levels. Importantly, serum 
PTH, 1,25(OH)2D3, and estrogen levels were not significantly different in ORX mice as compared 
to sham-operated and ORX+T mice.
Effects o f ORX and testosterone treatment on the expression of renal Ca2+ transporters 
To address the molecular mechanism responsible for the effect of testosterone on renal Ca2+ 
handling, the expression of TRPV5, calbindin-D28K, PMCAlb and NCX1 were examined using 
real-time quantitative reverse transcriptase (RT) PCR, immunoblotting and 
immunohistochemistry. ORX mice demonstrated a 3.2-fold increase in TRPV5 and a 2.0-fold 
increase in calbindin-D28K mRNA expression as compared to sham-operated mice (Figure 7A). 
Conversely, administration of testosterone to ORX mice (ORX+T) resulted in a significant 
decrease of TRPV5 and calbindin-D28K mRNA expression (Figure 7A, dashed bars). Similarly, 
NCX1 was increased in the ORX group, while both PM CAlb and NCX1 were decreased in the 
ORX+T group (Figure 7B). As determined by semi-quantitative immunoblotting, protein 
abundance of calbindin-D28K was increased in ORX mice compared to sham-operated mice 
(Figure 8A, B). In accordance, calbindin-D 2 8 K protein abundance in ORX+T mice was 
comparable to the sham-operated controls (Figure 8A, B). In line with the above, 
semi-quantification of protein expression, the immunohistochemical labeling experiments 
revealed a significant up-regulation of TRPV5 (2.7-fold) and calbindin-D28K (1.5-fold) signal in 
ORX mice when compared to sham-operated mice (Figure 9). Furthermore, treatment of ORX 
mice with testosterone led to a significant decline in TRPV5 and calbindin-D28K signals (Figure 9).
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Figure 4. Gender d ifferences in prote in expression o f Ca2+ transporte rs  in mouse kidney.
(A) Representative images of immunohistochemical staining of TRPV5 and calbindin-D28K in 
male and female kidney cortex. (B) Semi-quantification of renal TRPV5 and calbindin-D28K 
protein abundance was performed by computerized analysis of immunohistochemical images. 
Data were calculated as IOD (arbitrary units) and depicted as percentage of female mice. Data 
are presented as means ± S.E.M. * p < 0.05 male vs. female mice. n = 8 samples per group.
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TRPV5 AR DIC
Figure 5. C haracterization o f AR loca lization in kidney. Confocal laser microscopy of 
double-labeled mouse kidney sections using guinea pig anti-TRPV5 (TRPV5, upper left panel) 
and rabbit anti-AR antibodies (AR, upper middle panel). Differential interference contrast (DIC, 
upper right panel) and overlay (lower panel) are also presented.
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Figure 6. D ifferences in urinary Ca2+ excretion o f Sham-operated, ORX and ORX+T mice.
24 h urine Ca2+ excretion and Ca2+/Cr ratio were determined in Sham-operated, ORX and 
ORX+T mice. Data are presented as means ± S.E.M. Cr, creatinine. * p < 0.05 male vs. female 
mice. n = 8 per group.__________________________________________________________________
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Figure 7. E ffects o f ORX and testosterone treatm ent on renal mRNA expression o f Ca2+ 
transporters. (A) Renal mRNA expression of TRPV5 and calbindin-D28K in sham-operated, ORX 
and ORX+T mice were analyzed by quantitative real-time RT-PCR analysis, (B) Expression of 
PMCA1b and NCX1 in the kidney of sham, ORX, and ORX+T mice. In all cases expression was 
normalized to HPRT and depicted as percentage of sham-operated m ice .____________________
Effect o f DHT on transcellular Ca2+ transport in rabbit kidney CNT and CCD primary cell cultures 
The effect of androgen on renal Ca2+ handling in the ORX mice may be facilitated by the possible 
interference of other organs (e.g. bone). Therefore, the effect of androgen on TRPV5-mediated 
Ca2+ transport was studied in an isolated renal cell system.Primary cultures of rabbit CNT/CCD 
cells were grown to confluence on permeable supports. The cells were treated with DHT or
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Figure 8. E ffects o f ORX and testosterone treatm ent on renal prote in abundance o f 
ca lb ind in-D 28K. (A) Immunoblots of protein samples (10 pg each) from homogenates of kidney 
tissue of sham-operated, ORX and ORX+T mice were labeled with antibodies against 
calbindin-D28K or p-actin. (B) Expression of calbindin-D28K protein was quantified by 
computer-assisted densitometry analysis and presented as the ratio to p-actin expression levels, 
in relative percentages compared with sham-operated mice. Data are presented as means ±
S.E.M. Sham, sham-operated mice; ORX, orchidectomized mice; ORX+T, orchidectomized mice 
treated with Sustanon 250 subcutaneously (250 mg/kg/week) for 2 weeks. * p < 0.05 vs. 
sham-operated mice. # p < 0.05 vs. ORX mice. n = 8 samples per group.
vehicle, and the rate of transepithelial Ca2+ transport was determined. Application of 10 nM DHT 
to the polarized confluent cell monolayers for 24 h significantly inhibited the net 
apical-to-basolateral transport of Ca2+ (p<0.02) (Figure 10).
105
Chapter 4
Sham ORX ORX+T
B
£  Eo  «■o
(0 o
c >  _
I '«/>
m £
a  QO'
350
300
250
200
150
100
50
0
200  -
73 e ' I S O
0>m_oj o
■E sS 100 -
Q <2
50 -
Sham ORX ORX+T Sham ORX ORX+T
Figure 9. Im m unohistochem ica l sta in ing  o f renal Ca2 transporte rs  in sham-operated, 
ORX and ORX+T mice. (A) Representative images of immunohistochemical staining of TRPV5 
and calbindin-D28K in kidney cortex of sham-operated, ORX and ORX+T mice. (B) 
Semi-quantification of renal TRPV5 and calbindin-D28K protein abundance was performed by 
computerized analysis of immunohistochemical images. Data were calculated as IOD (arbitrary 
units), depicted as percentage of sham-operated mice, and presented as means ± S.E.M. Sham, 
sham-operated mice; ORX, orchidectomized mice, ORX+T, orchidectomized mice treated with 
Sustanon 250 subcutaneously (250 mg/kg/week) for 2 weeks. * p < 0.05 vs. sham-operated mice.
p < 0.05 vs. ORX mice. n = 8 samples per group.
D iscussion
The present study is to our knowledge the first to delineate the effect of androgens on renal 
handling of Ca2+ and TRPV5-mediated active Ca2+ transport. We find that testosterone 
contributes significantly to the sex differences observed in renal Ca2+ handling. This conclusion is 
based on the following observations: First, male mice have a greater urinary Ca2+ excretion
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compared to females, a feature accompanied by a reduced renal expression of Ca2+ transport 
proteins. Second, androgen-deficient ORX mice show a significant decline in the urinary 
excretion of Ca2+, which normalizes after testosterone replacement. Similar data was obtained 
when evaluating the fractional excretion of Ca2+, suggesting that the testosterone-induced 
increase of urinary Ca2+ excretion is due to inhibition of tubular Ca2+ reabsorption. Forth, the 
mRNA and protein abundance of renal Ca2+ transporters was up-regulated in ORX mice, while 
the expression of renal Ca2+ transporters was suppressed by resupplying these mice with 
testosterone. Fifth, the serum 1,25(OH)2D3, PTH, and estrogen levels did not differ between the 
sham-operated, ORX and ORX+T mice, suggesting that androgens may affect the transcription 
of the renal Ca2+ transporters. Finally, inhibition of transcellular Ca2+ transport after DHT 
treatment was observed in rabbit kidney CNT/CCD primary cell cultures.
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Figure 10. E ffect o f DHT on net apical to  basolateral Ca2+ transpo rt in prim ary cu ltu res o f 
rabbit CNT/CCD cells. Transepithelial Ca2+ transport across confluent monolayers was 
measured in the absence or presence of 10 nM DHT. At the end of the 90 minutes incubation 
period apical medium was collected to determine the amount of Ca2+ transport across the 
monolayer. Transepithelial Ca2+ transport is expressed nmol/h/cm2. Data from 3 independent 
experiments (n = 21 per condition) was combined. * p < 0.001.
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Our observation that male mice have an increased urinary Ca2+ excretion than females is in 
agreement with previous clinical studies evaluating gender differences in humans (1, 2). ORX 
induce hypocalciuria in male mice, while testosterone supplementation normalized their urinary 
Ca2+ excretion. This was accompanied by a decreased expression of renal Ca2+ transport 
proteins such as TRPV5, NCX1, PM CAlb and calbindin-D28K. Previous studies evaluating the 
effect of estrogen on renal Ca2+ handling, demonstrated that the hormone exerts a direct effect 
on renal Ca2+ reabsorption via up-regulation of these Ca2+ transport proteins (3). Thus, both 
testosterone and estrogen have opposing regulatory properties in terms of renal expression of 
Ca2+ transporters. Similar sex differences have been found for the regulation of the 
thiazide-sensitive sodium-chloride cotransporter (NCC) expressed in the DCT. Chen et al. (14) 
demonstrated that the density of NCC (quantified by [3H]metolazone binding) was two-fold higher 
in female, than in male rats. Furthermore, ORX resulted in an increase in metolazone binding 
sites in males, whereas ovariectomy decreased the binding density in females (14).
Role of calciotropic hormones in androgen regulation?
In the present study serum 1,25(OH)2D3 and PTH did not vary between sham-operated, ORX, 
and ORX+T mice, suggesting that up-regulation of TRPV5 in ORX mice is not mediated by these 
calciotropic hormones. Conversely, androgens have previously been suggested to affect Ca2+ 
homeostasis by altering the regulation of calciotropic hormones. Some discrepancy has been 
reported in the literature; in a study by Nyomba et al. (15), the serum concentration of
1,25(OH)2D3 was shown to decrease after ORX in male rats, while testosterone replacement 
therapy restored serum 1,25(OH)2D3 to normal levels. In agreement with our data, a study by 
Hope et al. (16), reported that ORX performed in male rats could not be associated with any 
changes in active 1,25(OH)2D3 levels. Possible explanations for these discrepancies are 
currently unclear and may not exclude a contribution of 1,25(OH)2D3 to overall Ca2+ handling by
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androgens.
Here, we showed that the AR is present in TRPV5-expressing cells, which is in line with 
earlier results demonstrating the presence of the AR in the distal part of the nephron (17). It is 
presently unclear whether the activated AR is directly or indirectly involved in decreasing the 
expression of the investigated Ca2+ transporters and hence a higher urinary Ca2+ excretion. We 
investigated this directly by expressing a 5 kb fragment (-5,000 to +1) of the mouse TRPV5 
promoter coupled to the luciferase gene in androgen-responsive human prostate 
adenocarcinoma (LnCAP) cells (data not shown). However in these cells, we were not able to 
observe any effect of DHT on luciferase activity. Currently, it remains unclear how large the 
promoter fragment should be to adequately drive TRPV5 transcription in response to androgens. 
In addition, transcriptional regulators that could be necessary for the androgen-mediated 
inhibition may be absent in this cell system. The exact mechanism whereby testosterone alters 
TRPV5 expression remains to be clarified.
Short vs. long term effects of androgens on Ca2+ homeostasis
In this study, we aimed to evaluate the primary effect of androgens on renal Ca2+ handling. The 
inhibitory effect of testosterone on renal Ca2+ reabsorption seems at variance with the increased 
Ca2+ excretion found in elderly men with androgen deficiency, which is thought to be associated 
with male osteoporosis during aging (18-20). However, the short-term renal effects of androgen 
deficiency presented here should be separated from the long-term consequences of andropause 
in terms of bone remodeling. This issue was appropriately addressed in a study of Mauras et al. 
(13). They studied young men who were made hypogonadal for different time periods by 
injection of a gonadotropin-releasing hormone agonist. The contribution of Ca2+ released from 
bone to urine losses was shown to remain unchanged for 4 weeks, but, thereafter, significantly 
increased upon 10 weeks after induction of hypogonadism. In our experiments, we studied the 
effects of androgen deficiency in mice within the time frame of 2 weeks, to avoid the possible
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interference of Ca2+ released from bone. We could clearly delineate a change in intrarenal Ca2+ 
transport. Furthermore, we substantiated our in vivo results by experiments in isolated rabbit 
kidney CNT/CCD primary cell cultures. These cells express endogenous TRPV5 and 
calbindin-D28K, and are a consistent model to investigate active transepithelial Ca2+ transport ex 
vivo (11). Here, we found that incubation with the non-aromatizable androgen DHT (10 nM, 
which is in line with a physiological concentration of testosterone) for 24 h resulted in a marked 
inhibition of apical-to-basolateral Ca2+ transport. This finding further supports the inhibitory role of 
androgen on the regulation of renal active Ca2+ reabsorption in vivo.
In conclusion, this study provides evidence that androgens contribute to sex differences 
observed in renal Ca2+ handling via inhibiting the expression of renal Ca2+ transport proteins. 
Furthermore, this effect is independent of calciotropic hormones or estrogen.
Methods
Animal experiments
Experiment A: male (n = 15) and female (n =15) C57BL6 mice, 12 weeks of age, were housed in 
a light and temperature-controlled room with ad libitum access to deionized drinking water and 
standard chow (0.28 % (wt/wt) NaCl, 1.00 % (wt/wt) Ca2+, 0.22 % (wt/wt) Mg2+; LabDiet, USA). 
After acclimatization, mice were housed in couples in metabolic cages and 24 h urine was 
collected. Animals were sacrificed at the end of the experiment. Blood was colleted and the 
kidneys dissected out and processed for further analyses.
Experiment B: male C57BL6 mice (n = 36), 12 weeks of age, were housed and fed as 
described for experiment A. After acclimatization, the mice were randomly allocated to either a 
sham or bilateral ORX operation under (1.5 %) halothane anesthesia and divided into three 
groups (n = 12 in each group): (i) sham-operated mice serving as control animals; (ii) ORX mice 
treated with vehicle; (iii) ORX mice treated with Sustanon 250 (ORX+T) subcutaneously (250
Chapter 4
110
mg/kg/week; Sustanon 250 is a long-acting mixture of testosterone ester (21)) (Organon 
Laboratories Ltd, Cambridge, UK). The operation was performed under halothane anesthesia. 
After 2 weeks, these mice were housed in couples in metabolic cages and 24 h urine was 
collected. Thereafter, animals were sacrificed as in experiment A. The animal ethics boards of 
the National Defense Medical Center (Taipei, Taiwan) approved all animal experimental 
procedures.
Urine and serum analyses
Urine and serum concentrations of Cr and Ca2+ were determined using an automated analyzer 
(AU 5000 chemistry analyzer, Olympus, Tokyo, Japan). Serum 1,25(OH)2D3 levels were 
determined by an [I125]1,25(OH)2D3 RIA assay (DiaSorin, Stillwater, MN, USA). Serum PTH 
concentrations were determined by IMMULITE PTH assay (Siemens Medical Solutions 
Diagnostics, Los Angeles, CA, USA). Both serum testosterone and estrogen concentrations 
were measured using chemiluminescence immunoassays (Siemens Medical Solutions 
Diagnostics, Tarrytown, NY, USA).
Determination of intestinal Ca2+ absorption
Male and female wild-type mice (7-8 weeks of age) breed off a C57Bl/6 strain, were used as 
previously described (22). Radioactive 45Ca2+ was given by oral gavage, after an overnight fast. 
Intestinal absorption was determined by repeatedly measuring serum 45Ca2+ content as 
described in detail (22). Briefly, the solution used to measure Ca2+ absorption contained 0.1 mM 
CaCl2, 125 mM NaCl, 17 mM Tris, 1.8 g/l fructose and 20 |iCi 45CaCl2/ml. Blood samples were 
obtained at 1, 2, 3, 4, and 7 min after oral gavage. Serum 45Ca2+ content was determined by 
liquid scintillation counting. Changes in serum Ca2+ concentration was calculated from the 45Ca2+ 
content of the serum samples and the specific activity of the administrated 45Ca2+.
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To determine mRNA expression levels, total RNA was extracted from kidney using Trizol Total 
RNA Isolation Reagent (Sigma, St Louis, MO, USA). The obtained total RNA was subjected to 
DNase treatment to prevent genomic DNA contamination. Thereafter, 1.5 |jg of total RNA was 
reverse transcribed by Moloney-murine leukemia virus-reverse transcriptase (Promega, Madison, 
WI, USA), as described previously (3). The obtained cDNA was used to determine TRPV5, 
calbindin-D28K, NCX1 and PMCA1b mRNA levels in kidney cortex by real-time quantitative 
RT-PCR (ABI Prism 7700 Sequence Detection System, PE Biosystems, Rotkreuz, Switzerland). 
The expression level of the housekeeping gene hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) was used as an internal control to normalize differences in RNA extractions 
and reverse transcription efficiencies. The primers and fluorescent probes used are as previously 
described (MDBIO, Taipei, Taiwan) (3, 23).
For protein expression quantification, total kidney lysates of the mice were prepared and 
analyzed as described previously (24). Briefly, proteins in kidney lysates were separated using 
SDS-PAGE and subsequent electro-transferred to polyvinylidene fluoride membranes 
(Immobilon-P, Millipore Corporation, Bedford, MA). Blots were incubated with rabbit 
anti-calbindin-D28K (Sigma, St Louis, MO, USA) or rabbit p-actin (Sigma) polyclonal antibodies. 
Subsequently, the blots were incubated with a goat anti-rabbit peroxidase-labeled secondary 
antibody (Sigma). Immunoreactive protein was detected by the enhanced chemiluminescence 
method (Pierce, Rockford, IL, USA). Protein expression of the immunopositive bands was 
quantified by the use of pixel density scanning and computed calculation using the Molecular 
Analyst software of BioRad Laboratories (Hercules, CA, USA).
Immunohistochemical labeling o f renal Ca2+ transporters
Kidneys were immersion-fixed in 1 % (wt/v) periodate-lysine-paraformaldehyde for 2 h at room 
temperature, and incubated overnight at 4 °C in phosphate-buffered saline containing 15 % (wt/v)
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sucrose. Subsequently, 7 |jm sections were cut from liquid nitrogen frozen kidney tissue samples 
for immunohistochemistry as described previously (25). For detection of TRPV5 protein 
abundance, kidney sections were stained with a guinea pig anti-TRPV5 antibody, as described 
(25), and a mouse anti-calbindin-D28K antibody (Sigma). TRPV5 and calbindin-D28K were 
visualized by staining those sections with goat anti-guinea pig and goat anti-mouse Alexa 
488-conjugated anti-IgGs (Sigma), respectively. Next, to semi-quantify the TRPV5 protein 
expression, 5 digital images of each kidney section were taken with a Zeiss Axioskop 
microscope (Carl Zeiss, Inc., Thornwood, NY, USA) and the integrated optical density (IOD) was 
measured by computer analysis with the Image-Pro Plus version 3.0 software (Media 
Cybernetics, Silver Spring, MD).
Double staining using anti-TRPV5 and a rabbit anti-AR antibody (N-20, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was performed using the TSA™ Plus Fluorescein 
amplification system (Perkin Elmer, Groningen, The Netherlands) for TRPV5 and a goat 
anti-rabbit IgG conjugated to Alexa 594 for visualization of the AR. Confocal pictures were 
acquired with an Olympus FV1000 laser scanning microscope (Center Valley, PA, USA). 
Differential interference contrast (DIC) was superimposed on the fluorescence images.
Primary cultures of rabbit CNT/CCD and determination o f transepithelial Ca2+ transport 
Rabbit kidney CNT and CCD cells were immunodissected from the kidney cortex of New 
Zealand White rabbits (5 weeks of age) using R2G9 antibodies and set in primary culture on 
permeable filter supports (0.33 cm2; Corning-Costar, Cambridge, MA, USA), as previously 
described in detail (26). The culture medium was a 1:1 mixture of Dulbecco's modified Eagle's 
medium and Ham's F12 (Gibco, Paisley, UK) supplemented with 5 % (v/v) decomplemented fetal 
calf serum, 10 |jg/ml ciproxin, 10 |jl/ml nonessential amino acids, 5 |jg/ml insulin, 5 |jg/ml 
transferrin, 50 nM hydrocortisone, 70 ng/ml prostaglandin E1 , 50 nM Na2 SeO3 , 5 pM 
triiodothyronine, and 5 jiM indomethacin. Before incubation with DHT, the transepithelial
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resistance (R) was measured to assure the integrity of the cells. In all filters used, the R was 
greater than 400 Q x cm2.
Five days after seeding, cells were incubated for 24 h with 10 nM 
(5a,17|3)-17-Hydroxy-androstan-3-one (dihydrotestosterone (DHT); Sigma), or vehicle (ethanol 
absolute), at the apical and basolateral compartments. Transport assays were performed on 
confluent monolayers the following day as described previously (26, 27). Briefly, Confluent 
monolayers were washed twice and pre-incubated in physiological salt solution (140 mM NaCl, 2 
mM KCl, 1 mM K2HPO4, 1 mM MgCl2, 1 mM CaCl2, 5 mM glucose, 5 mM L-alanine, 5 |jM 
indometacin, and 10 mM HEPES-Tris (pH 7.4)) for 15 min at 37°C. The cell monolayers were 
subsequently incubated in physiological salt solution for another 90 min to measure 
transepithelial Ca2+ transport. During the transport assay 10 nM of DHT was added to both the 
apical and basolateral compartments. At the end of the experimental period, the apical medium 
was removed and assayed for total Ca2+ concentrations, using a colorimetric assay kit (Roche, 
Mannheim, Germany). Under these experimental conditions, net apical-to-basolateral Ca2+ 
transport is linear for at least 3 h. Transepithelial Ca2+ transport was determined as nmol/h/cm2.
Statistical analyses
Values are expressed as means ± S.E.M. Statistical significance (p < 0.05) between groups was 
determined by an unpaired Student's t-test (for comparisons between two individual groups), or 
by one-way analysis of variance (for multiple comparisons). All analyses were performed using 
the Statview Statistical Package Software (Power PC, version 4.51, Berkeley, CA, USA).
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Abstract
Calcitonin (CT) is known to affect renal Ca2+ handling. However, it remains unclear how CT 
affects Ca2+ transport in the distal convolutions. The aim of this study was to investigate the 
contribution of the renal epithelial Ca2+ channel, TRPV5, to renal Ca2+ handling in response to CT. 
C57BL/6 mice received a single bolus injection of CT, which significantly reduced the urinary 
Ca2+ excretion. In addition, urinary Na+ and K+ excretion also decreased after CT administration. 
No apparent changes in renal TRPV5 and calbindin-D28K mRNA could be detected between CT- 
and vehicle-treated mice. To evaluate whether TRPV5 activity is needed for the CT-induced 
increase in Ca2+ reabsorption, mice with genetic ablation of TRPV5 (Trpv5-/~), were employed. 
Trpv5'/~ mice as well as their wild type (Trpv5++) controls, received three bolus injections of CT 
over a 40 hr study period. Overnight (16 hr) as well as the subsequent 24 hr urine was collected. 
Overnight urinary Ca2+ excretion was reduced in both Trpv5-/~ and Trpv5++ mice after a bolus 
injection of CT. The subsequent 24 hr urinary excretion of Ca2+ which was collected after the 
third bolus injection, showed no effect of CT on renal Ca2+ handling in either mice group. 
Accordingly, CT did not alter the intrarenal protein abundance of TRPV5 and Calbindin-D 2 8K after 
three bolus injections of CT. In conclusion, CT augments the renal reabsorptive capacity for Ca2+. 
This increase is likely to occur independently of TRPV5.
Introduction
Disturbances in the systemic Ca2+ concentration often result in instability of the neurological and 
cardiac systems (e.g. hypercalcemia causes fatigue, nausea, and abnormal heart rhythms (1)). 
Thus, maintenance of the serum Ca2+ concentration plays an important role in stabilizing these 
physiological processes. Several hormones have been known to affect the systemic Ca2+ 
concentration. Calcitonin (CT) is a 32 amino-acid peptide synthesized by posttranslational 
processing in the C cells of the thyroid gland in mammals (2). CT acts primarily by inhibiting
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osteoclast-mediated bone resorption and is secreted in response to increases in systemic Ca2+ 
concentration (2). Historically, CT has been extensively used in treating hypercalcemia, 
osteoporosis and Paget's disease (2). Throughout the kidney and elsewhere, CT acts primarily 
by activating the adenylate cyclase pathway (3, 4).
In the kidney, vectorial NaCl transport within the thick ascending limb (TAL) drives 
paracellular transport of Ca2+. Administration of CT to rats increases the renal reabsorption of 
Ca2+, which is in part achieved by increasing the reabsorption of Ca2+ in the TAL. Here 
application of CT also increases vectorial NaCl transport (5-7). Active transcellular Ca2+ transport 
is restricted to the distal convolutions. Here, luminal Ca2+ enters across the apical membrane via 
the epithelial Ca2+ channel, transient receptor potential vanilloid 5 (TRPV5) (8, 9). Studies in 
rabbit suggest that CT exerts its effect on Ca2+ reabsorption only in the distal convoluted tubule 
(DCT), while no stimulation occurs in the connecting tubule (CNT) (10). In addition, CT fails to 
stimulate cAMP accumulation in the CNT of rabbits (11). Our group has also been unable to 
show stimulatory effects of CT on cAMP production in rabbit primary CNT cultures (12). In the 
rabbit, TRPV5 localizes primarily to the CNT where CT does not affect Ca2+ reabsorption. 
However, in mouse, TRPV5 is highly expressed in apical membrane domains of particularly the 
late distal convoluted tubule (DCT2), with a gradual decrease along CNT and initial collecting 
duct (iCD) (13, 14), suggesting that TRPV5-mediated Ca2+ uptake predominates in the DCT2 
segment. Similarly, in rat, immunohistochemical data suggests that TRPV5 expression appears 
in the DCT2 and is further observed in the CNT (15). The intrarenal distribution of TRPV5 in 
human is currently not known.
In comparison to rabbit, the boundaries defining the DCT/CNT/iCD regions in human, rat, 
and mouse are morphologically less well defined, with cell types from different segments 
intermingled. In the kidney of rats, the “bright” portion of the DCT retains responsiveness to CT, 
resulting in increased cAMP production (4). CT binding sites have been identified in the rat 
kidney, including the TAL and DCT (16). Detailed micropuncture studies performed by Elalouf et
Chapter 5
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al. investigated the effects of CT on electrolyte transport in the distal tubules of rats deprived of 
vasopressin, parathyroid hormone (PTH), and glucagon. Here they demonstrated that NaCl, as
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as PTH affect TRPV5-mediated Ca2+ transport. PTH supplementation to parathyroidectomized 
rats increases the expression of TRPV5, independent of serum 1,25-dihydroxyvitamin D3 levels, 
suggesting that perhaps intracellular elevations in cAMP affect the abundance of TRPV5 (18). In 
addition, cAMP generation has been shown to increase TRPV5 single channel activity via a 
PKA-dependent mechanism (19). However, it is unclear whether there is a functional overlap 
between PTH and CT in the DCT2 regions of rats and mice and whether the CT-induced 
increase in cAMP could lead to a similar activation in the DCT2 segment as PTH.
In order to better understand the molecular actions of CT on overall renal Ca2+ balance 
and to delineate the potential effects of CT on TRPV5-dependent Ca2+ reabsorption, several 
experimental series were performed in wildtype and TRPV5-deficient mice. Due to the rapid 
action of CT we investigated the short-term effects by of CT on the renal Ca2+ excretion.
concentration 16 hrs after a bolus injection CT. Data is presented as mean ± SEM. * indicates statistical 
significance (p<0.05)._____________________________________________________________________
well as Ca2+ transport was increased by CT infusion (17). Other cAMP-elevating hormones such
A B
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Figure 1. CT reduces urinary Ca2+ excretion. (A) Renal Ca2+ excretion and (B) serum Ca2+
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Results
CTincreases renal Ca2+ reabsorption in mice
To assess the acute effects of CT, 16 hr urine from overnight collections was obtained following 
a bolus injection of the hormone (20U/100g bodyweight) or vehicle. The effect of overnight CT 
exposure on renal and systemic Ca2+ handling is depicted in Figure 1. Administration of CT 
resulted in a significant decrease in the urinary excretion of Ca2+ (p<0.05). Serum Ca2+ 
concentrations were slightly reduced after overnight CT administration (p<0.05). Urinary 
excretion of Na+ and K+ showed a significant decrease after CT injection (Table 1). In addition, 
the urinary Na+/K+ ratio remained unchanged excluding an effect on the collecting duct. These 
data are consistent with a primary effect of CT on electrolyte transport in the TAL and DCT (5-7,
Urine Serum
Diuresis
(ml)
Na'
(pmol)
K'
(pmol)
Na'/K’
ratio
Na’
(mM)
K* (mM)
Control
1.21 ± 
0.11
268 ± 
32
639 ±30
0 42 ± 
0.03
150 ± 
0.4
5.34 ± 
0.11
CT
0.9S ± 132 ± 305 ± 0 44 ± 152 ± 5.301
0.18 16* 50* 0.02 0.5 003
Table 1. Serum concentrations and urinary excretion of Na+ and K+ after a bolus 
injection CT. Data is presented as mean ± SEM. N=6 animals per group. * indicates statistical 
significance (*p<0 .05 versus controls). CT, calcitonin.
CT does not change the renal mRNA expression of TRPV5 and Calbindin-D28K
To evaluate whether the increased Ca2+ reabsorption could in part be due to transcriptional
changes in Ca2+ transport proteins located in the distal convolutions, semi-quantitative PCR was
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used to estimate TRPV5 and Calbindin-D28K abundance. As can be seen in Figure 2, no changes 
were observed in the renal mRNA expression of either transcript. Although CT did not modulate 
the changes of TRPV5, it does not exclude the potential involvement of TRPV5. Therefore, we 
investigated the effect of CT in Trpv5+/+ and 7rp\/5"/" mice after 1 and 3 injections of CT.
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Figure 2. Semi-quantitative mRNA expression of TRPV5 and Calbindin-D28K after overnight 
bolus injection of CT. Representative histograms of mRNA expression of (A) TRPV5 and (B) 
Calbindin-D28K in kidney. Data are presented as mean ± SEM.
CT stimulates Ca2+ reabsorption in Trpv5''' mice
Administration of CT to Trpv5+/+ and Trpv5'/' mice resulted in a decreased overnight urinary Ca2+ 
excretion in both groups. However, after repeated administration of CT, the urinary Ca2+ 
excretion returned to normal in both Trpv5+/+ and Trpv5'/  mice, as compared to their 
corresponding vehicle-injected controls (Figure 3). Serum Ca2+ concentrations were measured 
after 40 hrs, but no difference was observed after CT administration in either strain (Figure 3). 
This is in line with the observed rapid effect of CT.
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Figure 3. Renal Ca2+ excretion after 1 and 3 bolus injections spaced over 40 hrs in
Trpv5+/+ and Trpv5'f' mice. (A) 16 hrs urinary Ca2+ excretion after a single bolus injection of CT (B) 
and the consecutive 24 hrs of urinary Ca2+ excretion after 3 injections. (C) Serum Ca2+ concentrations 
after 3 CT bolus injections spaced over 40 hrs. Data is presented as mean ± SEM. * p<0.05 versus 
Trpv5+/+ controls. # p<0.05 versus T rp v 5 controls.
Renal protein expression of Ca2+ transporters remains unaltered after 3 CT injections 
Kidneys retrieved from Trpv5+/+ and Trpv5'/  mice by the end of the experiment were used to 
assess the effects of CT on renal Ca2+ transporter expression. TRPV5 and Calbindin-D28K protein 
abundance was semi-quantified by immunohistochemistry (Figure 4) and immunoblotting (Figure 
5), respectively. Computerized analysis of immunohistochemical images did not reveal any 
changes in TRPV5 protein expression after CT administration in Trpv5+/+ mice compared to their 
vehicle- injected control Trpv5+/+ mice (Figure 4). This is in line with the observation that CT 
affects renal Ca2+ transport independent of TRPV5. In addition, the renal Calbindin-D28K protein 
expression remained unchanged after CT administration in Trpv5'/' mice (Figure 4-5). The 
Calbindin-D28K protein expression of Trpv5'/' mice was significantly reduced compared to Trpv5+/+ 
mice (20) (Figure 4-5).
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Figure 4. Immunohistochemical staining of renal Ca2 transporters after 3 bolus injections
in Trpv5+/+ and Trpv54' mice. Representative images of immunohistochemical staining of (A) TRPV5 
and (B) Calbindin-D28K in kidney cortex. Semi-quantification of renal (C) TRPV5 and (D) Calbindin-D28K 
protein abundance was performed by computerized analysis of immunohistochemical images. Data were 
calculated as integrated optical density (IOD; arbitrary units) and depicted as percentage of Trpv5+/+
controls. Data is presented as mean 
animals per group.
± SEM. * p<0.05 versus Trpv5 vehicle-injected controls. N=6
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Figure 5. Effects of CT on renal Calbindin-D28K protein expression in Trpv5*'* and Trpv5'/' 
mice. (A) Immunoblots of protein samples (10^g each) from homogenates of kidney tissue were labeled 
with antibodies against Calbindin-D28K. (B) Expression of Calbindin-D28K protein was quantified by 
computer-assisted densitometry analysis and presented as the ratio to p-actin expression levels in relative 
percentages. Data are presented as mean ± SEM. * indicates statistical significance (p<0.05) versus 
Trpv5+/+ controls. N=6 animals per group.
Discussion
A bolus injection of CT significantly reduced the urinary excretion of Ca2+ in wildtype mice. This 
decrease was associated with a reduction in the urinary Na+ and K+ excretion, leaving the urinary
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Na+/K+ ratio unchanged. These data are consistent with the previously reported effects of CT on 
stimulating TAL and DCT transport of NaCl and K+ (6, 7, 17, 21). Earlier studies in the TAL of 
mice and rats have demonstrated that CT activates NaCl transport only in the cortical TAL (6, 21). 
This segment of the TAL is also thought to drive paracellular Ca2+ reabsorption in these species. 
Although never delineated in detail, CT is likely to activate a cAMP cascade leading to increased 
NKCC2 transport, perhaps via increased membrane trafficking and phosphorylation (5, 6, 22). 
Currently, it remains unknown which transporter CT stimulates in the DCT (17). One option is the 
thiazide-sensitive NCC transporter that resides there.
A significant, albeit small, change in serum Ca2+ concentrations was observed after 
overnight CT administration. Earlier reports showing that infusion of CT, depending on dose, 
acutely reduces serum Ca2+ concentrations, that frequently reverts to normal range within one 
day (23). In line with this, no change was observed in systemic Ca2+ concentrations after 3 
injections of CT spaced over 40 hrs. One may suggest that the reduced excretion of Ca2+ in the 
presence of CT occurs to compensate for the acute surge in systemic Ca2+ concentrations 
normally associated with CT administration. However, in thyroparathyroidectomized (TPTX) rats, 
Ca2+ infusion prior to CT treatment was given in order to avoid hypocalcemia in the animals. In 
these TPTX rats, CT was still able to reduce the fractional excretion of Ca2+ despite 
normocalcemia (24). This is consistent with a direct effect of CT on the kidney. The effect of CT 
on urinary Ca2+ excretion is also absent after repeated administration of CT to either Trpv5+/+ or 
Trpv5'/~ mice. Reduced surface expression of CT receptors and decreased mRNA expression 
has been shown to explain such escape phenomena in other cell types (25). This may also 
explain why patients with a CT-secreting tumor frequently have normal systemic concentrations 
of Ca2+ (26).
The present study was initiated to investigate the potential effect of CT on 
TRPV5-mediated Ca2+ reabsorption. Injections of CT for 16 or 40 hrs did not change the renal 
abundance of TRPV5. In addition, Trpv5+/+ and Trpv5-/~ mice responded in a similar manner to
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CT administration. Given the data obtained in these experimental models, it is likely that the 
effect of CT on renal Ca2+ transport occurs independently of TRPV5. Although CT does not affect 
TRPV5-mediated Ca2+ reabsorption, it is clear from this study that CT strongly stimulates renal 
Ca2+ reabsorption. The stimulatory effect of CT is likely to occur primarily through changes in 
Ca2+ transport, as previously described (6, 7, 21). It should be stated that although the effects of 
CT on renal Ca2+ transport are present in Trpv5+/+ as well as in Trpv5'/~ mice, and that TRPV5 
expression is unaltered after CT administration, does not fully exclude an effect upon TRPV5. 
Although unlikely, a lack of stimulation of CT on TRPV5 in Trpv5'/~ mice, may be masked due to 
the pronounced effect of CT in the TAL.
In the rat, CT has been shown to increase NaCl as well as Ca2+ transport in the DCT (17), 
thus vectorial transfer of Ca2+ does occur to a greater extent in the presence of CT. The present 
study suggests that these effects occur largely independent of TRPV5. In addition, 
microperfusion experiments in rabbits show that CT stimulates Ca2+ transport in the early DCT, 
where TRPV5 is not expressed (10). This raises the question, how does Ca2+ transport occurs in 
the early DCT and does it contribute significantly to overall renal Ca2+ handling? Further studies 
are needed to determine the potential effect of CT on electrolyte transporters in these segments.
In conclusion, overnight CT administration increases renal Ca2+ reabsorption in mice. 
This effect occurs independently of TRPV5 as no change can be detected in TRPV5 and 
Calbindin-D28K expression and similar responses to CT is observed in Trpv5+/+ and Trpv5-/~ mice.
Chapter 5
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Experimental protocol 1
Male C57BL/6 mice (12 weeks of age) were housed in a light and temperature-controlled room 
with ad libitum access to deionized drinking water and standard chow (0.28 % (wt/wt) NaCl, 1.00
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% (wt/wt) Ca, 0.22 % (wt/wt) Mg; LabDiet, USA). Mice were injected with a single dose of CT 
20U/100g bodyweight (Novartis Pharmaceuticals, Taiwan, n=6) or vehicle (n=6) and placed in 
metabolic cages. After 16 hrs, overnight urine was collected and the animals were sacrificed 
under halothane anesthesia. Blood was obtained via orbital puncture before cervical dislocation. 
The kidneys were dissected out and snap frozen for RNA extraction. The animal ethics boards of 
the National Defense Medical Center (Taipei, Taiwan) approved all animal experimental 
procedures.
Experimental protocol 2
Trpv5-/- mice were generated by targeted ablation of the TRPV5 gene as described previously 
(20). After acclimatization, Trpv5+/+ and Trpv5-/- mice were injected with CT (20U/100g body 
weight, n=6) or vehicle (n=6) in three subcutaneous bolus injections spaced over 40 hrs. During 
this period the mice were housed in metabolic cages. Overnight (16hr) urine was collected during 
the period between the first and second dose of CT. Subsequently, 24h urine was collected 
during the remainder of the study, where the mice received the last two injections. At the end of 
the experiment, animals were killed under halothane anesthesia, blood was removed and tissue 
samples were harvested for immunohistochemistry and Western blotting. The animal ethics 
board of the Radboud University Nijmegen approved the animal experimental procedures.
Urine and serum analyses
Urine and serum concentrations of Ca2+ were analyzed using a colorimetric assay kit (Roche, 
Mannheim, Germany). Urine and serum concentrations of Na+ and K+ were determined using an 
automated analyzer (AU 5000 chemistry analyzer, Olympus, Tokyo, Japan).
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Total RNA was extracted from kidney using Trizol Total RNA Isolation Reagent (Sigma, St Louis, 
MO, USA) as described previously (27). The obtained total RNA was subjected to DNase 
treatment to prevent genomic DNA contamination. Thereafter, 1.5 |jg of total RNA was reverse 
transcribed by Moloney-murine leukemia virus-reverse transcriptase (Promega, Madison, WI, 
USA). The cDNA was used to determine intrarenal mRNA levels of TRPV5 and calbindin-D28K in 
kidney cortex by real-time semi-quantitative polymerase chain reaction, using the ABI Prism 
7700 Sequence Detection System (PE Biosystems, Rotkreuz, Switzerland). The expression level 
of the housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT) was used 
as an internal control to normalize differences in RNA extractions and reverse transcription 
efficiencies. The primers and fluorescent probes used are as previously described (MDBIO, 
Taipei, Taiwan) (27, 28)
Immunohistochemistry
Kidney tissue was immersion fixed in 1 % (w/v) periodate-lysine-paraformaldehyde for 2 hours at 
room temperature, and subsequently incubated overnight at 4oC in phosphate-buffered saline 
(PBS) containing 15% (w/v) sucrose. The kidneys were snap frozen in liquid nitrogen and 7 |jm 
sections cut on a cryostat microtome (HM 550, MICROM International GmbH, Germany). For 
immunohistochemical detection of TRPV5, kidney sections were stained with a guinea pig 
anti-TRPV5 antibody (1:50) (8) or mouse anti-Calbindin-D28K antibody (1:1,000; Sigma). To 
visualize TRPV5 and Calbindin-D28K, sections were stained with goat anti-guinea pig Alexa 
488-conjugated anti-IgG (1:300; Sigma) and goat anti-mouse Alexa 488-conjugated anti-IgG 
(1:300; Sigma), respectively. TRPV5 protein expression was semi-quantified by taking 5 digital 
images of each kidney section on with a Zeiss Axioskop microscope (Carl Zeiss, Inc., Thornwood, 
NY, USA) and calculating the integrated optical density using Image-Pro Plus version 3.0 
software (Media Cybernetics, Silver Spring, MD).
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Immunoblotting
Total mouse kidney lysates were prepared as described previously (29). The protein 
concentration of the homogenates was determined with the Bio-Rad protein assay (Bio-Rad, 
München, Germany). Samples were submitted to 12% (wt/vol) SDS-PAGE and blotted to 
polyvinyldifluoride-nitrocellulose membranes (Immobilon-P, Millipore Corp., Bedford, MA). Blots 
were incubated overnight with a rabbit anti-Calbindin-D28K polyclonal antibody (1:5,000; Sigma) 
at 4°C. Subsequently, blots were incubated with a goat anti-rabbit peroxidase-labeled secondary 
antibody (1 hr; 1:10,000; Sigma, St. Louis, MO). Immunoreactive protein was detected by the 
chemiluminescence method (Pierce, Rockford, IL). Immunopositive bands were scanned using 
an imaging densitometer (Bio-Rad Gs-690) to determine pixel density (Molecular Analyst 
Software; BioRad Laboratories, Hercules, CA).
Statistical analyses
Values are expressed as mean ± SEM. Statistical significance (p<0.05) in experimental protocol 
1 was determined using the student's t-test. In experimental group 2, significance was 
determined by a one-way ANOVA. In case of significance the Tukey-Kramer multiple 
comparisons test was applied. The analyses were performed using the Statview Statistical 
Package Software (Power PC, version 4.51, Berkeley, CA).
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Abstract
Tissue transglutam inase (tTG) is a m ultifunctional Ca2+-dependent enzyme, catalyzing the 
covalent crosslinking of proteins. Recent studies have shown that the transient receptor 
potential vanillo id (TRPV) fam ily of cation channels can contribute to the regulation of TG 
activities in keratinocytes and hence skin barrier form ation. In the kidney, where active 
transcellular Ca2+ transport via TRPV5 predominates, the potential effect of tTG remains 
untested. TRPV5 is regulated by a multitude of factors, many secreted into the urine, acting 
from the extracellu lar side. We detected tTG in mouse urine and in the apical medium of 
polarized cultures of rabbit connecting tubule and cortical collecting duct (CNT/CCD) cells. 
Importantly, extracellular application of tTG significantly reduced TRPV5 activity in human 
em bryonic kidney (HEK293) cells transiently expressing the channel. S im ilar strong inhibition 
of transepithelial Ca2+ transport was observed after apical application of purified tTG to 
polarized rabbit CNT/CCD cells. tTG promoted the aggregation of the plasma 
m em brane-associated fraction of TRPV5. Using (whole cell) patch clamp, we observed a 
c lear reduction in the pore diam eter after tTG  treatment, suggesting distinct structural 
changes in TRPV5 upon crosslinking by tTG. As N-linked glycosylation of TRPV5 is a key 
step in regulating channel function, we determ ined the effect of tTG in the 
N-glycosylation-deficient TRPV5 mutant. In the absence of N-linked glycosylation, the 
TRPV5 channel was insensitive to tTG treatm ent. Taken together, these observations imply 
that tTG is a novel extracellu lar enzyme inhibiting the activity of TRPV5 via covalent 
crosslinking. The inhibition of TRPV5 occurs in an N-glycosylation-dependent manner, 
signifying a common final pathway by which different extracellular factors regulate the activity 
of the channel.
Introduction
M aintenance of the system ic Ca2+ concentration is essential for many physiological
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processes, ranging from  enzyme activation to bone mineralization. As such, the kidney plays 
a key role in stabilizing serum Ca2+, by changing the urinary excretion of Ca2+ in response to 
excess or depletion of the ion (1-3). In the kidney, most of the Ca2+ is reabsorbed via a 
passive paracellu lar pathway along the proximal tubule and the th ick ascending loop of Henle 
(3). Approxim ately 10% of the Ca2+ load re-enters the bloodstream  via an active transcellu lar 
transport process in the distal nephron (3, 4). The transient receptor potential vanillo id type 5 
(TRPV5) cation channel facilitates the apical uptake of Ca2+ in these segm ents (5). In rabbit, 
TRPV5 is expressed predom inantly in the collecting tubule (CNT), while in other species, 
such as mouse and rat; substantial expression of the channel is also observed in the distal 
convoluted tubule (DCT) (4, 6). Ablation of TRPV5 in mice (TRPV5-/-) impairs transcellular 
Ca2+ reabsorption, resulting in robust hypercalciuria (7) and com pensatory vitam in 
D-dependent hyperabsorption (7).
TRPV5 has unique electrophysio logical characteristics, including the constitutive 
inward rectifying activity at low intracellular Ca2+ concentrations and physiological membrane 
potentials, Ca2+-dependent inactivation and selectivity for Ca2+ (8). Monomers of TRPV5 
associate into functional tetram ers by facing each other with the ir pore-form ing regions (9). 
Furthermore, a single conserved N-glycosylation site at an asparagine-358 (N358), harbored 
in the firs t extracellular loop is another im portant structural feature of TRPV5. Native TRPV5 
has been shown to undergo N-glycosylation, resulting in high mannose and 
com plex-glycosylated proteins (9). The activity of TRPV5 is controlled at multiple levels by an 
array of different factors, including calciotropic horm ones (e.g. 1,25-dihydroxyvitam in-D3) and 
extracellular factors (e.g. the glycosidase klotho) (10-12). Klotho, as an extracellular 
glycosidase (10, 13, 14), hydrolyzes oligosaccharide chains from  the com plex N-glycan of 
TRPV5. This extracellu lar modification results in delayed retrieval of the Ca2+ channel from  
the apical plasma membrane and subsequently increases Ca2+ transport (10, 13). The 
stim ulatory effect of klotho is entirely dependent of the N-glycosylation of TRPV5, suggesting
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that the N-glycosylation status of TRPV5 is crucial for this type of extracellular regulation (10, 
13).
Tissue transglutam inase (tTG, also known as TGase2) is a m ultifunctional protein 
catalyzing the Ca2+-dependent covalent crosslinking of specific lysine (Lys) and glutam ine 
(Gln) residues of substrate proteins (15, 16). Interestingly, several Ca2+-binding proteins are 
known substrates of tTG. Calbindin-D28K, an intracellu lar protein involved in Ca2+ binding 
playing a key role in transcellu lar Ca2+ transport, has been shown to be a substrate of tTG (17, 
18). Furthermore, several members of the fam ily of S100A EF-hand proteins are also 
substrates of tTG (19, 20). This includes S100A10, which is involved in forward trafficking of 
TRPV5 to the plasma membrane, (20, 21).
A recent elegant study by Cheng et al. showed that TRPV3, another m ember of the 
TRPV fam ily, in part contributes to epidermal barrier function by affecting the activity of tTG 
(22). This is likely to occur via increased TRPV3-dependent Ca2+ influx and subsequent Ca2+ 
dependent activation of the enzyme. In addition to these observations, TGase1 expression 
has also been shown to be regulated by TRPV6 during Ca2+-induced differentiation of 
keratinocytes (23). Transporters in the renal epithelium can be directly affected by 
extracellular factors found in the urine, secreted by the cells them selves or filtered by the 
glomerulus from  the blood, constituting a unique environment. tTG is found in the intracellular 
com partm ent, but the enzyme is also secreted, indicating tha t in th is epithelia, the enzyme 
could act from  the urinary side. In term s of TRPV5-dependent transport, such a mechanism 
could suggest alternative mechanism of regulation, in comparison to what is observed in e.g. 
the skin barrier form ation. Our experiments describe the identification of tTG as a novel 
m olecular inhib itor of TRPV5. Furthermore, this study shows that the kidney secretes tTG into 
the pro-urine where it covalently crosslinks TRPV5 from  the extracellular com partm ent and, 
thereby reducing the pore size of the channel in an N-glycosylation-dependent manner.
tTG inhibits the activity of TRPV5
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tTG is secreted into the pro-urine and into the ap ica l m edium  o f CNT/CCD cells
24-hour urine sam ples from  w ild-type mice were desalted, concentrated and the total 
amounts were subsequently analyzed for tTG  expression by SDS-PAGE fo llowed by tTG 
W estern blotting. A band with a m olecular size slightly above 75 kDa was observed in the 
urine sam ples (Fig. 1A), corresponding to the known 75-78 kDa size of tTG. Since tTG was 
detected in the 24-hour urine of mice, we next analyzed the expression levels of tTG in the 
CNT/CCD region. To this end, polarized primary cultures of rabbit CNT/CCD were used. 
W estern blot analysis, wherein p-actin was used as loading control, revealed that polarized 
CNT/CCD cells abundantly express tTG (Figure 1B, upper panel) (n=3). In the apical 
conditioned media of primary CNT/CCD cells a significant am ount of tTG  could be detected 
(Figure 1C upper panel), In addition, tTG  was also abundantly present in the basolateral 
com partm ent (Figure 1C lower panel).
Figure 1. tTG is secreted into mouse urine and into the apical media o f rabbit prim ary  
CNT/CCD cells. (A) Mice (n=3) were housed in metabolic cages and 24 hour urine samples were 
collected. Samples were concentrated and subsequently analyzed for tTG expression by SDS-PAGE 
followed by anti tTG Western blotting. (B) Isolated rabbit primary CNT/CCD cells were allowed to 
polarize on filter supports. Polarized monolayers (n=3) were probed for tTG expression by SDS-PAGE 
and subsequent immunoblot with anti-tTG (upper panel), and anti-p-actin antibodies (lower panels) 
respectively. (C) Apical and basolateral media from polarized CNT/CCD cells were collected and 
concentrated, and subsequently analyzed for tTG secretion.
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Next, we investigated whether tTG can affect the activity of TRPV5. To th is end, HEK293 
cells transiently over-expressing the channel were treated with tTG (1 |jg/ml), for 6 hours and 
subjected to patch clamp (whole cell configuration) analysis (Figure 2A). Heterologous 
overexpression of TRPV5 yie lded a large, approxim ately 1500 pA/pF sodium  current density 
(Figure 2A). Incubation with tTG for 6 hours resulted in a significant, 50 % reduction of the 
current density (Figure 2A). Additionally, the tTG inhibitor cadaverine (150 jM )  prevented the 
tTG -m ediated inhibition of TRPV5 (Figure 2A and 2B), w ithout affecting the activity of TRPV5 
(Figure 2A and 2B).
To address whether tTG reduces the num ber of channels at the plasma membrane, 
the action of tTG on TRPV5 was assessed by cell surface biotinylation studies. TRPV5, with 
m olecular masses between approxim ately 70 and 85, representing the core and complex 
glycosylated monomers of the channel were detected in the plasma membrane fraction 
(Figure 2C). Com pared to the control (-tTG), a decrease in the am ount of TRPV5 monomers 
was observed after tTG treatm ent (Figure 2C). More importantly, after incubation with tTG, 
TRPV5 oligom ers with a m olecular mass of ~ 250 kDa were observed (Figure 2C).
The inhibitory effect of tTG was further investigated by transcellu lar Ca2+ transport 
assays in polarized rabbit primary CNT/CCD cell monolayers. The forskolin-stim ulated 
transcellular Ca2+ transport was significantly reduced by tTG and this inhibitory effect of the 
enzyme could be prevented by the tTG blocker cadaverine (Figure 2D). Additionally, 
incubating the cells with cadaverine did not result in any detectable changes in transcellu lar 
Ca2+ transport (Figure 2D).
tTG decreases the pore d iam eter o f TRPV5
To estimate whether tTG -induced aggregation of TRPV5 can affect the pore of the channel, 
the pore diam eter was determ ined both in the absence and the presence of the enzyme. To
tTG inhibits the activity of TRPV5
tTG inhib its the activ ity o f TRPV5
145
Chapter 6
1500-
1000-
500-
4 *  A* ' ^  A
*■ 4-
cadaverine
*  TRPV5 aggregate 
Cell surface
• -  TRPV5 monomer
»  TRPV5 aggregate 
1 % input
»- TRPV5 monomer
180-,
i " E 120H 
o  5
II
“  60 -
-tTG + tTG
Figure 2. tTG inhibits TRPV5-m ediated currents and transcellu lar Ca transport in 
prim ary CNT/CCD cells. (A) Na+ I/V relations were measured from TRPV5-transfected HEK293 
cells. The cells were subjected to 6 hour tTG treatment (1 |ig/ml) in the presence and absence of 
cadaverine (150 |iM) before the current measurements. Data are shown as mean ± S.E.M. * indicates 
significant difference from the cells expressing TRPV5 (n = 15; p < 0.05). (B) Representative Na+ I/V 
relations of TRPV5 treated with transglutaminase in the absence or presence of cadaverine. (C) 
HEK293 cells were transiently transfected with pCINeo-HA-TRPV5/IRES-GFP and treated for 6 hours 
with 1 |ig/ml tTG. After treatment cells were subjected to cell surface biotinylation, followed by 
neutravidin pull-down. Lysates were separated on SDS-PAGE and blots were probed with an anti-HA 
antibody. (D) Polarized rabbit primary CNT/CCD cells were treated for 6 hours with 1 |ig/ml apically 
administered tTG and transport was measured as described previously (23). Data are shown as mean 
± S.E.M. * indicates significant difference from the control situation (n = 15; p < 0.05).
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th is end, the perm eability ratios of currents carried by organic m onovalent cations of 
increasing size relative to Na+ current were measured. W hen Na+ was used as the sole 
charge carrier, the current reverted close to 0 mV with a clearly inward-rectifying shape 
(Figure 3A). Once all Na+ ions from the extracellular solution were substituted by 
m ethyl-am m onium  or its di-, tri- and tetra methyl derivatives (MA+, DMA+, TriMA+, TetMA+) 
and finally by the larger organic cation N-m ethyl-D-glutam ine (NMDG+). To a lesser extent, 
these cations, were also able to permeate TRPV5, and the recorded currents were directly 
proportional to the size of each cation (Figure 3B). More importantly, incubation with tTG 
resulted in significantly sm aller currents in the case of all cations (Figure 3B).
The perm eability ratios, relative to Na+ (PX/P Na), were calculated from  the recorded 
bi-ionic reversal potentials for all five cations (MA+, DMA+, TriMA+, TetMA+ and NMDG+) for 
both untreated and tTG -treated HEK293 cells expressing TRPV5, and subsequently plotted 
against the estim ated diam eter of each cation. In the control situation the pore diam eter for 
TRPV5 was calculated to be 6.44 ± 0.01 A. Treatm ent with tTG resulted in a decreased pore 
size as the diam eter was calculated to be 5.79 ± 0.02 A (Figure 3C).
N-glycosylation o f TRPV5 is im portant fo r tTG -m ediated inhibition
HEK293 cells expressing the N-glycosylation-deficient mutant form  of the channel 
(HA-TRPV5-N358Q ) were treated with tTG and subjected to patch clam p and cell surface 
biotinylation analyses. Patch clam p recordings showed identical Na+ currents for the 
untreated wild type and the mutant form of TRPV5 (Figure 4A). However, tTG  incubation 
reduced the activity of the wild type channel, but not of TRPV5-N358Q (Figure 4A). Cell 
surface labeling of HEK293 cells expressing either the wild type TRPV5-N358Q showed 
abundant expression of both wild type and mutant TRPV5 at the plasma membrane (Figure 
5B, upper panel). Treatm ent with tTG caused the aggregation of TRPV5 at the plasma 
m embrane and concom itantly decreased the am ount of w ild type TRPV5 monomers (Figure
tTG inhibits the activity of TRPV5
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Figure 3. tTG decreases the pore diam eter o f TRPV5. (A) Na+ traces and (B) Ca traces. 
(C) The permeability ratios of currents carried by organic monovalent cations of increasing size relative 
to Na+ current were measured in the absence and presence of tTG. The permeability of mono-, di-, tri- 
and tetra-methyl ammonium derivatives (MA+, DMA+, TriMA+, TetMA+) and of N-methyl-D-glutamine 
(NMDG) were measured using solutions in which Na+ was substituted by the respective cations, and 
finally by the larger organic cation (NMDG+). (D) Calculated relative permeability ratios of untreated 
and tTG treated TRPV5. (PX/PNa), were calculated from the recorded biionic reversal potentials for all 
five cations (MA+, DMA+, TriMA+, TetMA+ and NMDG+) for both untreated and tTG-treated TRPV5 and 
subsequently plotted against the estimated diameter of each cation. For curve-fitting, the points from 
the graph plotting permeability ratios of the different organic cations (X) versus the estimated 
diameters, the excluded volume considering friction of the permeating ion Eq. PX/PNa = k(1-a/d)2/a 
was used where a is the organic cation diameter, k a constant factor and d is the minimal pore 
diameter. (E) Histogram representing change in pore diameter.
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Figure 4. N -glycosylation-deficient mutant TRPV5 is insensitive to tTG-m ediated  
inhibition. (A) Na+ currents were measured from wild type TRPV5 and N-glycosylation-deficient 
TRPV5-N358Q mutant channels. The cells were subjected to 6 hour tTG treatment (1 |ig/ml) before 
the current measurement. Data are shown as mean ± S.E.M. * indicates significant difference from the 
cells expressing either wild type or N-glycosylation-deficient mutant TRPV5 (n =11; p < 0.05). (B) 
Representative Na+ I/V relations of wild type TRPV5 and TRPV5N358Q in the absence or presence of 
purified transglutaminase. (C) Cell surface biotinylation of HEK293 cells transiently expressing 
HA-TRPV5 or HA-TRPV5-N358Q, after for 6 hours of tTG treatment (1 ^g/ml) tTG. (D) 
Semi-quantitative analysis of C. (E) Wild type TRPV5 and TRPV5N358Q bind tTG with equal efficiency 
HA-tagged wild type TRPV5 or TRPV5-N358Q was immunoprecipitated with HA-antibody from 
transiently transfected HEK 293 cells. The precipitated fractions were incubated over night at 4 °C with 
1 |ig/ml purified tTG in EDTA-containing Ca2+ free buffer to prevent any enzymatic activity of tTG. The 
beads with TRPV5 and tTG were successively washed and subjected to SDS-PAGE followed by 
anti-tTG or anti-TRPV5 immunoblot, respectively.
4B, upper panel). However, this aggregation could not be observed in case of the mutant 
channel (Figure 4B, upper panel). Additionally, incubation with tTG did not alter the total 
expression of the wild type or the mutant form of TRPV5 (Figure 4B).
Finally, we investigated the binding capacity of tTG  to wild type and the N-glycosylation 
deficient mutant Ca channels. The im m unoprecipitated wild type and mutant TRPV5 were 
incubated with or w ithout tTG at 4 °C in the absence of Ca2+ to reduce the enzym atic activity 
of tTG. These im m uno-precipitation experim ents revealed tha t tTG binds to both wild type 
and the mutant form  of TRPV5 with equal affin ity (Figure 4C).
Discussion
Active transcellu lar Ca2+ transport in the kidney takes place exclusively in the DCT/CNT 
segm ents of the nephron, where the epithelial Ca2+ channel TRPV5 controls the Ca2+ entry. 
In this study we identified tTG as a novel inhibitor of TRPV5 activity, acting from the 
extracellular side in a N -glycosylation-dependent manner. This conclusion is based on the 
following observations: 1) tTG is found in the urine in mice, in line with the expression and 
secretion of the enzyme in polarized primary CNT/CCD cells. 2) tTG decreases the activity of 
TRPV5 in transiently transfected HEK293 cells and inhibits transcellu lar Ca2+ transport in 
polarized primary CNT/CCD cells; 3) crosslinking of TRPV5 by tTG decreases the pore size 
of the channel; 4) the inhibitory effect of tTG  depends on the N-glycosylation state of TRPV5
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as the N-glycosylation-deficient mutant is not susceptible to tTG -catalyzed modifications.
Increased expression and activity of tTG have been previously observed in renal 
disorders such as diabetic nephropathy or chronic kidney disease (24-29). In these diseases, 
tTG activity has been associated with tissue fibrosis and scar form ation, taking place in the 
extracellular matrix (24, 30). However, whether tTG is secreted into the urine during these 
conditions, has not been tested. We established the presence of tTG in the urine of mice, 
which indicates the presence of tTG in the urine during normal physiological conditions. The 
fact that primary cultures of polarized rabbit CNT/CCD cells also secrete a large fraction of 
endogenously expressed tTG into the apical medium further corroborates this finding. The 
presence of tTG has been reported previously in the DCT region and in other nephron 
segm ents as well (24, 26, 30). Tubular secretion is therefore likely to contribute significantly 
to the amount of tTG found in the urine. These observations imply that tTG could function as 
a novel urinary factor, involved in regulating Ca2+ reabsorption in the distal nephron.
Patch clamp recordings of TRPV5 and transcellular transport assays in primary 
CNT/CCD cells showed a s ignificant inhibitory effect of tTG on Ca2+ transport. Earlier studies 
have reported that tTG had the ability to modify the activity of the large conductance 
Ca2+-activated K+ (Maxi-K) channel (31). Using the non-hydrolyzable GTP analogue GTPyS, 
these studies showed that the GTPyS-stimulated channel activity was decreased to control 
levels when cells were treated with an antibody against tTG (31). Such a G-protein like effect 
of tTG on TRPV5 is unlikely, as cadaverine, the inhibitor of the crosslinking activity of the 
enzyme, abolishes the effect of tTG. Next to the functional assays, cell surface biotinylation 
studies revealed the form ation of SDS-resistant, probably covalently crosslinked TRPV5 
aggregates in the plasm a membrane upon tTG incubation. tTG  is known to be externalized 
into the extracellu lar space where it crosslinks and therefore stabilizes the heteromeric 
assem blies of several matrix and basolateral membrane proteins (32-36). In case of the tTG 
substrate small heat shock proteins (aB-crystallin , Hsp27, Hsp20 and HspB2), crosslinking
tTG inhibits the activity of TRPV5
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between different small heat shock proteins has been demonstrated to be more efficient 
when they interact with each other in the sam e m acrom olecular assembly (37). These 
observations suggested that tTG -substrate proteins in close proxim ity to each other are more 
prone to crosslinking than those of existing in different complexes. The functional TRPV5 
exists in a hom otetram eric form , as four monomers need to associate into operational 
tetram ers prior to plasma membrane insertion (9). Furthermore, it also harbors several 
glutam ine and lysine residues facing the extracellu lar environment. S ince the extracellular 
environm ent as well as the pro-urine contains suffic ient am ount of Ca2+ for the activation of 
tTG, the tTG -m ediated aggregation of TRPV5 monomers could take place from  the 
extracellular side.
tTG did not change the protein stability, membrane expression or trafficking/recycling 
properties of TRPV5. Instead, we found that extracellular addition of tTG  results in a 
decreased pore size of TRPV5. TRPV5 harbors several glutam ines and two lysines in the 
firs t extracellular loop, which are the potential substrate sites fo r tT G. Crosslinking these sites 
could introduce extra rig idity or tension into the structure of the m em brane-inserted TRPV5 in 
such a way that it results in pore deform ation and subsequent reduction in ion permeability. 
Previously, acidification of both the intra- and extracellu lar environm ent has been shown to 
decrease the pore diam eter of TRPV5 intracellu lar pH (38). Our observations suggest that 
not only pH changes, but also tTG could inhibit the activity of TRPV5 by reducing its pore 
size.
N-glycosylation of TRPV5 is crucial for the extracellular regulation of the channel by 
klotho (10, 13). Surprisingly, tTG had no inhibitory effect on TRPV5-N358Q, suggesting that 
the presence of the sugar tree is critical for tTG action. Negatively charged 
glycosam inoglycans such as heparin are known to bind tTG (39-41). We speculated tha t the 
sialic acid containing, and therefore negatively charged N-glycan of TRPV5 may bind tTG, 
providing better accessibility to the substrate sites located in the vicinity of the N-glycan.
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However, co-im m unoprecipitation experiments showed that tTG equally binds to both the wild 
type and to the N-glycosylation-deficient TRPV5 mutant. Because of the equal binding 
efficiency, the substrate site exposure is more likely to depend on the N-glycosylation status 
of TRPV5. Klotho (as well as other g lycosidases) can hydrolyze sugar residues from the 
N-glycan of TRPV5 and thereby increase the activity of the channel (10, 13, 14). The fact that 
these different enzym es require intact N-glycosylation of TRPV5 for the ir actions could imply 
a central role fo r the N-glycan in the extracellular regulation of the channel. Thus, a cross-talk 
between the tTG -m ediated inhibition and the activating mechanism by klotho could also be 
speculated. M odification of the N-glycan by klotho might safeguard TRPV5 from the 
tTG -m ediated inhibition. However, further experim ents should clarify the presence of such 
cross-ta lk between klotho and tTG.
Taken together, our observations suggest that the apically secreted tTG  functions as 
an inhib itor of TRPV5 and thereby contributes to the regulation of body Ca2+ homeostasis. 
Currently, it remains unclear whether an increased urinary tTG concentration is observed in 
conditions related to defective Ca2+ handling. One could envision several pathological 
conditions in which tTG reaches higher urinary concentrations, due to increased tissue 
damage or secretion of the enzyme. As such, rats with experimentally-induced diabetes and 
diabetic nephropathy have increased renal tTG expression and activity resulting in abnormal 
extracellular crosslinking.
Here, we delineate a potential m olecular mechanism by which tTG  inhibits TRPV5 
channel activity by changing the pore diameter. The change is functionally coupled with 
crosslinking of the channel and seem s to occur in a N-glycosylation dependent manner. 
Further studies are needed to establish the physiological role of tTG  in regulating 
TRPV5-dependent Ca2+ transport.
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DNA constructs
The pC INeo/IRES-GFP plasmid encoding HA-TRPV5 was generated as described previously 
(21). HA-TRPV5-N358Q was obtained by in vitro mutagenesis of 
HA-TRPV5-pCINeo/IRES-G FP cDN A according to the m anufacturer's instructions 
(Stratagene, La Jolla, CA, USA) (10). All constructs were verified by DNA sequence analysis.
Cell lines and transfections
Human em bryonic kidney (HEK293) cells were cultured in Dulbeccco's modified essential 
medium (DMEM) supplem ented with 10 % v/v fetal calf serum and 2 mM L-glutamine. For cell 
surface biotinylation experiments, cells were transiently transfected in petri dishes, using 
polyethylene-im ine (PEI).
Collection and concentration o f pre-conditioned culture m edium
CNT/CCD cells were isolated from  New Zealand W hite rabbits as described previously (42) 
and grown to confluence on 0.33 cm 2 perm eable filte r supports (Corning-Costar, Cambridge, 
MA, USA). Apical and basolateral media were collected after seeding the cells on permeable 
supports. All collected media were concentrated 3 tim es (M illipore), and salts and proteins < 
30 kDa were removed by using centriprep ultracel YM -30 colum ns (M illipore corporation, 
Bedford, MA, USA) as described (10).
Im m unoblotting, and protein concentration determ ination
TRPV5 protein expression was determ ined by SDS-PAGE followed by im m unoblotting, using 
anti-HA (Cell Signaling, Danvers, USA) and peroxidase-labeled goat anti-guinea pig IgG 
(S igma-Aldrich, St. Louis, MO, USA) antibodies. Protein concentration was m easured by 
using the bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL, USA),
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according to the m anufacturer's manual.
Plasma m em brane biotinylation
HEK293 cells were transfected with HA-TRPV5 or HA-TRPV5-N358Q in pCINeo/IRES-GFP, 
or the em pty vector (mock). One day after transfection, cells were re-seeded on 
poly-L-lysine-coated (0.1 mg/ml) culture dishes and incubated with tTG (1 |jg/ml, 
Sigma-Aldrich, St. Louis, MO, USA) fo r 6 hours at 37 °C, respectively. Subsequently, cells 
were biotinylated, and TRPV5 was precipitated from  the cell lysates with neutravidin beads 
(Pierce, Etten-leur, The Netherlands) as described previously (10). Briefly, cells were 
collected from the plates and disrupted in 1 ml lysis buffer (1 % v/v Triton-X100, 150 mM 
NaCl, 5 mM EDTA, 50 mM Tris (pH 7.5 adjusted with HCl), PMSF 1 mM, leupeptin 5 |ig/ml, 
aprotinin 5 |ig/m l, pepstatin-A 1 |ig/m l), im m ediately after biotinylation. Cells were 
subsequently washed with ice-cold PBS, and homogenized in 1 ml lysis buffer, followed by 
precipitation using neutravidin beads. TRPV5 protein expression at the cell surface and in 
total cell lysates was measured as described above.
Electrophysiology
W hole-cell currents were m easured with an EPC-10 (HEKA electronic, Lambrecht, Germany) 
am plifier using Patch m aster V2.20 software. The borosilicate glass electrode resistance was 
between 2.5 and 4 MQ. The ramp protocol for measuring the current-voltage (I/V) relationship 
of Na+ consisted of linear voltage ramps from  -100 to +100 mV within 450 m illiseconds 
repeated every 5 seconds. The step protocol for measuring the Ca2+ current consisted of a 10 
seconds long voltage step applied from  +70 to -100 mV. Current traces were sam pled at 0.5 
ms for the ramp and 2 ms for the step protocol. Current densities were calculated from  the 
current at -80 mV during the ramp protocol. The standard extracellular solution contained 150 
mM NaCl, 6 mM CsCl, 10 mM HEPES, 50 jM  EDTA and 10 mM glucose, (pH 7.4 adjusted
tTG inhibits the activity of TRPV5
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with NaOH) for divalent free Na+, and 10 mM CaCl2 was supplem ented for the Ca2+ 
measurement. The internal (pipette) solution contained 20 mM CsCI, 100 mM Cs-aspartate, 1 
mM MgCl2 , 10 mM BAPTA, 4 mM NaCl, 2 mM ATP and 10 mM HEPES (pH 7.2 adjusted with 
CsOH). Data was analyzed using Igor-pro software (W aveMetrics, Oswego, OR, USA).
Pore m easurem ents
The standard pipette solution contained Tris-HCl buffered 150 mM NaCl, 10 mM EDTA and 
10 mM HEPES (pH 7.2 adjusted with Tris-HCl) whereas the extracellular solution contained 
150 mM NaCl and 10 mM HEPES (pH 7.4 adjusted w ith Tris-HCl) The relative permeabilities 
(PX/P Na) of mono-, di-, tri- and tetra-m ethyl amm onium  derivatives and of 
N-m ethyl-D-glutam ine chloride (NMDG) were measured using solutions in which Na+ was 
substituted by the respective cations. Reversal potentials were calculated from  the bi-ionic 
reversal potentials furthermore, all potentials were corrected fo r possible liquid junction 
potentials calculated according to Barry et al (43). In these permeation experiments, the 
standard pipette solution was used as intracellular solution. For the amm onium  derivates, the 
following com pound diam eters were used (in nm): 0.36, 0.46, 0.52, 0.58 and 0.68 for 
m onom ethylam m onium  (MA+) dim ethylam m onium  (DMA+), trim ethylam m onium  (TriMA+), 
tetram ethylam m onium  (TetMA+) and for NMDG+ (all com pounds obtained from  Sigma), 
respectively. For curve-fitting, the points from  the graph plotting perm eability ratios of the 
different organic cations (X) versus the estimated diameters, the excluded volume 
considering friction of the perm eating ion Eq. PX/P Na = k (1 -a /d )2/a  was used (43) where a is 
the organic cation diameter, k  the constant factor and d  is the minimal pore diameter.
Statistical analysis
In all experiments, the data were expressed as mean ± S.E.M. Statistical significance (p <
0.05) was determ ined by analysis of variance (ANOVA) and a Bonferroni post-hoc test.
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Abstract
Nephrolith iasis is a highly prevalent clinical condition that increases with age. Hypercalciuria 
remains a major risk factor for kidney stone form ation. Twin and fam ily studies indicate a genetic 
basis fo r hypercalciuria. To investigate novel genetic defects underlying hypercalciuria, we 
established H ca lc l, a mouse model with autosomal dom inant hypercalciuria by screening mice 
from  a N-ethyl-N-nitrosourea mouse mutagenesis resource. Linkage studies mapped the locus 
to chrom osom e 6. Candidate gene sequence analysis revealed a T>C transition in codon 682 of 
the transient receptor potential cation vanillo id 5 (TRPV5) gene, converting a conserved serine to 
a proline (S682P). Heterozygous and hom ozygous Hca lc l mice had a ~10-25-fold higher urinary 
Ca2+/C r ratio than the ir w ild-type littermates. Furthermore, histological exam ination showed that 
~10% of H ca lc l male mice had primary tubulo interstitia l nephritis, consistent with urinary reflux. 
Im m unostaining of H ca lc l kidneys revealed a loss of TRPV5 from  the distal convoluted tubules 
(DCT), with a selective decrease in TRPV5 positive DCT cells in kidneys of Trpv5682PI+ and 
Trpv5682PI682P mice (100 ± 13%, 56 ± 6% and 27 ± 5% for w ild-type, Trpv5682P/+ and Trpv5682P/682P, 
respectively, P<0.05 com pared to wild-type). Furthermore, a reduction in calbindin-D28K 
expression was observed by sem i-quantitative im m unohistochem ical analysis in kidneys of 
Trpv5682PI682P mice (100 ± 11%, 108% ± 32 and 8 ± 2% for w ild-type, Trpv5682PI+ and Trpv5682PI682P, 
respectively, P<0.05 com pared to wild-type). This reduction was also observed by western blot, 
albeit less prom inent (100 ± 6%, 120 ± 13% and 52 ± 3% for wild-type, Trpv5es2PI+ and 
Trpv5682PI682P, respectively, P<0.05 com pared to wild-type). This is in line with a defect in 
TRPV5-m ediated renal Ca2+ reabsorption. In support of this, transient expression studies of 
w ild-type and mutant TRPV5 in human em bryonic kidney 293 cells using the Ca2+-binding dye 
Fura-2 revealed a lower baseline in tracellular Ca2+ concentration in the TRPV5-S682P mutant 
expressing cells (0.77 ± 0.06 and 0.51 ± 0.02 for TRPV5-w ild-type and TRPV5-S682P, 
respectively, P<0.05). Thus, the Hcalc1 mouse with a TRPV5 S682P mutation represents a 
novel model for autosomal dom inant hypercalciuria.
TRPV5 and autosomal dominant hypercalciuria
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Introduction
Kidney stone disease (nephrolith iasis) is a global health problem that affects 12% of men and 
5% of women by the seventh decade of life and has a recurrence rate of ~10% per annum (1). 
Ca2+ stones, com prising Ca2+ oxalate and/or Ca2+ phosphate, account for up to 80% of kidney 
stones and hypercalciuria is the most common and correctable m etabolic abnorm ality found in 
Ca2+ stone form ers (1, 2). Hypercalciuria and kidney stone disease are strongly influenced by 
genetic factors. Between 35-65% of patients with hypercalciuric stone disease have affected 
fam ily members (2) and twin studies have estimated the heritability of kidney stones and urine 
Ca2+ excretion to be 56% (3) and 52% (4), respectively. In addition, hypercalciuria and kidney 
stone disease are genetically heterogeneous disorders that may be inherited as polygenic 
quantitative traits, or as monogenic disorders of autosomal dominant, autosomal recessive or 
X-linked recessive modes of transm ission (2, 5).
The etiology of hypercalciuria is complex. In the body, extracellular free ionized Ca2+ 
concentrations are maintained by a balance between intestinal absorption o f dietary Ca2+, renal 
Ca2+ reabsorption and excretion, and bone turnover. Thus, a disturbance in Ca2+ handling in any 
of these three organs could result in hypercalciuria. The pathophysiology of hypercalciuria has 
been classified as absorptive, renal, or resorptive hypercalciuria, depending on whether the 
primary defect is due to intestinal hyperabsorption, im paired renal tubular reabsorption, or 
increased bone resorption (6). In addition, hypercalciuria may occur in association with other 
metabolic or renal tubular disturbances, thus confounding efforts to identify the genetic factors 
underlying fam ilial hypercalciuria and Ca2+ stone disease (5, 7). Past successes include one 
study in 3 fam ilies with severe absorptive hypercalciuria that linked haplotypes on chrom osom e 1 
to the disorder and identified a candidate gene, the human soluble adenylyl cyclase (8, 9). A 
recent genome wide association study in Icelandic and Dutch populations also identified 
susceptib ility risk variants in the CLDN14 gene for hypercalciuric kidney stone disease (10), 
although the underlying m echanisms have not been elucidated. Furthermore, studies of rare
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m onogenic disorders associated with hypercalciuric stone disease such as Dent's disease, 
Bartter's syndrom e and autosomal dom inant hypocalcaem ia with hypercalciuria, have given us 
much insight into the receptors, channels and transporters im portant in Ca2+ hom eostasis and 
kidney stone form ation (2, 11, 12). However, large extended fam ilies needed for such studies are 
limited.
We have utilized a N-ethyl-N-nitrosourea (ENU) mouse mutagenesis resource (13, 14) in 
a phenotype-driven screen, to identify new genetic models of hypercalciuria. ENU is a chemical 
mutagen that causes random point m utations by alkylation of nucleic acids, which leads to 
mispairing and subsequent single base substitutions during DNA replication. The resulting 
m utations can lead to loss-of-function, hypomorphic, hyperm orphic or dom inant-negative 
changes in protein function (14). Its ability to produce single base pair mutations in mouse has 
made the ENU mouse m utagenesis program an ideal resource for uncovering new genes 
involved in disease phenotypes, novel function to known genes, and in identifying amino acid 
residues crucial fo r protein function that is not possible in a whole gene deletion approach (14).
Here we report the identification of a mouse, designated Hcalc1, with severe autosomal 
dom inant hypercalciuria. This defect is caused by a novel m issense S682P mutation in the 
TRPV5 gene. The present study delineates the identification and functional characterization of 
this gene defect.
Results
Phenotype-driven screen, genetic m apping and m utational analysis in Hcalc 1 mice 
The Hcalc1 founder mouse was identified from  a urine and plasma biochem ical screen of 598 F1 
male mice derived from  matings of ENU-m utagenised C57BL/6J (B6J) male mice and wild-type 
C3H/HeH (C3H) fem ale mice. This single founder mouse had a urine Ca2+/creatinine (Ca2+/Cr) 
value that was >10 SD above the mean of age-m atched control males at an age of 16 weeks
TRPV5 and autosomal dominant hypercalciuria
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(2.49 vs. 0.26 ± 0.20), and at 24 weeks (3.93 vs. 0.28 ± 0.21). Inheritance testing of the 
second-generation (G2) offspring from the Hcalc1 founder male crossed with normal C3H 
females revealed tha t 10 o f its 23 offspring were hypercalciuric, consistent with an autosomal
dom inant phenotype (x2 = 0.39, d f = 1, P=0.53). y l  or Chi-square G oodness-of-fit test is used to
Figure 1. Inheritance testing, m apping and identification of a Trpv5 mutation in Hcalc1 
mice. (A) Scatter plot showing urine Ca2+/creatinine values of 23 G2 offspring of the Hcalcl founder male. 
Inheritance testing revealed that 10 of the 23 mice were hypercalciuric, consistent with an autosomal 
dominant phenotype. Bar, mean Ca2+/creatinine values. Mean ± SEM: hypercalciuric mice = 0.91 ± 0.10; 
normocalciuric mice = 0.15 ± 0.01 (B) Haplotype analysis of G2 mice with and without hypercalciuria 
mapped Hcalcl to a 11.94-Mbp candidate interval on mouse chromosome 6, between rs13478709 and 
rs30110406 (double-headed arrow). Each box represents a genetic marker typed. Each column 
represents the chromosome identified in the backcross progeny that was inherited from the (C57BL/6J x 
C3H/HeH) F1 founder parent. The number of animals observed for each haplotype is shown beneath each 
column. Filled box, C57BL/6J allele; open box, C3H/HeH allele. (C) DNA sequence analysis of Trpv5 
identified a heterozygous T>C transition in codon 682 in hypercalciuric mice that is predicted to alter a 
wild-type serine (Ser) to a mutant proline (Pro). This mutation results in a gain of a SsaJI restriction 
enzyme site that was used to confirm the presence of the mutation in hypercalciuric mice and its absence 
in normocalciuric mice. wild-type, wild-type; m, mutant. (D) Multiple sequence alignment shows 
evolutionary conservation of the wild-type mouse TRPV5 serine (S) residue encoded by codon 682 
(arrowed) across species and in mouse TRPV6. Sequence shaded with box shade. Identical residues are 
shaded black, conservative changes are shaded grey.
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test whether the observed value deviates significantly from  the expected value of a given null 
hypothesis, in this case, whether the num ber of offspring for the Hcalc1 founder that are 
hypercalciuric and norm ocalciuirc (observed value) deviates significantly from the expected 
numbers if the phenotype were inherited in an autosom al dom inant manner (null hypothesis). D f 
(degree of freedom ) is calculated as n-1, in which n=the num ber of groups or observations (in 
this case n=2 for hypercalciuric and norm ocalciuric mice). We accepted the null hypothesis that 
the phenotype is inherited in an autosomal dom inant manner, since P=0.53  (Figure 1A).
A genome wide scan using DNA from  10 hypercalciuric mice and 3 normocalciuric 
littermates identified co-segregation of the Hcalc1 locus with B6J alleles of 3 SNPs on 
chrom osom e 6 (LOD score = 3.91, 0% recombination). Haplotype analysis of all 23 G2 mice and 
a further 66 G2 offspring (29 hypercalciuric, 37 norm ocalciuric) derived by IVF, using additional 
chrom osom e 6 markers, mapped the Hcalc1 locus to a ~11.94-Mbp interval on chromosome 
6B1/B2, between rs13478709  and rs30110406, with a peak LOD score = 26.8 at 0% 
recombination (Figure 1B). This interval contains 176 genes, including those for Trpv5 and 
TRPV6
Sequence analysis of the entire coding region of Trpv5 and TRPV6 using DNA from a 
hypercalciuric G2 mouse and wild-type BL6 and C3H mice did not identify a mutation in TRPV6. 
However, a heterozygous T>C transition in codon 682 of Trpv5 was found in the hypercalciuric 
mouse that is predicted to alter a w ild-type serine (S) to a mutant proline (P) (Figure 1C). This 
mutation results in a gain of a SsaJI restriction enzyme site, which was used to confirm  the 
presence of the mutation in all hypercalciuric mice, and its absence in all norm ocalciuric mice 
(Figure 1C). This S682 residue, which is located in the cytoplasm ic carboxyl-term inal region of 
TRPV5, is conserved across species and in TRPV6 (Figure 1D). S682 is not predicted to be 
phosphorylated based on phospho-database prediction servers nor is it located in a known 
functional or protein-binding domain.
TRPV5 and autosomal dominant hypercalciuria
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Urine and plasm a biochem istry o f Hcalc1 mice
TRPV5 is an epithelial Ca2+ channel highly expressed in the DCT and connecting tubule (CNT), 
and is vital to active renal Ca2+ reabsorption (15, 16). To further characterize the H ca lc l 
phenotype, urine and plasma chem istry were assessed in wild-type, heterozygous ( Trpv5682P/+) 
and hom ozygous mutant (Trpv5682P/682P) mice. Trpv5682P/682P mice were generated from
Figure 2. Phenotypic characterization of Hcalc1 mice. (A-B) Water intake and urine output of 
wild-type (wild-type), Trpv56&2PI+ (het) and 7rpv5682P/682P (hom) mice individually housed in metabolic cages 
for 24 hours (N=17-72 mice/group). (C-E) Analysis of Ca2+/Cr and Phos/Cr ratios, and pH of urine samples 
from wild-type (wild-type), Trpv5682P/+ (het) and Trpv5682P/682P (hom) mice (N= 17-72 mice/group). (F-H) 
Analysis of plasma Ca2+, phosphate (N=15-50 mice/group), and PTH (N=17-22 mice/group) of wild-type 
(wild-type), Trpv5682P/+ (het) and Trpv5®82P/682P (hom) mice. All data are presented as means ± 
SEM.*P<0.05, significantly different from wild-type mice. #P<0.05, significantly different from Trpv5682P/+ 
mice, with Bonferroni correction for multiple comparisons.
( Trpv56a2PI+x Trpv5682P/+) crosses, and are viable, fertile and outwardly indistinguishable from
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the ir w ild-type and Trpv5682P/+ littermates. Mice aged between 12-20 weeks of age were housed 
in metabolic cages fo r 24 hours and urine sam ples collected for biochemical analysis. 
Trpv5682P/682P mice of both genders were polydypsic and polyuric com pared with w ild-type mice 
(Figure A-B). B iochemical analysis of urine sam ples revealed tha t the mean urine Ca2+/C r of 
Trpv5682P/+and Trpv5682P/682P mice were ~9- and ~24-fold greater fo r males, and ~10- and 
~27-fold greater for females, com pared with the ir gender matched contro ls (P<0.05, Figure 2C). 
In addition, the hypercalciuria in Trpv5682P/682P mice was significantly greater than that in 
Trpv5682P/+ mice (P<0.05, Figure 2C). Trpv5682P/+and Trpv5682P/682P mice also had elevated urine 
phosphate/creatinine ratios (Phos/Cr) com pared with w ild-type mice indicating 
hyperphosphaturia (Figure 2D). Furthermore, urine sam ples of both Trpv5682P/+ and Trpv5682P/682P 
mice were significantly more acidic than those from  w ild-type litterm ates (Figure 2E).
To determ ine if the observed increased urinary Ca2+ and phosphate excretion in Hca lc l 
mice is accom panied by alterations in system ic Ca2+ and phosphate levels, plasma sam ples 
were obtained from  mice aged 18-25 weeks old for analysis. Plasma Ca2+ and phosphate were 
not significantly different between gender-m atched Trpv5682P/+ and w ild-type mice (Figure 2F-G). 
However, Trpv5682P/682P mice had significantly lower plasm a Ca2+ concentrations com pared with 
gender-m atched wild-type mice (Figure 2F). Furthermore, plasma phosphate concentrations in 
Trpv5682P/682P fem ale mice were significantly lower com pared with fem ale w ild-type and 
Trpv5682P/+ mice (Figure 2G). Plasma PTH for Trpv5682P/+ and Trpv5682P/682P mice were not
significantly different from wild-type mice (Figure 2H).
Renal h istopathology
We examined kidneys dissected from  wild-type, Trpv5682P/+and Trpv5682P/682P mice between the 
age of 17 and 25 weeks for the presence of renal abnormalities. H istological analysis of
TRPV5 and autosomal dominant hypercalciuria
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Figure 3. Tubulointerstitial nephritis in kidneys o f Trpv5S2Ph and Trpv5682P/682P male mice.
(A) Left kidneys from a wild-type male mouse (wild-type), and a Trpv56S2PI+ mutant (het) male mouse with 
renal scarring (arrowed). Representative images of: (B) H&E staining of the renal cortex of an affected 
Hcalc1 male mouse showing interstitial infiltrations of mononuclear cells and dilated tubular lumen filled 
with cells and cell debris (arrowheads), (C-D) anti-CD3-labelling (green) of the renal cortex of a wild-type 
male (C) and an affected Hcalc1 male (D) mouse. A large number of T-lymphocytes were present in the 
interstitial regions of the affected Hcalc1 mouse kidney (D, arrowheads), (E-F) TUNEL-labelling (green) of 
the renal cortex of a wild-type (E) and an affected Hcalc1 (F) male showing the presence of tubular cell 
apoptosis in the Hcalc1 mouse kidney (F, arrowheads). DAPI (blue) labels nuclei (C-F). Scale bar = 50|im.
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kidney sections using von Kossa staining which detects Ca2+ deposits, revealed the occasional 
interstitial calcification (one or more calcified foci/ renal cross-section) in the renal cortex in a 
number of hypercalciuric mice (26% G2 mice). However, such calcification was also present in 
w ild-type litterm ates (24% G2 mice), and thus not considered to be associated w ith the 
hypercalciuric phenotype in H ca lc l mice. Interestingly, kidneys from  ~9% (6/66) of Trpv5682P/+ 
and 13% (3/23) Trpv5682P/682P male mice were grossly abnormal with the appearance of renal 
scarring (Figure 3A). Histological examination of these kidneys revealed the presence of 
inflam m atory cell infiltrates, tubular dilatation, flattening of tubular epithelia and the presence of 
num erous cells and/or cell debris within the dilated lumen of some cortical tubules (Figure 3B). 
Im m unohistochemical staining with antibodies against CD3, which form s part of the T-cell 
receptor complex, confirm ed an abundance of T-lym phocytes within the interstitial regions of the 
renal cortex of affected mice that was not present in w ild-type mice (Figure 3C-D). In addition, 
TUNEL-staining showed apoptosis of renal tubular cells in affected kidneys that were not 
observed in w ild-type kidneys (Figure 3E-F). Glomeruli and blood vessels appeared normal. 
These features are consistent with prim ary tubulointerstitia l nephritis, which could result from 
vesicoureteral reflux (VUR) or urinary flow  obstruction tha t may be com pounded by the 
increased volum e of urine produced in these mice. Obstruction of urine flow  can occur as a result 
of obstruction of tubular lumen by renal calculi. However, histological examination of these 
kidneys revealed only an occasional, but not generalized presence of calcification within renal 
tubular lumen, indicating that renal tubular obstruction by Ca2+ phosphate crystals is unlikely to 
be the cause of tubulo interstitia l nephritis in these mice.
Assessm ent o f Trpv5 and calbindin-D28K expression in wild-type and m utant kidneys 
To assess the effect of the S682P mutation on TRPV5 expression in the kidney, 8-^m  kidney
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Figure 4. Effect of TRPV5-S682P mutation on TRPV5 and calbindin-D28K expression in 
kidney. (A-B) Representative immunohistochemical images of kidney sections from wild-type (wild-type), 
Trpv56 2P/+ (het) and Trpv5®82P/682P (hom) mice, co-stained for (A) TRPV5 and NCC, and (B) TRPV5 and 
AQP2. * denotes co-localisation. Scale bar = 50^m. (C) Histogram depicting the ratio of the number of 
TRPV5-NCC co-positive cells to the total number of TRPV5-positive cells (N=5 mice/group). V5, TRPV5 
(D) Representative immunohistochemical images of calbindin-D28K (CaBP28K) stained kidney sections 
from wild-type (wild-type), Trpv5®82P/+ (het) and Trpv5®82P/682P (hom) mice. Scale bar = 200^m (E) 
Histogram depicting calbindin-D28K protein abundance determined by computerized analysis of 
immunohistochemical images (N=4-6 mice/group) (F) Semi-quantitative western blotting of calbindin-D28K 
in kidney. The a-1 subunit of the Na/K-ATPase was used as a housekeeping gene to normalize for equal 
loading. All histogram data are presented as means ± SEM. *P<0.05, **P<0.01 are considered significantly 
different from wild-type mice.
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cryosections were co-stained with anti-TRPV5 antibodies, and antibodies against the 
thiazide-sensitive sodium /chloride co-transporter (NCC) or aquaporin-2 (AQP2) to distinguish the 
expression of TRPV5 in the DCT2 and CNT, respectively. In the adult mouse kidney, NCC is 
expressed at the apical regions of DCT cells, with a slight decrease in expression towards the 
most distal part of the DCT segm ent (16), whereas AQP2-expression begins at the CNT and 
extends throughout the collecting ducts (17, 18). In kidneys of w ild-type mice, im m unostaining of 
TRPV5 was observed in the apical regions of the second half of the DCT (DCT2), and in the 
cytoplasm ic regions of CNT cells (Figure 4A-B), as previously described (16). By contrast, in 
kidneys of Trpv5682PI682P mice, overall TRPV5-im m unofluorescence was greatly reduced, 
especially in NCC-positive (AQP2-negative) tubular cells. In these cells, TRPV5-sta ining was 
absent or appeared diffusely cytoplasm ic (Figure 4A-B). Overall TRPV5-im m unofluorescence in 
Trpv5682PI+ kidneys appeared to be unaffected com pared with w ild-type kidneys (Figure 4A-B), 
although a functional effect on renal Ca2+ excretion was still apparent. Careful exam ination of 
TRPV5-NCC co-stained sections revealed tha t in Trpv5682P/+ kidneys, TRPV5-expression 
appeared confined to the most distal portion of the DCT2 where NCC-im m unostaining was 
weakest (Figure 4A). To test this observation, the num ber of TRPV5-positive and TRPV5-NCC 
co-positive cells in wild-type, Trpv5682P/+ and Trpv5682P/682P mice were counted in a m inimum of 3 
different fie lds per kidney section and the % of TRPV5-positive cells tha t were NCC co-positive 
was determ ined (N=5 mice/group). Our results showed that TRPV5-NCC co-positive cells in 
kidneys of Trpv5682P/+ and Trpv5682P/682P mice were reduced in com parison to w ild-type kidneys 
(100% ± 13%, 56% ± 6% and 27% ± 5% fo r wild-type, Trpv5682P/+ and Trpv5682P/682P, respectively, 
P<0.05 com pared to wild-type) (Figure 4C).
The in tracellular vitam in D-regulated Ca2+-binding protein calbindin-D28K is co-expressed 
with TRPV5 in the DCT2/CNT. We therefore investigated calbindin-D28K expression in Trpv5682PI+ 
and Trpv5682PI682P kidneys by sem i-quantitative im m unohistochem istry and W estern blot analysis. 
Expression levels of calb indin-D28K in Trpv5682PI+ kidneys were not significantly different from
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wild-type kidneys (Figure 4D-F). However, sem i-quantitative im m unohistochem ical analysis of 
Trpv5682P/682P kidneys revealed tha t calbindin-D28K-expression was significantly decreased (100 ± 
11%, 108% ± 32 and 8 ± 2% for wild-type, Trpv5682P/+ and Trpv5682P/682P, respectively, P<0.05 
com pared to wild-type). This observation was confirm ed by W estern blot (100 ± 6%, 120 ± 13% 
and 52 ± 3% for wild-type, Trpv5es2PI+ and Trpv5682P/682P, respectively, P<0.05 com pared to 
wild-type). (Figure 4D-F).
Functional assessm ent o f Trpv5-S682P channels
W e next investigated the effect of the S682P mutation on TRPV5 function in intact cells. Human 
Embryonic Kidney (HEK) 293 cells were transiently transfected with constructs encoding 
enhanced green fluorescent protein (eGFP)-tagged wild-type mouse TRPV5 
(m TRPV5-w ild-type), mouse TRPV5 with the S682P mutation (m TRPV5-S682P), or the empty 
mock vector. eGFP positive cells were monitored for changes in intracellular Ca2+ ([Ca2+]i) in 
response to changes in extracellular Ca2+ ([Ca2+]o) using the Ca2+-sensing dye, Fura-2. Transient 
expression of mTRPV5-w ild-type resulted in an elevated basal [Ca2+]i level com pared to 
m ock-transfected cells, due to increased Ca2+ perm eability of the cell. When the cells were 
superfused with Ca2+-free medium, the [Ca2+]i in TRPV5-expressing cells dropped to levels 
sim ilar to mock-transfected cells. Reapplication of 1.4 mM Ca2+ solution induced a rapid increase 
of [Ca2+]i followed by a gradual decrease back to basal levels (Figure 5A). No significant changes 
in [Ca2+]i were observed in m ock-transfected cells (Figure 5A). By comparison, cells transfected 
with m TRPV5-S682P showed a lower basal [Ca2+]i than mTRPV5-w ild-type transfected cells 
(N=24/group, P<0.05, Figure 5A-B). The m TRPV5-S682P transfected cells had a sim ilar 
response in [Ca2+]i to Ca2+ depletion and Ca2+ reapplication as tha t observed in 
m TRPV5-w ild-type transfected cells. These data strongly suggest tha t the S682P mutation in 
TRPV5 affects Ca2+ perm eability of the cell, a feature consistent with the hypercalciuric 
phenotype observed in Trpv5682PI+ and Trpv5682PI682P mice.
TRPV5 and autosomal dominant hypercalciuria
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Figure 5. Monitoring TRPV5 activ ity using Fura-2. (A) Representative trace of Fura-2 ratio in 
HEK293 cells transiently transfected with an empty EGFP vector (mock), or EGFP-tagged 
mTRPV5-wild-type (V5-wild-type) or mTRPV5-S682P (V5-S682P). Cells expressing EGFP were selected 
and monitored for changes in intracellular Ca2+ levels when extracellular Ca2+ concentrations were varied 
from 1.4 mM Ca2+ to 2mM EDTA and 1.4mM Ca2+ which was facilitated by superfusion. (B) Fura-2 levels 
under resting conditions (t0), minimal Fura-2 ratio after EGTA treatment (tmin) and peak level (tmax) upon 
administration of 1.4mM Ca2+ after EGTA treatment. Average data of cells transfected with the empty 
vector (N=7), mTRPV5-wild-type (N=24) and mTRPV5-S682P (N=24) from at least three independent 
experiments. * P<0.05 is considered significantly different from cells transfected with empty vector. # 
P<0.05 is considered significantly different from mTRPV5-wild-type transfected cells.
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Our studies have identified a novel mouse model, H ca lc l, for autosomal dom inant hypercalciuria 
and increased susceptib ility to primary tubulo interstitia l nephritis. Importantly, we have provided 
evidence that the mutation in the mouse TRPV5 gene underlies the observed hypercalciuria. 
This is based on the follow ing observations: i) The T>C substitution in codon 682 of mouse 
TRPV5 results in substitution of a highly conserved serine residue, making it unlikely to be simply 
a silent polym orphism  (Figure 1); ii) Expression of TRPV5 in Trpv5682PI+ and Trpv5682PI682P 
kidneys was altered, particularly in the DCT2 segm ent (Figure 4A-C); iii) Renal 
calbindin-D28K_expression in Trpv5682PI682P mouse kidneys was greatly reduced, further supporting 
a specific defect in TRPV5-m ediated Ca2+ reabsorption (Figure 4D-F); iv) The alteration from  
S682 to a proline leads to a reduced basal [Ca2+]i level in HEK293 cells transfected with 
m TRPV5-S682P, indicating a defect in the TRPV5-m ediated Ca2+ perm eability of the cell (Figure 
5).
Hcalc1 is the firs t reported genetic model with autosomal dom inant hypercalciuria due to 
a mutation in TRPV5. Hcalc1 mice are hypercalciuric, hyperphosphaturic, polyuric, polydipsic 
and have a low urine pH. However, despite extreme calciuresis, renal calcification was only very 
occasionally found in Hcalc1 kidneys, and this was not different from  wild-type mice. These 
features are s im ilar to the reported phenotype in Trpv5'l~ mice (7). It has been postulated that 
polyuria and low urine pH reduce the risk of Ca2+ phosphate precip itations in hypercalciuric mice 
(7, 19). Indeed, studies in Trpv5'l~ mice have shown that increased luminal Ca2+ activates the 
apical Ca2+-sensing receptor in collecting duct cells. This, in turn, leads to the downregulation of 
the AQP2 water channel and increased activity of the proton pump H+-ATPase, resulting in 
polyuria and increased acid secretion into the urine, respectively (19). Abolishm ent of this 
com pensatory urinary acidification in Trpv5'l~ mice by genetic ablation of the B1 subunit of the 
H+-ATPase resulted in severe Ca2+ phosphate precipitation in the renal medulla (19). S im ilar 
m echanisms may occur in Hcalc1 mice fo r reducing the risk of Ca2+ precipitation in the presence
TRPV5 and autosomal dominant hypercalciuria
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of hypercalciuria.
Although TRPV5 is a major protein involved in active Ca2+ reabsorption in the kidney, to 
date, no TRPV5 mutation has been identified in patients with hypercalciuric kidney stone disease 
(20, 21). However, in a recent paper investigating the functional s ignificance of common TRPV5 
SNPs in A frican Am ericans who have lower urine Ca2+ excretion and reduced risk of kidney 
stones com pared with white Americans, the TRPV5 A563T and L712F variants were shown to 
exhibited an increased Ca2+ influx in Xenopus laevis  oocyte assays com pared with the reference 
TRPV5, suggesting that these alleles may contribute to the superior ability of African Am ericans 
to conserve Ca2+ (20). More importantly, th is increase in TRPV5 Ca2+ uptake in the A563T variant 
was observed even under experimental conditions m im icking com pound heterozygous state, or 
in com bination with other TRPV5 nonsynonym ous SNP variations (20). Interestingly, the L712F 
residue, like our S682P mutation, is located in the cytoplasm ic C-term inal tail of TRPV5, although 
the basis of the increased efficiency of th is variant was not investigated.
The TRPV5 S682P mutation identified in the H ca lc l mice was shown in heterologous 
expression studies to result in reduced TRPV5-m ediated Ca2+ perm eability (Figure 5). Transient 
expression of m TRPV5-S682P into HEK293 cells revealed a lower [Ca2+]i, than observed in the 
m TRPV5-w ild-type-transfected cells. This observation is in agreem ent w ith a reduction in cellular 
Ca2+ transport in the S682P mutant. Changing the extracellu lar Ca2+ concentration (from 
depletion to reapplication) in HEK293 cells, leads to an overshoot of [Ca2+]i fo llowed by a gradual 
decrease in [Ca2+]i, which likely reflects Ca2+-dependent inactivation of the channel. This feature 
has been described in detail previously (22). As the response to Ca2+ depletion and Ca2+ 
reapplication was sim ilar between the m TRPV5-S682P and mTRPV5-w ild-type transfected cells, 
it is unlikely that the mutation directly affects the Ca2+-induced channel inactivation. The 
intracellular C-term inal region of TRPV5 contains several protein-binding and regulatory motifs, 
including three predicted protein kinase C phosphorylation sites and binding dom ains for the 
Na+/H+ exchanger regulatory factors 2 and 4 and Rab11a, tha t have been shown to regulate the
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subcellu lar localization and trafficking of TRPV5 (23-25). Although S682 is not a predicted 
phosphorylated residue and does not form  part of a known protein interaction or regulatory 
dom ain, it is possible that the alteration from  a serine to a proline could result in protein 
m isfolding which m ay alter protein binding and/or regulatory s ites, and in turn affect TRPV5 
channel function and/or trafficking to the apical membrane. A phosphorylation site has been 
reported close to the C-term inal end (T709), which affects the single-channel activity of the 
TRPV5 channel. W hether th is mutation could influence phosphorylation kinetics remains to be 
determ ined (26).
Despite the presence of a w ild-type TRPV5 allele in Trpv5682P/+ mice, the observed 
hypercalciuria in Trpv5682P/+ mice is at least as severe as tha t reported for the Trpv5~ mice 
(Figure 2C) (7). This suggests tha t in Trpv5682P/+ mice, the TRPV5-S682P protein is exerting a 
dom inant-negative or antagonistic effect on the w ild-type TRPV5 protein. This can be explained 
by the fact that the TRPV5 channel com prises four TRPV5 monomers tha t form  a central pore 
(15). Thus in Trpv5682P/+ DCT/CNT, there would be a 1 in 16 probability that a TRPV5 tetram er 
com prising four w ild-type subunits is formed, and a 15 in 16 probability that an assembled 
TRPV5 tetram er com prises at least one mutant subunit. A TRPV5 channel com prising at least 
one TRPV5-S682P subunit would be predicted to be less efficient than one com prising four 
w ild-type TRPV5 subunits. The hypercalciuria in Trpv5682P/682P mice is much more pronounced 
than that in observed in Trpv5682P/+ mice and Trpv5'l~ mice (Figure 2C) (7), suggesting a dosage 
effect of the mutated allele. TRPV6 is co-expressed with TRPV5 in the DCT2/CNT of w ild-type 
mouse kidney (17). It has been previously shown by heterologous expression studies in HEK293 
cells tha t TRPV5 and TRPV6 can form  functional heterotetram eric com plexes and that the 
electrophysiological properties of the resulting channel depend on the com bination/ratio of 
TRPV5/TRPV6 subunits that make up the tetram er (7). W hilst studies in Trpv5~ mice have 
shown tha t expression of TRPV6 in DCT2/CNT is not suffic ient to com pensate fo r the loss of 
TRPV5 in the mouse kidney, in Trpv5682P/682P mice, heteromerisation of TRPV5-S682P with the
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endogenous TRPV6 monomers would be predicted to result in TRPV5/TRPV6 com plexes with 
lower Ca2+ permeability, thereby leading to an even more severe phenotype.
The reduction in Ca2+ perm eability of m TRPV5-S682P-transfected HEK293 cells (Figure 
5), however, does not fully explain the degree of hypercalciuria observed in Trpv5682P/+ and 
Trpv5682P/682P mice (Figure 2). Im m unofluorescence studies in Trpv5682P,+ and Trpv5682P/682P 
kidneys have shown that TRPV5-expression is greatly reduced from  the apical membrane of 
DCT2 cells, suggesting tha t the S682P mutation could be affecting TRPV5 trafficking or 
regulation in these cells. W hile TRPV5 prim arily localizes to the CNT in rabbit, th is protein is 
highly expressed in apical m embrane domains of the DCT2 cells in the mouse. Here, a gradual 
decrease in TRPV5 expression is observed from  the DCT2 towards the CNT, suggesting that the 
majority of TRPV5-m ediated Ca2+ transport occurs in the DCT2 segm ent (15, 16). It is not known 
why TRPV5-expression in DCT2 cells of Trpv5682P/+ and Trpv5682P/682P kidneys appeared more 
affected than TRPV5-expression in the CNT, but this could be due to potential TRPV5 
regulatory/interacting proteins present in DCT2 cells tha t are not expressed in the CNT. These 
findings underscore the im portance of the DCT2 in active Ca2+ uptake, as strong 
TRPV5-expression in the CNT alone is not suffic ient to prevent hypercalciuria in Trpv5682P/+ mice.
Expression of the vitam in D-regulated calb indin-D28K protein was also found to be 
significantly reduced, but only in the Trpv5682P/682P mice. Such reductions have previously been 
observed in models with defective Ca2+ influx via TRPV5, such as the Trpv5'l~ and Klotho~/~ mice 
(7, 27). It is interesting that calb indin-D28K-expression is reduced in these animals, as they have 
severe hypervitam inosis D3, a feature that is likely to exist in the H ca lc l model as well. This 
observation suggests that cellu lar Ca2+ concentration is an im portant regulator of calbindin-D28K 
expression, overriding the stim ulatory effects of vitamin D. Indeed, previous experiments in 
primary cultures of im m uno-isolated rabbit CNT cells have dem onstrated that inhibiting Ca2+ 
influx via TRPV5 using the channel blocker, ruthenium  red, significantly reduces calbindin-D28K 
abundance (28). This may also explain why a change in calb indin-D 2 8 K expression in Trpv5682P/+
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mice was not observed, as som e Ca2+ influx is still expected, via the w ild-type TRPV5 channel. 
Thus, our data are in line with previously published observations, suggesting a functional defect 
in TRPV5-m ediated Ca2+ transport in our mice.
One unexpected finding in our Hcalc1 model was that ~9% of Trpv5682P/+ and ~13% of 
Trpv5682P/682P male mice developed primary tubulo interstitia l nephritis by the age of 25 weeks 
(Figure 3). Primary tubulo interstitia l nephritis may result from  urinary reflux due to possible 
obstruction by kidney stones or VUR, which would be com pounded by the polyuria in these mice. 
However, histological examination of kidneys from  these mice indicate that Ca2+ precipitation 
within tubular lumen were uncommon and therefore unlikely to be the cause of the 
tubulointerstitia l nephritis. In a recent study of 11 inbred mouse strains for susceptib ility to VUR, 
C57BL/6J mice were found to be VUR-resistant, while the C3H/HeJ inbred mouse was identified 
as a VUR-susceptible strain w ithout kidney m alformations (29). The authors showed that the 
predisposition of C3H/HeJ mice to reflux was as a result of a defective uretero-vesical junction 
characterized by a short intravesical ureter. This phenotype was shown to be inherited in an 
autosomal recessive manner and the VUR locus (V u rm l)  was mapped to mouse chrom osom e 
12 (29). Since the H ca lc l model was generated on a mixed B6J/C3H genetic background, it is 
possible tha t the tubulo interstitia l nephritis in this subset of Trpv5SS2PI+ and Trpv5ss2pms2p male 
mice is a result of an increased susceptib ility to VUR from  a com bination of uretero-vesical 
junction defect and polyuria. Tubulointerstitia l nephritis has not been previously been reported in 
Trpv5-/- mice, although special focus has not been placed on this feature (7). This difference 
between the Trpv5-/- mice and our hypercalciuric model is likely to be due to the difference in the 
genetic background of these two models, since the Trpv5~ mice were generated on a 129/Sv 
background (7), a mouse strain tha t is resistant to VUR (29).
In summary, H ca lc l is the first model reported to have dom inant hypercalciuria and a 
m issense mutation in TRPV5. Our model will prove useful in understanding the interplay 
between TRPV5 and other factors regulating Ca2+ hom eostasis and factors underlying
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susceptib ility to tubulo interstitia l nephritis.
Methods
Experim ental Animals
All studies were perform ed in accordance with guidelines provided by the UK Home Office 
Project license. All animals were maintained in specific pathogen-free fac ilities, in individual 
ventila ted cages and a 12 hrs light-dark cycle, with free access to food and water. Mice were fed 
on Rat and Mouse No.3 diet contain ing 1.15% (w/w) Ca2+, 0.82% (w/w) total phosphorus and 
approx. 4,100 units/kg of vitam in D (Special Diets Services, W ytham, Essex, UK).
Generation o f m utant mice
ENU-m utagenesis of C57BL/6J (B6J) male mice was performed as described in detail previously 
(13). F1 mice were obtained by crossing ENU-m utagenised B6J male mice with C3H/HeH (C3H) 
fem ale mice. G2 mice were subsequently obtained by mating the founder male mouse with C3H 
fem ale mice, or by in vitro fertilization of C3H eggs using sperm from  the founder male. These 
mice were used for inheritance testing and mapping studies. Hom ozygous mutant mice 
( Trpv5682P/682P) mice were generated by intercrossing heterozygous ( Trpv5682P/+) male and female 
mice.
Phenotype screen
16-week old F1 male mice were kept in m etabolic cages (Techniplast, Kettering, UK) for 24 hrs 
with free access to food and water. Bodyweight was determ ined before and after the experiment. 
Food and water intake was also monitored. 24 hrs urine sam ples were collected in the presence 
of NaN3 and stored at -70°C. Blood sam ples were collected from  the tail vein using lithium 
heparin-coated M icrovette tubes (Sarstedt, Leicester, UK). Urine and plasma chem istry were
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measured using an O lympus AU400 m ulti-channel analyser. Urine param eters were calculated 
as a ratio of sam ple creatinine, and plasma Ca2+ was adjusted for plasma albumin concentration 
using the formula: Plasma Ca2+ (mM) -  [(plasma albumin (g/L) -  30) x 0.017], as previously 
described (30).
Urine and p lasm a chem istry
Urine sam ples were collected in m etabolic cages as above. Blood sam ples were collected 
following term inal anesthesia from the internal jugu lar vein in lithium heparin Microvette tubes as 
previously described (30). Urine and plasma chem istry were perform ed as above.
G enetic m apping
DNA was isolated from ear or tail biopsies using the Gentra PureGene DNA isolation kit 
(QIAGEN, Crawley, UK). A genome wide scan was performed on 13 mice by Pyrosequencing on 
the PSQ HS 96A Instrum ent (QIAGEN), using a panel of ~60 inform ative SNPs, distributed at 
20-30cM intervals across 19 autosom es (http://www.pyrosequencing.com /). Further mapping 
was carried out using more mice and additional inform ative SNPs across the candidate interval.
DNA sequence analysis
Exons and the corresponding intron-exon boundaries of the mouse Trpv5 and TRPV6 genes 
were amplified by PCR using gene specific primers. DNA sequences were determ ined by 
sem i-autom ated DNA sequencing. The DNA sequence abnorm ality identified was confirm ed by 
SsaJI restriction enzyme digest of PCR products.
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Kidney h isto logy and im m unohistochem istry
Kidneys were cut in half, im mersion-fixed in 10% (w/v) form alin overnight, and subsequently 
embedded in paraffin. 4 |im -sections were prepared and stained w ith H&E, and von Kossa to 
evaluate the presence of renal calcifications as described previously (31). TUNEL-sta in ing for 
detection of apoptotic cells was performed using the ApopTag Fluorescein In Situ Apoptosis 
Detection kit (M illipore, W atford, UK) according to the m anufacturer's instructions. The presence 
of T-lym phocytes was detected using rabbit anti-CD3 monoclonal antibodies (ab16669, Abcam, 
Cambridge, UK), and subsequently visualized by secondary detection using A lexa Fluor 
488-conjugated donkey anti-rabbit (M olecular Probes, Invitrogen, Paisley, UK). Stained sections 
were mounted in a mounting medium contain ing DAPI (Vector Labs, Peterborough, UK).
For TRPV5 detection, dissected kidneys were cut in half and embedded in OCT 
embedding medium on liquid nitrogen-cooled isopentane. 8-^m  kidney cryosections were 
co-stained w ith rabbit anti-TRPV5 (ACC-035, Alom one Labs, Jerusalem, Israel) and goat 
anti-AQP2 (sc-9882, Santa Cruz, Insight Biotechnology, W embley, UK) polyclonal antibodies, or 
with goat anti-TRPV5 (sc-23379, Santa Cruz) and rabbit anti-NCC polyclonal antibodies, 
followed by the appropriate A lexa Fluor 488- or 594-conjugated secondary antibodies (M olecular 
Probes). Photoghraps of TRPV5 stained sections were taken on a Nikon Eclipse E400 
microscope equipped with a Nikon DXM1200C digital camera. Images of kidney sections stained 
for each antibody were photographed under identical exposure conditions for all mice. The 
NIS-Elem ents BR 3.0 software was used to count the num ber of TRPV5-positive and 
TRPV5-NCC co-positive cells.
For calbindin-D 2 8 K detection, kidneys were immersion fixed in 2% (w/v) 
periodate-lysine-paraform aldehyde (PLP), followed by overnight incubation in 15% (w/v) sucrose. 
7-|im  cryosections were prepared and stained with rabbit anti-calbindin-D28K. Photographs of 
calbindin-D28K staining in kidney cortex were taken through a 10x objective on a Zeiss 
fluorescence m icroscope (Sliedrecht, The Netherlands) equipped with a digital photo camera
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(Nikon DMX1200). Sem i-quantitative determ ination of calbindin-D28K protein expression was 
done using Image J (image processing program, NIH, USA), s im ilar to previous publications
(32).
Western b lot analysis o f renal calbindin-D28K
For quantification of renal calbindin-D28K protein expression, mouse total kidney lysates were 
prepared and analyzed as described previously (33). Briefly, proteins in kidney lysates were 
separated using SDS-PAGE and subsequently electro-transferred to polyvinylidene fluoride 
membranes (Immobilon-P, Millipore Corporation, Bedford, MA, USA). Blots were incubated 
overnight with rabbit anti-calbindin-D28K polyclonal antibodies (Sigma, St Louis, MO, USA) and 
mouse anti-Na/K-ATPase a1-subunit monoclonal antibodies (generously provided by Professor 
Michael J. Caplan, Yale University School of Medicine, New Haven, CT, USA). Subsequently, 
the blots were incubated with A lexa Fluor 680-conjugated goat anti-rabbit (M olecular Probes, 
Invitrogen) and IRDye 800CW  conjugated goat anti-m ouse (LI-COR B iosciences GmbH, Bad 
Homburg, Germany) secondary antibodies. Imm unoreactive protein was detected using the 
Odyssey infrared detection system  (W estburg, Leusden, The Netherlands). Densiometric 
analysis was done using Image J.
Video im aging o f [Ca2+]i using Fura-2-AM
Functional studies were perform ed using cDNAs encoding full-length w ild-type (w ild-type) and 
mutant (S682P) mouse TRPV5 tha t were cloned in-frame with EGFP in the mammalian vector 
pCINeo/IRES-EGFP. HEK293 cells were seeded on fibronectin-coated coverslips (0  25 mm) 
and transfected with the appropriate pCINeo/IRES-EG FP vector. A fte r 24hr, cells were loaded 
with 3|iM Fura-2-AM (M olecular Probes) and (0.01% v/v) pluronic F-129 (M olecular Probes) in 
DMEM medium at 37°C for 20 min. A fter loading, cells were washed tw ice with PBS and allowed 
to equilibrate at 37°C for another 10 min in HEPES-Tris buffer (132.0 mM NaCl, 4.2 mM KCl, 1.4
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mM CaCl2, 1.0 mM MgCl2, 5.5 mM D-glucose and 10 mM HEPES, titrated to pH 7.4 with Tris). 
For Ca2+ free conditions, a sim ilar buffer com position was used in which Ca2+ was substituted 
with 2  mM EGTA.
After Fura-2 loading, cells were placed in an incubation cham ber and attached to the 
stage of an inverted m icroscope (Axiovert 200M, Carl Zeiss, Jena, Germany). Extracellu lar Ca2+ 
was changed using a perfusion system  and resulting changes in cytosolic Ca2+ levels were 
monitored with Fura-2 excited at 340 and 380 nm using a m onochrom ator (Polychrome IV, TILL 
Photonics, Grafelfing, Germany). F luorescence emission light was directed by a 415DCLP 
dichroic mirror (Omega Optical Inc., Brattleboro, VT, USA) through a 510W B40 emission filter 
(Omega Optical Inc.) onto a CoolSNAP HQ monochrome CCD-cam era (Roper Scientific, Vianen, 
the Netherlands). The integration time of the CCD-cam era was set at 200m sec with a sampling 
interval of 3sec. All hardware was controlled with M etafluor 6.0 software (Universal Imaging 
Corporation, Downingtown, PA, USA). Quantitative image analysis was performed with 
Metamorph 6.0 (M olecular Devices Corporation, Sunnyvale, CA, USA). For each wavelength, 
the mean fluorescence intensity was monitored in an intracellular region and, for purpose of 
background correction, an extracellular region of identical size. A fter background correction, the 
fluorescence em ission ratio of 340 nm and 380 nm excitation was calculated to determ ine the 
intracellular Ca2+ concentration. All m easurem ents were performed at room temperature. 
Numerical results were visualized using Origin Pro 7.5 (OriginLab Corp., Northampton, MA, 
USA).
Statistical analysis
Data are presented as mean ± SEM unless otherwise stated. Statistical significance between two 
groups was determ ined by pair-wise com parisons using a two-tailed unpaired Student's t-test. 
For com parisons of param eters between wild-type, Trpv5682P/+ and Trpv5682P/682P mice, ANO VA 
analysis with Bonferroni's correction for multiple com parisons was used.
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CHAPTER 8
General discussion and summary

The kidney stabilizes the system ic electrolyte concentrations within normal ranges. This is 
achieved by am ending the renal reabsorptive capacity fo r these electrolytes. The distal 
convolution (an anatom ical structure encom passing the distal convoluted tubule (DC T), the 
connecting tubule (CNT), and the initial collecting duct (CD) (1)) plays a central role in 
reabsorbing Na+, Cl-, Mg2+, and Ca2+ from  the renal ultrafiltrate. As such, NaCl transport within 
these segm ents contributes greatly to the maintenance and adjustm ent of blood pressure. 
Reabsorption of divalent cations by the distal convolution allows the maintenance of adequate 
plasma levels of Mg2+ and Ca2+, which are essential for many physiological processes, such as 
neuronal excitability, muscle contraction, and bone formation. The distal convolution is under 
intense hormonal regulation to balance the urinary excretion of electrolytes in response to 
system ic changes in these ions. Thus, understanding the m olecular pathways tha t regulate ion 
transport in the distal convolution, contributes im portantly to the understanding of the physiology 
and pathophysiology of these aforem entioned processes. As such, dysregulation of electrolyte 
transport in these segm ents (as exemplified by m onogenic disorders affecting the distal 
convolution) may impose a sh ift or even com plete ly blunt the renal reabsorptive capacity for 
these ions. Therefore, the overall aim of this thesis was to gain more knowledge about the 
regulation of electrolyte transport processes that are involved in the vectorial movem ent of Na+, 
Cl-, Mg2+, and Ca2+ across the distal convolution.
The distal convolution is com posed of several cell types, which each are im portant for the 
transport of Na+, Cl-, Mg2+, and Ca2+. Thiazide-sensitive NaCl transport occurs in the DCT cells, 
while am iloride-sensitive Na+ transport predom inates in the CNT and CD. The DCT2 is a 
segm ent in which the thiazide- and am iloride-sensitive Na+ transport co-exists. Additionally, Mg2+ 
transport is localized exclusively in the DCT, while the cells of DCT2, CNT, and initial CD 
transport Ca2+. The thiazide-sensitive NaCl cotransporter (NCC) localize to the DCT1 and DCT2 
segments. NCC colocalizes with the Transient Receptor Potential Melastin 6 channel (TRPM6),
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a divalent cation channel im portant for the apical uptake of Mg2+ in the DCT. In the DCT2, CNT 
and CD, the am iloride-sensitive epithelial Na+ channel (ENaC) transports Na+ from the filtrate. 
Similarly, the transient receptor potential vanillo id 5 channel (TRPV5), co-localizes with ENaC in 
the distal convolution and play an instrum ental role in the apical uptake of Ca2+. The distribution 
of electrolyte transport system s in the distal convolution is depicted in Figure 1.
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F igu re  1. D is tr ib u tio n  o f  e le c tro ly te  tra n s p o rt pa thw ays  in the  d is ta l c o n v o lu tio n . NCC, 
thiazide-sensitive NaCl cotransporter; TRPM6, transient receptor potential melastatin 6 Mg2+ channel; 
ENaC, epithelial Na+ channel; TRPV5, transient receptor potential vanilloid 5 Ca2+ channel. PMCAlb, 
plasma membrane Ca2+ ATPase 1b; NCX1, Na+/Ca2+ exchanger. DCT, distal convoluted tubule; CNT, 
connecting tubule; CD, collecting duct.
NCC and y -ad du c in
Hypertension remains a key player in the developm ent of cardiovascular com plications and 
chronic renal failure. NCC is of crucial im portance for the reabsorption of NaCl by the distal 
convolution, thus influencing arterial pressure. In addition, thiazides that block NCC-dependent
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NaCl reabsorption are frequently prescribed fo r the treatm ent of hypertension. A better 
understanding of how NaCl transport is regulated via NCC may ultimately increase our 
understanding of how blood pressure is maintained and the etiology underlying primary 
hypertension. C hap te r 2 aimed to identify novel in teractors of NCC, which could be involved in 
modulating its function. As the amino (N)-term inal domain has been shown to play an important 
role in activating the transporter, we performed pull down experim ents using the N-terminal 
domain of NCC as bait. Mouse kidney lysates were screened and precipitates were 
subsequently sent for mass spectrom etry analysis. Here we identified y-adducin as a novel 
auxiliary factor interacting with NCC. The adducin gene fam ily had previously been im plicated in 
arterial hypertension. As such, one single nucleotide polym orphism  (SNP) in the y-adducin gene 
has been described, which is involved in systolic pressure regulation in certain individuals (2). 
Thus, y-adducin was an interesting candidate gene for the regulating of NCC.
Our study identified y-adducin as a strong interactor of the N-terminal domain of NCC. 
Using 22Na+ uptakes in Xenopus laevis oocytes injected with NCC in the presence and absence 
of y-adducin, we found that y-adducin markedly stim ulated the activity of the transporter. siRNA 
directed against the endogenous Xenopus laevis  y-adducin reduced NCC-dependent 22Na+ 
uptake. Competition with increasing am ounts of the N-term inal part of NCC com pletely reverted 
the stim ulatory action of y-adducin on thiazide-sensitive 22Na+ transport. In addition, the 
y-adducin binding site is mapped to the exact region encom passing three phosphorylation sites 
in the cotransporter. NCC form s lacking phosphorylatable sites in the N-term inus do not exhibit 
increased 22Na+ transport rates when co-injected with y-adducin. Moreover, y-adducin 
dissociates from  NCC when the phospho-residues are converted to aspartates, m im icking a 
constitutively active phosphorylated state of the transporter. Based on the data generated in 
C hap te r 2, we could generate a model predicting the role of y-adducin in activating NCC. 
y-Adducin may stim ulate NCC activity by anchoring a kinase, likely members of the STE20 fam ily 
(encom passing the Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress
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response 1 (OSR1)) to the dephosphorylated transporter. Subsequently, the kinase increases 
the phosphorylation level of NCC, thereby stim ulating the activity of the transporter. A fter the 
kinase-mediated phosphorylation event, y-adducin dissociates from NCC and may also facilitate 
the release of the associated kinase. Dephosphorylation of the transporter reduces the activity of 
NCC to its basal state. The data obtained in C hap te r 2 strongly suggest that y-adducin may 
contribute im portantly to the regulation of NCC and hence blood pressure maintenance.
The role of the W NK fam ily in the maintenance of am bient blood pressure has been firm ly 
established as pseudohypoaldosteronism  type II, due to defects in the WNK1 and WNK4 genes 
results in an augm ented renal reabsorption of NaCl and an increased arterial pressure (3, 4). 
Moreover, renal NaCl wasting and secondary hypokalem ic m etabolic alkalosis is observed in 
Gitelman patients with a defect in the SLC12A3  gene encoding NCC (5, 6). G itelman patients 
have been reported with m utations in one of the phosphorylation sites (threonine 60 converted to 
methionine) (7), further solidifying the need for intact NCC phosphorylation sites in am bient blood 
pressure m aintenance and renal NaCl reabsorption. These observations also suggest that 
changes in y-adducin function could influence the arterial pressure, by a skewed regulation of the 
NCC phosphorylation state. Interestingly, one intronic SNP has been described in the y-adducin 
gene, which corre lates with systolic pressure, but only in individuals tha t also harbor the G460W  
polym orphism  in a-adducin (2). These observations suggest that y-adducin can affect blood 
pressure, potentially by altering the phosphorylation level of NCC, however in order to be visible 
clinically, arterial pressure needs to be perturbed by the G 460W  polym orphism  in a-adducin. The 
findings of C hap te r 2 may aid in the understanding of the complex cascade regulating NCC 
activity in the distal convolution and may help elucidate the m olecular events underlying the 
formation of primary hypertension.
Figure 2 depicts the complex interplay between the different factors regulating NCC. It 
also attem pts to place these previously known findings in the context of y-adducin. 
Phosphorylation of the N-terminal domain in NCC seems to be a common final pathway by which
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several stimuli converge to regulate the activity of the transporter. As such, SPAK and OSR1 
have both been shown to m odulate the direct phosphorylation of NCC (8, 9). A lso both 
W ith-No-Lysine (WNK) kinases 1 and 4 regulate the phosphorylation level of NCC by modulating 
the STE20 kinases (8, 10). The positive effect of W NK4 on NCC phosphorylation, occurs only in 
the presence of angiotensin II, via activating phosphorylation upon sites in the STE20 fam ily of
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F igu re  2. P rop ose d  m odel d e p ic tin g  the  c o m p le x  re g u la tio n  o f NCC and th e  p o te n tia l ro le  
o f y -ad d u c in . AngII, angiotensin II; WNK, with-no-lysine, SPAK, Ste20-related proline-alanine-rich 
kinase; OSR1, oxidative stress response 1; PKA, protein kinase A; PKC, protein kinase C.______
kinases (10). It is likely the in tracellular Ca2+ concentration that dictates w hether W NK4 acts as 
an activator of NCC. Thus, when the angiotensin II type I receptor is activated, intracellu lar
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elevations in Ca2+ causes WNK4 to act as an activator of NCC, by modulating phosphorylation. 
In the absence of angiotensin II-dependent increases in intracellular Ca2+, WNK4 functions by 
removing NCC from the membrane, diverting it to the lysosomal compartment (11, 12). As 
several of the mutations in WNK4 which are observed in PHAII are located near a putative Ca2+ 
binding site, it may be that these mutations mimic Ca2+ binding, hence leading to increased 
phosphorylation of NCC and hypertension. y-Adducin reverted the inhibitory effect of WNK4 on 
NCC in its basal state (i.e. without activation of thel angiotensin II receptor). Moreover, our data 
suggest that y-adducin stimulates a process occurring before the lysosomal removal of NCC, 
namely phosphorylation. It is currently unclear whether WNK4 can stimulate or interact with 
y-adducin in its angiotensin II activated state, a matter for future studies. Another, and perhaps 
even more interesting point which could be addressed experimentally is the potential 
involvement of WNK1 in the phosphorylation cascade, leading to NCC activation. WNK1 
increases the transport activity and phosphorylation level of NCC during Cl--depleted conditions, 
due to activation of SPAK and OSR1 (8). Whether a potential additional effect could be on 
y-adducin remains to be determined, but should be considered likely. As will be discussed below, 
several other kinases can activate the adducin family leading either to changes in its localization 
or function. WNK1 also plays an additional role in NCC trafficking, as the protein can block the 
lysosomal shuttling of NCC mediated by WNK4, via interaction with the kinase (11, 13).
The adducin family of kinases contains several phosphorylation sites, making them 
substrates for protein kinases A (PKA) and protein kinase C (PKC). In addition, the adducin's 
also bind calmodulin, another Ca2+-activated protein (14). PKA-dependent phosphorylation of 
adducin causes a reduced affinity for spectrin-F-actin complexes (14). Moreover, 
phosphorylation of adducin by PKC has been shown crucial for platelet activation and for the 
localization of the protein (15-17). It is currently difficult to translate potential changes in the 
phosphorylation level of y-adducin by either PKA or PKC into functional changes in NCC. 
However, it has been shown that NCC is phosphorylated upon vasopressin dependent PKA
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activation (18). Moreover, both PKA and PKC phosphorylation at certain sequences leads to 
inhibition of calmodulin-binding in the p-adducin subunit. Whether, this is also occurring in the 
y-adducin subunit remains unclear. It is however noteworthy that calmodulin, similarly to WNK4, 
is activated by elevations in intracellular Ca2+ (14). Future experiments are necessary to dissect 
whether there is a functional overlap between these signaling pathways and the coordinated 
function of y-adducin and NCC.
Another pathway potentially activating y-adducin deserves mentioning. Aldosterone is an 
important hormone involved in blood pressure maintenance and potassium secretion. These 
actions are in part mediated by increasing transport capacity in the DCT. Aldosterone has been 
shown to affect NCC phosphorylation as blockade of the mineralocorticoid receptor by 
spironolactone prevents phosphorylation of NCC during dietary Na+ restriction (19). The 
expression of the serum- and glucocorticoid-inducible kinase 1 (SGK1) is increased by 
aldosterone, leading to several of the so-called early responses of aldosterone. Lack of SGK1 in 
mice has recently been shown to attenuate the increase in NCC phosphorylation, normally 
observed after dietary Na+ deprivation (20). Interestingly, y-adducin contains a predicted SGK1 
site at serine 42. Given the available data of aldosterone on NCC activation, the potential 
involvement of this putative SGK1 phosphorylation site deserves further investigation.
E rlo tin ib  and EGF-stimulated TRPM6 activ ity
TRPM6 is critically involved in active Mg2+ reabsorption in the distal convolution, acting as the 
apical entry step for Mg2+ in the DCT. Thus, the regulation of TRPM6 determines the final 
concentration of Mg2+ in the blood. Overall maintenance of plasma Mg2+ concentrations is 
essential for many cellular processes, including adequate function of neurological and 
cardiovascular systems. Therefore, factors affecting TRPM6 may cause e.g. neuromuscular 
dysfunction (tetany, muscle cramps and weakness as well as cardiac arrhythmias and
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tachycardia) in certain pathological states. Anti-cancer treatments with Cetuximab, a monoclonal 
antibody targeting the epidermal growth factor receptor (EGFR), causes hypomagnesemia in 
patients with colorectal cancer (21). However, numerous patient groups suffering from cancer 
receive tyrosine kinase inhibitors, such as Erlotinib (see figure 3 for summarized mechanisms of 
action). There are no published clinical reports detailing the potential effect of tyrosine kinase 
inhibitors on systemic and renal Mg2+ handling. Chapter 3 shows that Erlotinib is capable of 
affecting TRPM6 regulation and thereby altering Mg2+ handling. We observed that mice, which 
received supraphysiological doses of Erlotinib for 23 days, developed a decrease in their serum 
Mg2+ concentration. In addition, these Erlotinib-injected mice failed to reduce the fractional renal 
excretion of Mg2+ in response to a decreased serum Mg2+ concentration. Whole-cell patch clamp 
analysis can be used to determine the cellular permeability of an ion, generated by one or more 
channels. Using this technique in human embryonic kidney (HEK) 293 cells, we found that 
Erlotinib significantly inhibited EGF-stimulated TRPM6 channel activity. The HEK293 cells 
received dosages in the same range as the expected plasma concentration in mice (30 |iM of 
Erlotinib). Although moderate effects of Erlotinib were observed in vivo, application of the 
compound could still block EGF-stimulated TRPM6 currents and routing in HEK293 cells. Given 
that the free circulating concentration of Erlotinib is likely to be around 0.3 |iM in human patients, 
we tested whether this concentration would be able to block the effect of EGF on TRPM6 
currents. Here we could not detect any significant differences from EGF-stimulated cells. 
Evaluating EGF-induced tyrosine phosphorylation of its receptor substantiated these data. In 
addition, the inhibitory effect of Erlotinib on Mg2+ transport is likely to occur via inhibition of 
TRPM6 routing, by preventing EGF-mediated changes in the mobile fraction of TRPM6 proteins.
As many as 97% of colorectal cancer patients treated with the monoclonal antibody 
EGFR inhibitors such as Cetuximab develop hypomagnesemia to varying degree (21). These 
compounds are currently being considered as first-line treatment for metastatic colorectal cancer. 
However, side-effects due to these drugs are largely unexplored. It is now becoming increasingly
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Figure 3. EGFR blockade by E rlo tin ib  and Cetuxim ab can prevent EGF-induced changes 
in TRPM6 channel activ ity . (top) The blocking effects of Cetuximab on EGFR activity. The antibody 
binds with a 10 times higher affinity to the EGFR, as compared to EGF, thereby preventing EGFR 
dimerization and activation. (bottom) Erlotinib binds to the ATP binding pocket on the EGFR. This blocks 
tyrosine kinase activity and hence EGFR signalling. These effects are likely not observed at the dosages 
given to humans.
clear that hypomagnesemia is one of the most commonly reported side-effects. Chapter 3 is the 
first to delineate the effects of Erlotinib on Mg2+ handling in vivo. The effect on the systemic Mg2+ 
concentration seems less potent than that observed with antibody-based EGFR inhibitors. Still, 
clinical data detailing the effect of Erlotinib on Mg2+ handling is lacking. However, based on the 
doses given to cancer patients it is unlikely that Erlotinib severely affects serum Mg2+ 
concentrations in these individuals. As a result of mutations, the EGFR is overexpressed in many 
types of cancer, presumably leading to uncontrolled cell division. Blocking the receptor either 
using monoclonal antibodies or tyrosine kinase inhibitors would therefore slow cancer 
progression. However, while Erlotinib blocks the EGFR by binding to the ATP pocket, Cetuximab
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binds the receptor with almost 10 times higher affinity than that of EGF. One could envision that 
while Erlotinib only blocks the overexpressed EGFR often found in tumors, due to its affinity for 
the receptor and overall circulating levels in the body, this inhibitor is unlikely to interfere with the 
normal functions of the EGFR, such as the reabsorption of Mg2+ in the distal convolution. 
However, due to the high affinity of the Cetuximab compound, hypomagnesemia might develop. 
Many patients undergoing chemotherapy are receiving combination therapy with nephrotoxic 
and potential Mg2+-wasting drugs such as Cisplatinum. It should be noted that Erlotinib has the 
potential to modulate renal and systemic Mg2+ handling in vivo. Therefore, caution should be 
given when treating individuals prone to developing hypomagnesemia, such as patients 
receiving combinational treatment with Mg2+ lowering compounds.
Androgens and TRPV5-dependent Ca2+ transport
Active renal Ca2+ reabsorption in the distal convolution is critical in determining the final urinary 
Ca2+ excretion. Mice with a targeted deletion of the TRPV5 gene show augmented renal Ca2+ 
loss, due to a blunted Ca2+ reabsorption in the distal convolution (22). The Ca2+ transport 
capacity in this segment is regulated by calciotropic hormones, such as parathyroid hormone 
(PTH) and 1,25-dihydroxyvitamin D3 (23-25). In addition, estrogen has been shown to affect 
active renal Ca2+ transport (23, 26). Studies have previously addressed the impact of gender on 
the expression of renal transport proteins and consequently renal electrolyte handling. For 
instance, the density of NCC (quantified by 3H-metolazone binding) was two-fold higher in female, 
than in male rats (27). Furthermore, orchidectomy (ORX) resulted in an increase in 
3H-metolazone binding sites in males, whereas ovariectomy decreased the binding density in 
females (27). In terms of the maintenance of overall Ca2+ balance, several gender differences 
exist. Males have greater urinary Ca2+ losses than females (28, 29). In addition, estrogens have 
been shown to increase the renal reabsorption of Ca2+, in agreement with the observed gender
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differences (30). Presently, it remains unclear whether androgens play an opposing role to 
estrogens in modulating renal Ca2+ reabsorption. Thus, in Chapter 4 we elucidated whether 
androgens contribute to the gender differences in renal Ca2+ handling. As such, we investigated 
its ability to regulate the expression of renal Ca2+ transport proteins, in particular the Ca2+ 
channel, TRPV5. The study showed that testosterone contributes significantly to the sex 
differences observed in renal Ca2+ handling. Male mice had a greater urinary Ca2+ excretion 
compared to females, which is accompanied by a reduced renal expression of Ca2+ transport 
proteins. Androgen-deficient ORX mice showed a significant reduction in the urinary excretion of 
Ca2+. This reduction in urinary Ca2+ excretion was reverted after testosterone replacement. 
Similar data was obtained when evaluating the fractional excretion of Ca2+, suggesting that the 
testosterone-induced increase of urinary Ca2+ excretion is due to inhibition of tubular Ca2+ 
reabsorption. Renal mRNA and protein abundance of Ca2+ transporters was up-regulated in 
ORX mice, a feature which was normalized when the mice were resupplied with testosterone. In 
addition, inhibition of transcellular Ca2+ transport after dihydrotestosterone treatment was 
observed in rabbit kidney CNT/cortical CD (CCD) primary cell cultures.
Chapter 4 provides evidence that androgens contribute to the gender differences in renal 
Ca2+ handling. These effects occur by inhibiting the expression of renal Ca2+ transport proteins 
and independent of changes in calciotropic hormones or estrogen. Thus, as the role of estrogens 
on overall Ca2+ metabolism and Ca2+ storage in bone are well known. It is also widely accepted 
that the presence or absence of estrogen is critically involved in setting the urinary excretion of 
Ca2+ as well as determining the bone mineral density. However, the effect of androgens on 
mineral metabolism have only now been delineated and one has to reconsider previous gender 
differences relating to the effect of estrogen alone, and perhaps reevaluate these gender 
differences, not only as a result of estrogen levels, but also in part due to differences in the 
circulating levels of androgens. In that respect, males have larger urinary Ca2+ excretion than 
females as well as higher incidence for the development of kidney stones (31). The exact
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contribution of androgens to the development of kidney stones in males (or absence thereof in 
females) remains to be studied in detail, but based on the observations made in Chapter 4, it is 
likely that androgens contribute importantly to the differences observed between males and 
females.
It seems that the distal convolution is a target for sex hormones and that the regulation of 
the different transporters is highly dependent on gender. We as well as others have now shown 
that key transporters in this segment are regulated by not only estrogens, but also by androgens.
C alcitonin and renal Ca2+ transport
Active transcellular Ca2+ transport is restricted to the distal convolution. Studies in rabbit 
suggested that calcitonin (CT) exerted its effect on Ca2+ reabsorption only in DCT, while no 
stimulation occurs in the CNT (32). In addition, CT fails to stimulate cAMP accumulation in the 
CNT of rabbits (33). In the rabbit, TRPV5 localizes primarily to the CNT where CT does not affect 
Ca2+ reabsorption. However, in rats and mice, TRPV5 is highly expressed in apical membrane 
domains of particularly the DCT2 segment, with a gradual decrease along CNT and initial CD (23, 
34). The intrarenal distribution of TRPV5 in human is currently not known, however the structure 
of the distal convolution is similar to that of mouse. The bright portion of the DCT retains 
responsiveness to CT in the rat kidney, resulting in increased cAMP production (35). In addition, 
binding sites for CT have been identified in the rat kidney, including the thick ascending limb and 
DCT (36). Other cAMP-elevating hormones including PTH affect TRPV5-mediated Ca2+ 
transport by modulating expression and channel activity (25, 37). Currently, it is unclear whether 
there is a functional overlap between PTH and CT in the DCT2 regions of rats and mice and 
whether the CT-induced increase in cAMP could lead to a similar activation in the DCT2 segment 
as PTH.
Chapter 5 determined the molecular actions of CT on overall renal Ca2+ balance and
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delineates the potential effects of CT on TRPV5 dependant Ca2+ reabsorption in the distal 
convolution. Injections of CT for 16 or 40 hrs did not change the renal abundance of TRPV5. In 
addition, wild-type (TRPV5+/+) and TRPV5 deficient (TRPV5"/_) mice responded in a similar 
manner to CTl administration. Given the data obtained in these experimental models, it is likely 
that the effect of CT on renal Ca2+ transport occurs independently of TRPV5. Although CT does 
not affect TRPV5-mediated Ca2+ reabsorption, it is clear from this study that CT strongly 
stimulates renal Ca2+ reabsorption. The stimulatory effect of CT is likely to occur primarily 
through changes in Ca2+ transport in the thick ascending limb, as previously described (38-40) 
and in the DCT via an unknown mechanism (41). In conclusion, CT augments the renal 
reabsorptive capacity for Ca2+. This increase is likely to occur independently of TRPV5.
The distribution of electrolyte transport pathways and receptor signaling systems in the 
distal convolution is still being explored. It is difficult to separate experimentally the actions of 
DCT1, DCT2, and CNT cells without a detailed knowledge of the transport systems located in 
these segments and their pharmacological inhibition profile. In the rat, CT increases Ca2+ 
transport in the DCT (41), while the present study suggests that these effects occur largely 
independent of TRPV5. In rabbit, CT stimulates Ca2+ transport in the early DCT, where TRPV5 is 
not expressed (32). This raises the question of how Ca2+ transport occurs in the early DCT. 
Weak immunostaining for the Na+/Ca2+ exchanger (NCX1) and the plasma membrane Ca2+ 
pump (PMCA1b) has been observed in DCT1 segments of the mouse, suggesting that perhaps 
transepithelial Ca2+ transport also occurs in these cells (23, 34). Earlier studies in non-polarized 
immortalized mouse DCT cells, have demonstrated that CT increases chloride conductance 
resulting in membrane hyperpolarization, thereby driving Ca2+ entry through 
dihydropyridine-sensitive Ca2+ channels (42). TRPV5 mediated transport has been shown to be 
dihydropyridine-insensitive (43). L-type Ca2+ channels are particularly sensitive to 
dihydropyridine. Other voltage-dependent Ca2+ channels also exist including the T, N, and P
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Figure 4. D istribu tion  o f cAM P-dependent Ca2+ transport m echanism s in the distal 
convo lu tion  o f the mouse and rabbit. PMCAlb, plasma membrane Ca2+ ATPase 1b; NCX1, 
Na+/Ca2+ exchanger; TRPV5, transient receptor potential vanilloid 5 Ca2+ channel; PTH, parathyroid 
hormone; PTHR, parathyroid hormone receptor; CT, calcitonin; CTR, calcitonin receptor. Adapted 
from T. de Groot (37).
types which show different electrophysiological characteristics and pharmacological inhibition 
profiles (44). Voltage-dependent Ca2+ channels have previously been located to the kidney. A 
gene encoding the pore-forming alpha 1-subunit was identified in kidney and found expressed 
predominantly in the DCT (45). In addition, a pore-forming alpha (1G) subunit with T-type 
characteristics has been detected in apical membrane domains of the DCT (46). However, how 
much such a mechanism would contribute to overall Ca2+ transport in the distal convolution and 
within the kidney remains entirely unclear. Future studies are needed to further evaluate the role 
of potential Ca2+ transporting proteins in this segment. A schematic model predicting the
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segmentation of receptor systems and electrolyte transporters in the distal convolution, can be 
found in figure 4.
T issue Transglutam inase and inh ib ition  o f TRPV5-mediated Ca2+ transport
Transport in the distal convolution is tightly regulated, by a large variety of molecular factors, 
hormones, and other signaling molecules. A group of regulating factors acting from the 
extracellular side, has recently been described to modulate the function of electrolyte 
transporters within the distal convolution. Several extracellular proteases have been shown to 
modulate the transport of Na+ via ENaC expressed in the distal convolution and the remaining 
CD. In terms of Ca2+, several factors have been shown to affect channel function from the luminal 
side. Tissue Kallikrein (TK) is one of the major proteins synthesized within the distal convolution 
and secreted into the tubular fluid. TK has been shown to stimulate Ca2+ reabsorption via protein 
kinase C-dependent plasma membrane accumulation of TRPV5 (47). Similarly, Klotho is another 
protein that acts from the extracellular side, removing oligosaccharides from the complex 
N-glycan of TRPV5. This extracellular modification results in delayed retrieval of the Ca2+ 
channel from the apical plasma membrane and subsequently increased Ca2+ transport (48). The 
stimulatory effect of Klotho was entirely dependent on the N-glycosylation of TRPV5. 
Extracellular protons have also been shown to alter the plasma membrane recruitment of TRPV5 
and hence the activity of the channel. Chapter 6 describes the identification of Tissue 
Transglutaminase (tTG) as a novel molecular inhibitor of TRPV5, acting from the extracellular 
side in a N-glycosylation-dependent manner.
tTG is a multifunctional Ca2+-dependent enzyme, catalyzing the covalent crosslinking of 
proteins. tTG is an intracellular enzyme, which is also secreted by cells, suggesting that in kidney, 
the enzyme could act from the urinary side. tTG has been shown to be regulated by TRPV 
channels, in other epithelia (49, 50). In terms of TRPV5-dependent transport, it is not know
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whether this Ca2+-activated enzyme affects Ca2+ transport in the distal convolution. We found 
that tTG is secreted into the urine in mice, expressed in polarized primary CNT/CCD cells from 
rabbit, and secreted into the apical medium of these cells. In addition, tTG decreases the activity 
of TRPV5 in HEK293 cells and inhibits transcellular Ca2+ transport in polarized primary 
CNT/CCD cells. This process likely occurs via covalent crosslinking of TRPV5 monomers, 
effectively decreasing the pore size of the channel. The inhibitory effect of tTG depends on the 
N-glycosylation state of TRPV5 as the N-glycosylation-deficient mutant is not susceptible to 
tTG-catalyzed modifications.
The findings in Chapter 6 suggest a possible crosstalk between these two molecular 
factors (Klotho and tTG), both acting from the extracellular side, affecting TRPV5 transport in a 
N-glycosylation dependent manner, but via two distinct molecular mechanisms. Thus, while 
Klotho can cleave the N-glycan of TRPV5 and stimulate transport, tTG needs the N-glycan to 
exert its covalent cross-linked inhibition. Such an observation also suggests that Klotho could 
have the ability to overrule the effect of tTG, by cleaving the sugar tree of TRPV5. However, 
before such conclusions can be drawn firmly, two important experiments have to be performed. 
One that tests the effect of Klotho on tTG mediated inhibition of TRPV5 and one that tests 
whether Klotho can access the sugar tree, when tTG is present in sufficient quantity to normally 
inhibit TRPV5 transport. So although not fully delineated in detail yet, such a cross talk would be 
a novel mechanism by which several extracellular factors can interact via a common structure on 
the extracellular side of the protein. It is likely that future studies will uncover more of such factors, 
potentially secreted by the cells in the distal convolution, acting on channels and transports in 
these segments.
Autosom al dom inant hyperca lc iu ria  due to  a m issense m utation in TRPV5
Ca2+ transport in the distal convolution contributes greatly to the total amount of Ca2+ reabsorbed
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by the kidney. This is evident as absence of TRPV5 leads to an elevated amount of Ca2+ in the 
urine of mice with a targeted deletion of the TRPV5 gene. Hypercalciuria can lead to kidney 
stone disease (nephrolithiasis). Nephrolithiasis is a major health problem affecting approximately 
10% of elderly in their seventh decade of life (51). As many as 80% of kidney stones formed are 
Ca2+ based (51, 52). In addition, hypercalciuria is the most common metabolic abnormality found 
in Ca2+ stone formers. Hypercalciuria and nephrolithiasis are strongly influenced by genetic 
factors and between 35-65% of patients with hypercalciuric stone disease have affected family 
members (52). In order to investigate the possible genetic influence on hypercalciura, and hence 
the generation of nephrocalcinosis and nephrolithiasis, we utilized a W-ethyl-W-nitrosourea (ENU) 
mouse mutagenesis resource in a phenotype-driven screen, to identify new genetic models of 
hypercalciuria. Chapter 7 reports the identification of a mouse with severe autosomal dominant 
hypercalciuria. This defect was caused by a novel missense S682P mutation in the TRPV5 gene. 
The study delineates the identification and functional characterization of this gene defect. We 
found that thel expression of TRPV5 in Trpv5682P/+ and Trpv5682P/682P kidneys is altered. In the 
Trpv5682P/+ mice, expression of TRPV5 is affected only in DCT2, while TRPV5 expression is 
reduced in both the DCT2 and CNT in the Trpv5682P/682P mice. In addition, renal 
calbindin-D28K_expression in Trpv5682P/682P mouse kidneys was greatly reduced, further supporting 
a specific defect in TRPV5-mediated Ca2+ reabsorption. The alteration from serine 682 to a 
proline resulted in a reduced basal intracellular Ca2+ level in HEK293 cells transfected with the 
TRPV5 mutant, indicating a defect in the TRPV5-mediated Ca2+ permeability of the cell. In 
addition, approximately 10% of the male mice develop primary tubulointerstitial nephritis, 
consistent with urinary reflux.
TRPV5 is highly expressed in apical membrane domains of the DCT2 cell with a gradual 
decrease in TRPV5 expression is observed along the CNT and CD in the mouse, suggesting that 
the majority of TRPV5-mediated Ca2+ transport occurs in the DCT2 segment of the distal 
convolution. Chapter 7 supports this observation as selective loss of TRPV5 from the DCT2
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results in hypercalciuria in the Trpv5682P/+ mice. The reason for this type of selective loss remains 
unexplored. Potentially, this could be due to proteins regulating TRPV5, that are expressed only 
in DCT2 cells, but not in the CNT segment. Thus, this observation further underscores the axial 
heterogeneity within the distal convolution.
The hypercalciuria in these mice is inherited in an autosomal dominant fashion. This can 
be explained by the observation that the TRPV5 channel comprises four TRPV5 monomers that 
form a central pore. Thus, it is likely that the TRPV5-S682P protein is exerting a 
dominant-negative effect on the wild-type TRPV5 protein. No syndromes of hypercalciuria 
resulting in mutations of TRPV5 have previously been described. However, a recent paper found 
that SNPs in the TRPV5 gene correlates with increased Ca2+ transport via TRPV5, potentially 
explaining the lower urine Ca2+ excretion and reduced risk of kidney stones in African Americans 
compared with white Americans (53).
It should also be noted that these mice do not display nephrolithiasis, as would be 
expected in conditions of hypercalciuria. The reason for this has been delineated in mice with a 
targeted deletion of the TRPV5 gene (54). Due to the elevated loss of Ca2+ in these mice, the 
Ca2+-sensing receptor becomes activated. This leads to an increased H+ excretion acidifying the 
urine and a downregulation of the aquaporin 2 water channel causing polyuria. Disrupting these 
processes in part by deleting the collecting duct-specific B1 subunit of H+-ATPase in TRPV5 
deficient mice, eliminates urinary acidification and results in tubular precipitations of Ca2+ stones 
in the renal medulla (54). The Trpv5682P/682P mouse is the first model reported to have dominant 
hypercalciuria and a missense mutation in TRPV5. This model may therefore prove useful in 
understanding the interplay between TRPV5 in the distal convolution and other factors potentially 
involved in the underlying genetic basis of hypercalciuria and perhaps nephrolithiasis.
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Figure 5. Schem atic model o f new ly identified regu la tory pathways w ith in  the distal 
convo lu tion . NCC, thiazide-sensitive NaCI cotransporter; CLC-Kb, Cl- channel Kb; TRPM6, transient 
receptor potential melastatin 6 Mg2+ channel; EGFR, epidermal growth factor receptor. Na+, K+-ATPase 
consisting of a, p, and y subunits. ENaC, epithelial Na+ channel; ROMK, renal outer medullary K+ 
channel; TRPV5, transient receptor potential vanilloid 5 Ca2+ channel. PMCAlb, plasma membrane Ca2+ 
ATPase 1b; NCX1, Na+/Ca2+ exchanger.
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Chapter 8 
Conclusion
The overall aims of this thesis were to elucidate the molecular pathways that govern electrolyte 
transport in the distal convolution. The thesis investigated in detail the molecular regulation of 
NCC, TRPM6, and TRPV5 in an effort to understand how the transport of electrolyte by these 
carriers can be affected. The necessity of maintaining the systemic concentrations of electrolytes 
such as Na+, Cl", Ca2+, and Mg2+ within normal limits is evident, as disturbances in these ions 
affect many important physiological processes. The detailed characterization of the molecular 
mechanisms regulating these transport systems, may aid in providing sufficient knowledge to 
treat or manage diseases related to defective renal electrolyte transport within the distal 
convolution.
The findings of this thesis are summarized in figure 5. As outlined in the figure, 
Y-adducin regulates the activity of NCC, which is expressed exclusively in the DCT1 and DCT2 
segments within the kidney. Furthermore, Erlotinib can inhibit the EGF-stimulated activity of 
TRPM6, a protein co-localizing to the DCT1 and DCT2 with NCC. As calcitonin stimulates Ca2+ 
transport in the early distal segment (DCT1), but does not seem to affect TRPV5, we can 
assume that it potentially activates another carrier for Ca2+. However, the physiological relevance 
of such a transport system remains incompletely understood. In the DCT2 and CNT, androgens 
inhibit the expression of Ca2+ proteins, including TRPV5. Moreover, tTG also impose an inhibition 
of TRPV5 in these segments, by chemically crosslinking the channel monomers and changing 
pore diameter. In the Trpv5682P/+ mice, selective loss of TRPV5 from the DCT2 segment is 
observed, while in the Trpv5682P/682 homozygotes loss of TRPV5 occurs from both the DCT2 and 
CNT segments.
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Future perspectives
In recent years, many studies have elucidated new roles for the distal convolution in renal 
electrolyte transport and regulation thereof. This has contributed importantly to the 
understanding of the physiology and pathophysiology of the distal convolution. The new 
regulatory pathways found in this thesis will further help in expanding this understanding. We 
showed that y-adducin regulates the activity of the NCC cotransporter. A future goal involves 
identifying the possible involvement of the a-adducin family member, which also is expressed 
within the kidney, in addition to the many kinases involved in NCC regulation. We elucidated the 
molecular effect of Erlotinib and its potential relation to clinical hypomagnesemia. Thereby, an 
alternative treatment could be suggested in some forms of cancer where there is an often 
occurrence of hypomagnesemia due to anti-EGFR therapy. We identified new molecular and 
physiological regulators of TRPV5, including tTG, and the androgenic hormones. Furthermore, 
we found that calcitonin was unable to stimulate TRPV5 dependent Ca2+ transport. Future 
studies directed at identifying the overall contributions of these factors to Ca2+ homeostasis by 
regulating transport within the distal convolution are needed. Also, the potential regulation of 
these newly identified regulators by other calciotropic factors may help to further solidify their 
roles in renal Ca2+ handling. Finally, the S682P mutations in the TRPV5 gene confer a phenotype 
resembling that of the TRPV5 deficient animals, although in a dominant negative fashion. New 
studies should aim at elucidating the molecular mechanism by which Ca2+ permeability and 
expression of TRPV5 is impaired due to this missense mutation.
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CHAPTER 9
Samenvatting/Sammendrag

De nier zorgt voor stabilisatie van de systemische elektrolytenconcentraties binnen de 
normaalwaarden. Dit wordt bereikt door continue aanpassingen van de renale 
reabsorptiecapaciteit voor deze elektrolyten. Het distaal convoluut speelt een centrale rol in de 
reabsorptie van Na+, Cl-, Mg2+ en Ca2+ uit het renale ultrafiltraat. Als zodanig draagt het 
NaCl-transport binnen dit segment aanzienlijk bij aan de stabilisatie en regulatie van de 
bloeddruk. Reabsorptie van tweewaardige kationen door het distaal convoluut zorgt voor de 
handhaving van adequate plasmaspiegels van Mg2+ en Ca2+, ionen die essentieel zijn voor vele 
fysiologische processen zoals zenuwexcitatie, spiercontracties en botvorming. Zodoende draagt 
kennis over de moleculaire mechanismen betrokken bij de regulatie van het iontransport in het 
distaal convoluut in hoge mate bij aan het begrip van de fysiologie en pathofysiologie van deze 
bovengenoemde processen. Als zodanig kan de ontregeling van het elektrolyttransport in dit 
segment (zoals wordt geïllustreerd door monogene erfelijke aandoeningen waarbij het distaal 
convoluut aangedaan is, zoals Gitelman syndroom en pseudohypoaldosteronisme) zorgen voor 
een verlaging of zelfs gehele afwezigheid van de totale renale reabsorptiecapaciteit voor deze 
ionen. Het algemene doel van dit proefschrift was daarom om meer inzicht te krijgen in de 
regulatie van processen betrokken bij het transport van Na+, Cl-, Mg2+ en Ca2+ in het distaal 
convoluut.
Hypertensie speelt een sleutelrol in de ontwikkeling van cardiovasculaire complicaties en 
chronische nierinsufficiëntie. De thiazide-gevoelige cotransporter (NCC) is van cruciaal belang 
voor de reabsorptie van NaCl in het distaal convoluut waardoor de arteriële bloeddruk 
beïnvloedend. Meer kennis over de regulatie van NaCl-transport via NCC zal leiden tot een beter 
inzicht in de bloeddruk-handhaving en de etiologie van primaire hypertensie. Het doel van 
hoofdstuk 2 was het identificeren van nieuwe interactiepartners van NCC, die betrokken 
zouden kunnen zijn bij het moduleren van de functie van NCC. Aangezien van het 
amino-terminale domein is aangetoond dat het een belangrijke rol speelt bij de activatie van de
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transporter, werden pull-down experimenten uitgevoerd met behulp van dit domein van NCC, en 
werden lysaten van een muizennier gescreend voor mogelijke interactiepartners van de 
transporter. Met behulp van massaspectrometrie werd y-adducin geïdentificeerd als een nieuwe 
interactiepartner van NCC. Ons onderzoek laat zien dat y-adducin een sterke interactie aangaat 
met de amino-terminus van NCC. Met behulp van 22Na+-opnames in NCC-geïnjecteerde 
Xenopus laevis oöcyten in de aan- en afwezigheid van y-adducin werd aangetoond dat y-adducin 
aanzienlijk de activiteit van de transporter verhoogt. siRNA gericht tegen endogeen Xenopus 
laevis y-adducin verlaagde de NCC-afhankelijke 22Na+-opname. Competitie met grotere 
hoeveelheden van de amino-terminus van NCC remde volledig de stimulerende werking van 
y-adducin op het thiazide-gevoelige 22Na+-transport. Daarnaast werd aangetoond dat de 
bindingsplaats van y-adducin zich bevindt in de amino-terminus van NCC, waar zich drie eerder 
beschreven fosforyleringsplaatsen bevinden. In mutanten waarbij de fosforyleringsplaatsen 
constitutief inactief werden gemaakt verhoogde y-adducin het thiazide-gevoelige Na+-transport 
niet. Bovendien bond y-adducin niet aan NCC wanneer de fosforyleerbare residuen waren 
vervangen door aspartaatresiduen, wat een constitutief actieve gefosforyleerde toestand 
nabootst. Deze gegevens uit hoofdstuk 2 suggereren dat y-adducin de NCC-activiteit stimuleert 
door de verankering van een kinase, waarschijnlijk een STE20-kinase, aan de gedefosforyleerde 
transporter. Vervolgens zorgt het kinase voor een toename van de NCC-fosforylering, wat 
vervolgens resulteert in een toename in de transporter-activiteit. Na de kinase-gemedieerde 
fosforylering wordt de binding tussen y-adducin en NCC verbroken, en faciliteert y-adducin 
mogelijk ook het loslaten van het geassocieerde kinase. Defosforylering van de transporter 
verlaagt de activiteit van NCC tot het basale niveau. De gegevens in hoo fdstuk 2 geven sterke 
aanwijzingen dat y-adducin in belangrijke mate bijdraagt aan de regulatie van NCC en hierdoor 
ook aan de bloeddrukregulatie.
Het epitheliale kanaal voor tweewaardige kationen, Transient Receptor Potential 
Melastatin 6 (TRPM6), is verantwoordelijk voor de apicale influx van Mg2+ in het distaal convuluut
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en speelt zo een belangrijke rol bij de actieve Mg2+-reabsorptie in dit segment. Op deze manier 
bepaalt de regulatie van TRPM6 de uiteindelijke Mg2+-concentratie in het bloed. Het is bekend 
dat behandeling van colonkanker met Cetuximab, een monoklonaal antilichaam tegen de 
epidermale groeifactorreceptor (EGFR), hypomagnesiëmie veroorzaakt bij de behandelde 
patiënten. Echter, veel patiënten die lijden aan kanker krijgen tyrosine-kinaseremmers, zoals 
Erlotinib. Er zijn geen klinische onderzoeken gepubliceerd over het potentiële effect van 
tyrosine-kinaseremmers op de systemische en renale Mg2+-huishouding. H oofdstuk 3 toont aan 
dat TRPM6 wordt gereguleerd door Erlotinib wat leidt tot een veranderde 
Mg2+-huishouding. Muizen die gedurende 23 dagen suprafysiologische doseringen Erlotinib 
kregen ontwikkelden een daling in de serum Mg2+-concentratie. Bovendien slaagden deze 
Erlotinib-geïnjecteerde muizen er niet in de fractionele renale uitscheiding van Mg2+ te 
verminderen als reactie op de verlaagde serum Mg2+-concentratie. Om het effect van Erlotinib op 
TRPM6 verder te onderzoeken is het belangrijk om de transportactiviteit van het kanaal te meten. 
Whole-cell patch-clamp is een techniek die kan worden gebruikt om de cellulaire permeabiliteit 
voor een ion te bepalen, gegenereerd door één of meer kanalen in het 
celmembraan. Gebruikmakend van deze techniek in humane embryonale nier (HEK) 293 cellen, 
werd aangetoond dat Erlotinib aanzienlijk de activiteit remt van het EGF-gestimuleerde 
TRPM6-kanaal. De HEK293 cellen werden blootgesteld aan doseringen in dezelfde orde van 
grootte (30 |iM Erlotinib gedurende 1 uur) als de verwachte plasma-concentratie in 
muizen. Hoewel matige effecten van Erlotinib werden waargenomen in vivo, kon het medicijn wel 
EGF-gestimuleerde TRPM6-stromen en routing van TRPM6 in HEK293 cellen 
blokkeren. Gezien het feit dat de vrij circulerende concentratie van Erlotinib ongeveer 0.3 |iM is 
in patiënten, onderzochten we of ook deze concentratie in staat zou zijn om het effect van EGF 
op TRPM6-stromen te blokkeren. Hierbij konden we echter geen effect op EGF-gestimuleerde 
cellen waarnemen. Het remmende effect van Erlotinib op Mg2+-transport gaat waarschijnlijk via 
remming van TRPM6-routing, door het voorkomen van EGF-gemedieerde veranderingen in de
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Actieve Ca2+-reabsorptie in het distaal convoluut is van cruciaal belang bij het bepalen 
van de uiteindelijke Ca2+-excretie in de urine. De transportcapaciteit in dit segment wordt 
geregeld door calciotrope hormonen, zoals parathyroïd hormoon (PTH) en 
1,25-dihydroxyvitamine D3. Mannen hebben een groter Ca2+-verlies via de urine dan vrouwen. In 
overeenstemming met dit verschil is aangetoond dat oestrogenen de renale reabsorptie van Ca2+ 
verhogen. Het is niet bekend of androgenen een tegengesteld effect hebben ten opzichte van 
oestrogenen in de modulatie van renale Ca2+-reabsorptie. Daarom hebben we in hoofdstuk 4 
onderzocht of androgenen bijdragen aan het verschil tussen de geslachten in de renale 
Ca2+-homeostase. Als zodanig onderzochten we het vermogen van androgenen om de 
expressie van Ca2+-transporteurs in de nier te veranderen, in het bijzonder het Transient 
Receptor Potential Vallinoid 5 (TRPV5) Ca2+-kanaal. Het onderzoek toonde aan dat testosteron 
aanzienlijk bijdraagt aan de waargenomen geslachtsverschillen in de renale 
Ca2+-huishouding. Mannelijke muizen hadden een hogere Ca2+-excretie in de urine vergeleken 
met vrouwelijke muizen, en een verminderde expressie van Ca2+-transporteurs in de 
nier. Androgeen-deficiënte muizen waarbij de testes waren verwijderd (ORX muizen) bleken 
een significant verminderde Ca2+-uitscheiding in de urine te hebben. Deze vermindering van de 
Ca2+-excretie werd opgeheven door toediening van testosteron. Vergelijkbare gegevens werden 
verkregen bij de beoordeling van de fractionele Ca2+-excretie, hetgeen suggereert dat de 
testosteron-geïnduceerde stijging van de Ca2+-excretie in de urine het gevolg is van de remming 
van de tubulaire Ca2+-reabsorptie. De hoeveelheid mRNA en eiwit van Ca2+-transporteurs in de 
nier was toegenomen in ORX-muizen, hetgeen werd genormaliseerd wanneer de muizen 
testosteron kregen toegediend. Bovendien zorgde dihydrotestosteron-behandeling voor een 
remming van het transcellulaire Ca2+-transport in primaire celkweken van verbindingsbuizen / 
corticale verzamelbuizen uit de konijnennier.
Een ander calciotroop hormoon betrokken bij de regulatie van de Ca2+-huishouding is
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calcitonine (CT). In ratten en muizen komt TRPV5 hoog tot expressie in het apicale membraan 
van met name cellen in het tweede deel van het distaal convoluut (DCT2), met een geleidelijke 
afname in de verbindingsbuis en het eerste deel van de verzamelbuis. De exacte lokalisatie van 
TRPV5 in de humane nier is momenteel niet bekend, maar de structuur van het distaal convoluut 
is gelijk aan die van de muis. Het "lichte" gedeelte van het distaal convoluut reageert op CT in 
nieren van de rat, wat resulteert in een verhoogde productie van cAMP. Andere 
cAMP-stimulerende hormonen, waaronder PTH beïnvloeden TRPV5-gemedieerd Ca2+-transport 
door het moduleren van de expressie en de activiteit van het kanaal. Momenteel is het 
onduidelijk of er een functionele overlap is tussen PTH en CT in de DCT2 regio's van ratten en 
muizen, en of de CT-geïnduceerde toename van cAMP kan leiden tot een soortgelijke activering 
in het DCT2-segment zoals PTH.
In H oofdstuk 5 is het effect van CT bestudeerd op de totale Ca2+-balans in de nier en zijn 
de mogelijke effecten van CT onderzocht op de TRPV5-afhankelijke Ca2+-reabsorptie in het 
distaal convoluut. Injecties van muizen met CT gaven binnen 16 of 40 uur na toediening geen 
verandering in de expressie van TRPV5 in de nier. Bovendien was er geen verschil in de 
CT-respons tussen wild-type (TRPV5+/+) en TRPV5-deficiënte (TRPV5-/-) muizen. Gezien de 
gegevens die zijn verkregen in deze experimentele modellen, is het waarschijnlijk dat het effect 
van CT op het Ca2+-transport in de nier onafhankelijk is van TRPV5. Hoewel CT geen invloed 
heeft op TRPV5-gemedieerde Ca2+-reabsorptie, blijkt uit dit onderzoek dat CT de 
Ca2+-reabsorptie in de nier in hoge mate stimuleert. De stimulerende werking van CT kan 
mogelijk worden verklaard door veranderingen in het Ca2+-transport in het dikke opstijgende 
been van de lis van Henle, zoals eerder beschreven, en in het distaal convoluut via een nog 
onbekend mechanisme. Concluderend kan gesteld worden dat CT de reabsorptie-capaciteit 
vergroot voor Ca2+ in de nier.
Recent is er een groep van regulerende factoren beschreven die vanuit de 
extracellulaire zijde de functie van de elektrolyttransporteurs binnen het distaal convoluut
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moduleert. Klotho is zo'n eiwit dat werkt door het afsplitsen van oligosacchariden uit de 
complexe N-glycaan van TRPV5. Deze extracellulaire modificatie resulteert in een vertraagde 
internalisatie van het Ca2+-kanaal vanuit het apicale plasmamembraan wat vervolgens leidt tot 
een verhoogd Ca2+-transport. De stimulerende werking van klotho wordt bepaald door de 
N-glycosylering van TRPV5. Tissue transglutaminase (tTG) wordt net als klotho uitgescheiden in 
de urine en komt daardoor in direct contact met TRPV5 vanuit de pro-urine zijde. H oofdstuk 6 
beschrijft de ontdekking van tTG als een nieuwe remmer van TRPV5, handelend vanuit de 
extracellulaire zijde in een N-glycosylering-afhankelijke manier.
tTG is een multifunctioneel Ca2+-afhankelijk enzym dat de covalente binding van eiwitten 
katalyseert. tTG is een intracellulair enzym dat echter ook wordt uitgescheiden door cellen, wat 
suggereert dat in de nieren het enzym zou kunnen werken vanuit de urinezijde. In ander epitheel 
is aangetoond dat tTG wordt gereguleerd door TRPV-kanalen. Het is niet bekend of dit 
Ca2+-geactiveerde enzym Ca2+-transport in het distaal convoluut via TRPV5 beïnvloedt. Ons 
onderzoek toonde aan dat tTG wordt uitgescheiden in de urine van muizen, tot expressie komt in 
gepolariseerde cellen uit de verbindingsbuizen / corticale verzamelbuizen van het konijn, en 
werd uitgescheiden in het apicale medium van deze cellen. tTG remt het transcellulaire 
Ca2+-transport in deze cellen en vermindert de activiteit van TRPV5 in HEK293-cellen. Dit proces 
gebeurt via covalente binding van TRPV5 monomeren, waardoor de poriegrootte van het kanaal 
kleiner wordt. Het remmend effect van tTG is afhankelijk van de N-glycosylering van TRPV5 
aangezien de N-glycosylering-deficiënte mutant niet gevoelig is voor tTG-gekatalyseerde 
modificaties.
Ca2+-transport in het distaal convoluut draagt sterk bij aan de totale hoeveelheid Ca2+ die 
wordt gereabsorbeerd door de nieren. Dat blijkt uit een verhoogde hoeveelheid Ca2+ in de urine 
van muizen met een geïnactiveerd TRPV5-gen. Hypercalciurie is de bekendste risicofactor voor 
verkalking van de nieren. Voor het onderzoeken van een mogelijke genetische invloed op 
hypercalciura, en dus het ontstaan van nierverkalking en nierstenen, hebben we gebruik
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gemaakt van N-ethyl-N-nitrosourea (ENU)-mutagenese muizen in een fenotype-gerichte 
screening, om zo nieuwe genetische modellen van hypercalciurie te identificeren. H oofdstuk 7 
beschrijft de identificatie van een muis met een ernstige autosomaal dominante 
hypercalciurie. Dit defect werd veroorzaakt door een nieuwe S682P missense mutatie in het 
TRPV5-gen. De studie bevat de identificatie en functionele karakterisatie van dit gendefect. Ons 
onderzoek liet zien dat de expressie van TRPV5 in de nieren van Trpv5682P/+ en Trpv5682P/682P 
muizen is veranderd. In de Trpv5682P/+ muizen is de expressie van TRPV5 alleen aangedaan in 
het tweede gedeelte van het distaal convoluut, terwijl TRPV5-expressie in de Trpv5682P/682P 
muizen zowel in de het tweede deel van het distaal convoluut als in de verbindingsbuis is 
afgenomen. Bovendien was de calbindine-D28K-expressie in Trpv5682P/682P muizennieren sterk 
verminderd, wat een specifiek defect in TRPV5-gemedieerde Ca2+-reabsorptie bevestigt. De 
verandering van de serine 682 naar een proline resulteerde in een verlaagd basaal intracellulair 
Ca2+-niveau in HEK293 cellen getransfecteerd met de TRPV5 mutant, hetgeen wijst op een 
defect in de TRPV5-gemedieerde Ca2+-permeabiliteit van de cel. Daarnaast ontwikkelt ongeveer 
10% van de mannelijke muizen primaire tubulo-interstitiële nefritis, waarschijnlijk veroorzaakt 
door urinaire reflux.
De algemene doelstelling van dit proefschrift was het ophelderen van de moleculaire 
mechanismen die het elektrolyttransport regelen in het distaal convoluut. Daarom onderzochten 
we in detail de moleculaire regulatie van de NCC, TRPM6 en TRPV5 om te begrijpen hoe het 
transport van elektrolyten door deze transporteurs kan worden beïnvloed. De noodzaak van het 
behoud van de plasmaspiegels van elektrolyten zoals Na+, Cl", Ca2+ en Mg2+ binnen de normale 
grenzen is duidelijk, aangezien een verstoring hierin invloed heeft op tal van belangrijke 
fysiologische processen. De gedetailleerde karakterisatie van de moleculaire mechanismen die 
deze transportsystemen reguleren, kan bijdragen aan het verkrijgen van kennis voor de 
behandeling of genezing van ziekten gerelateerd aan een defect elektrolyttransport in het distaal 
convoluut van de nier.
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Sammendrag
Nyren stabiliserer de systemiske koncentrationer af elektrolytter ved at «nd re  nyrens 
reabsorptive kapacitet for disse ioner. Den distal b0jede del (anatomisk struktur som inkluderer 
den distal b0jede tubuli (DCT), samle tubulien (CNT), samt starten af samle r0ret (CD)) spiller en 
central rolle i reabsoptionen af Na+, Cl", Mg2+, and Ca2+ fra det renale ultrafiltrat. NaCl transport i 
disse segmenter kontribuerer signifikant til opretholdelsen og reguleringen af blodtrykket. 
Reabsorption af divalente kationer i den distal b0jede del er ogsa vigtig for opretholdelse af 
stabile serum koncentrationer af Mg2+ og Ca2+, der spiller en vigtig rolle i mange fysiologiske 
processer, sasom neuronal excitabilitet, muskel kontraktioner, og knogle dannelse. En bedre 
forstaelse af de molekytere signalveje som regulerer ion transporten i den distal b0jede del, kan 
ogsa h j^ lp e  til at forsta den distal b0jede dels indflydelse pa nyrens funktion i forskellige 
fysiologiske og patofysiologiske tilstande. For eksempel, fejl-regulering af elektrolyt transport i 
disse segmenter (som ses i monogene sygdomme der rammer den distal b0jede del) kan «ndre  
eller ligefrem 0detegge nyrens reabsorptive kapacitet for disse ioner. Det overordnede formal 
med denne afhandling er at 0ge forstaelsen omkring de elektrolyt transport processer som 
deltager i at flytte Na+, Cl", Mg2+, and Ca2+ over den distal b0jede del.
Arteriel hypertension er en vigtig faktor i udviklingen af hjerte-kar sygdomme og kronisk 
nyresvigt. Den thiazid-f0 lsomme cotransporter (NCC) er af afg0rende betydning for 
reabsoptionen af NaCl i den distal b0jede del. En bedre forstaelse af, hvordan NaCl transport 
reguleres via NCC kan i sidste ende 0ge vores forstaelse af, hvordan blodtryk opretholdes og 
«tiologien bag den p rim ^re  hypertension. Kapitel 2 omhandler identifikationen af nye 
bindingspartnere til NCC, som kunne v ^ re  involveret i at regulere denne transporters funktion. 
Eftersom det er blevet pavist at den N-terminale del af proteinet spiller en vigtig rolle for 
aktiveringen af transporteren, udf0rte vi pull down eksperimenter med dette dom ^ne af NCC og 
nyre lysater fra mus. Masse spektrometri identificerede y-adducin som en ny bindingspartner til 
NCC. Ved brug af 22Na+ uptake eksperimenter i Xenopus laevis oocytter injeceret med NCC,
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med ell er uden y-adducin, kunne vi vise at y-adducin stimulerede NCC transporteren. siRNA 
rettet mod den endogene Xenopus Laevis y-adducin reducerede det NCC afh^ngige Na+ optag i 
oocytterne. Konkurrence med stigende m ^ngder af den N-terminal del af NCC, fjernede helt den 
stimulerende effekt af y-adducin pa den thiazid f0lsomme 22Na+ transport. Desuden fandt vi at 
y-adducin bandt til p rec is  den region som tidligere havde v ^ re t vist at indeholde tre 
fosforylerings sekvenser i transporteren. NCC transporterer som mangler fosforylerbare 
sekvenser i deres N-terminale del 0ger ikke deres 22Na+ transport aktivitet nar de co-injiceres 
sammen med y-adducin. Ydermere, y-adducin dissociere fra NCC nar den N-terminale 
fosfosekvenser er omdannet til aspartater.
Baseret pa data det blev genereret i Kapitel 2, foreslar vi at y-adducin stimuler NCC 
aktiviteten ved binde en kinase, sandsynligvis medlemmer af STE20 familien til den 
defosforylerede transporter. Derefter kan kinasen 0ge NCCs fosforylerings niveau og saledes 
stimulere aktiviteten for transporteren. Efter det kinase medierede fosforylering event, 
dissocierer y-adducin fra NCC og kan maske ogsa fa stimulere frigivelsen af den associerende 
kinase. Defosforyleringen af transporteren reducerer NCCs aktivitet tilbage til det basale niveau. 
De observationer som bliver lavet i Kapitel 2 indikerer kraftigt at y-adducin kan bidrage 
v^sen tlig t til regulering af NCC og dermed til vedligeholdelsen af det arterielle blodtryk.
Den divalente kation kanal Transient Receptor Potential Melastatin 6 (TRPM6), er en 
vigtig komponent i den aktive Mg2+ reabsorption i den distal b0jede struktur, hvor den danner den 
apikale Mg2+ pore i DCT segmentet. Reguleringen af TRPM6 bestemmer derfor ogsa den 
endelige koncentration af Mg2+ i blodet. K r^ftbek^m pende behandlinger med Cetuximab, et 
monoklonalt antistof mod den epidermal growth factor receptor (EGFR), er arsag til 
hypomagnesemi hos mange patienter med kolorektal k r^ ft. Imidlertid er der mange 
patientgrupper der lider af k r^ f t  som modtager behandling med de sakaldte tyrosin kinase 
inhibitorer sasom f. eks. Erlotinib. Der findes ingen offentliggjort kliniske revisionsrapporter om 
de potentielle bivirkninger af tyrosin kinase inhibitorer pa den systemiske og renale Mg2+
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handtering. Kapitel 3 viser, at Erlotinib kan pavirke reguleringen af TRPM6 og derved «ndre 
Mg2+ handteringen i nyren. Vi observerede at mus, som modtog suprafysiologiske doser af 
Erlotinib i 23 dage, reducerede deres serum koncentration af Mg2+. De Erlotinib-injicerede mus 
havde en u^nd re t fraktionel renal udskillelse af Mg2+, selvom der var et fald i serum Mg2+ 
koncentrationen, hvilket indikere at nyren ikke reagerer normalt. Patch-clamp analyse kan 
anvendes til bestemmelse af den cellu lare permeabilitet af et ion, skabt af en eller flere kanaler. 
Ved brug af denne teknik i humane embryoniske nyre celler (HEK293), kunne vi vise at Erlotinib 
inhiberede den EGF stimulerede TRPM6 aktivitet. HEK293 cellerne modtog en dosis af samme 
st0rrelsesorden (30 |jM af Erlotinib) som den forventede plasma koncentration i mus. Selv om en 
moderat effekt af Erlotinib blev observeret in vivo, kunne denne dosis fu ldstendig blokere EGF 
inducerede 0gning i TRPM6 aktiviteten in vitro. Eftersom den frie plasma koncentration af 
Erlotinib sandsynligvis vil v ^ re  omkring 0,3 jM  i mennesker, testede vi om denne koncentration 
var i stand til at blokere virkning af EGF pa aktiviteten af TRPM6. Her kunne vi ikke pavise en 
betydelige forskel fra de EGF stimulerede celler. Den inhiberende virkning af Erlotinib pa Mg2+ 
transporten i den distal b0jede del sker sandsynligvis igennem inhibering af TRPM6 routing, ved 
at blokere EGF stimulerede 0gninger i den mobile fraktion af TRPM6 proteiner.
Den aktive renale Ca2+ reabsorption som foretgar i det distal b0jede del spiller en kritisk 
rolle i den totale renale Ca2+ transport. Transport kapaciteten i dette segment er reguleret af 
calciotropiske hormoner som f. eks. parathyridea hormonet og 1,25-dihydroxyvitamin D3. M ^nd 
har et st0rre Ca2+ tab i urinen end kvinder. Man har ydermere pavist at 0strogen kan 0ge den 
aktive renale Ca2+ transport, hvilket er i overensstemmelse med de kendte k0nsforskelle. Det 
forholder sig uklart om androgener kan spille en opponerende rolle til 0strogener ved at regulere 
den renale Ca2+ udskillelse. I Kapitel 4 unders0gte vi om androgener kunne bidrage til de 
k0nsforskelle som ses i den m ^ngde af Ca2+ der udskilles af nyren af m ^nd  og kvinder. Her 
unders0gte vi om androgener kunne regulere m ^ngden af de renale Ca2+ transport proteiner, 
is ^ r  Ca2+ kanalen Transient Receptor Potential Vallinoid 5 (TRPV5). Studiet viser at testosteron
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spiller en v^sen tiig  rolle i de k0nsforskelle som der ses i den renale Ca2+ udskillelse i mus. 
Hanner havde en 0get Ca2+ udskillelse i forhold til hunnerne, hvilket sammenfaldt med en 
reduceret m ^ngde af Ca2+ transport proteiner. Kastrerede hanner uden cirkulerende androgener 
(ORX) viste en signifikant reduktion in den u rin^re  udskillelse af Ca2+, hvilket blev normaliseret 
efter musene fik testosteron injiceret (ORX+T). Lignende observationer sas for den fraktionelle 
renale udskillelse af Ca2+, hvilket indikerer at den testosteron induceret 0gning i den urin^re  
Ca2+ udskillelse, skyldes h^m ning af Ca2+ transport i nyren. M ^ngden af renalt Ca2+ tranporter 
mRNA og protein var 0get i ORX mus, men normaliseret i ORX+T musene. Derudover 
observerede vi at den transcellutere Ca2+ transport var inhiberet i isolerede kanin tubuli fra CNT 
og de corticale CD (CCD) segmenter efter behandling med dihydrotestosterone.
Calcitonin (CT) er et vigtigt hormon involveret i Ca2+ metabolismen. Studier i kaniner har 
vist at CT kun 0ger Ca2+ transporten i DCT, imens hormonet ikke kan stimulere transporten af 
Ca2+ i CNT. I overensstemmelse med disse observationer er det blevet vist at CT ikke kan 
stimulere cAMP produktionen i kaniners CNT. I kaniner findes TRPV5 i de apikale membraner af 
CNT, hvor CT ikke har nogen effekt. I rotter og mus derimod er TRPV5 h0jt udtrykt i de apikale 
dom ^ner i DCT, og mindre udtrykt i CNT og CD. Den intrarenale distribution af TRPV5 i 
mennesker kendes ikke, men strukturen af deres distal b0jede del ligner den som findes i mus. 
Den lyse del af DCT er responsiv til CT i rotter, hvilket resulterer i en 0get cAMP produktion i 
dette segment nar de behandles med hormonet. Ydermere, findes der bindings steder for CT i 
rotte nyre i bade TAL og DCT. Andre cAMP 0gene hormoner sasom PTH pavirker TRPV5 
medieret transport ved at 0ge m ^ngden og aktiviteten af kanalen. Det er pa nuv^rende 
tidspunkt uklart om der er et overlap imellem PTH og CT i DCT2 regionen af rotter og mus.
Kapitel 5 unders0gte de m olekyl^re mekanismer som CT bruger til at 0ge den renale 
Ca2+ reabsoption, samt den potentielle effekt af CT pa den TRPV5 medierede Ca2+ reabsorption i 
den distal b0jede del af nefronet. Injektion af CT «ndrede ikke den renale m ^ngde af TRPV5. 
Vildtype mus (TRPV5+/+) og mus der manglede TRPV5 genet (TRPV5"/_) havde den samme
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respons til CT. Baseret pà de observationer lavet i vores studie, er det usandsynligt at den 0gede 
Ca2+ reabsoption som man ser efter CT injektion er afhængig af TRPV5. Selvom CT ikke har 
nogen effekt pà den TRPV5 medierede Ca2+ reabsorption, stàr det klart fra vores studier at CT 
kraftigt stimulerer den renale Ca2+ transport. Den stimulatoriske effekt af CT pà Ca2+ transporten 
foregàr sandynligvis via primære ændringer i det tykke ascenderende ben og i DCT via en 
ukendt mekanisme. Vi kan derfor konkludere at CT 0ger den renale reabsoptive kapacitet for 
Ca2+ uafhængigt af TRPV5.
En gruppe af regulatoriske proteiner som ud0ver deres effekt fra den ekstracellulære side 
af cellen er for nyligt blevet vist at pàvirke funktionen af elektrolyt transporter i den distal b0jede 
del. Klotho er et protein som agerer fra den ekstracellulære side af cellen, ved at fjerne 
oligosaccharider fra den komplekse N-glycan pà TRPV5. Denne ekstracellulære modifikation g0r 
at TRPV5 kanalen bliver længere pà den apikale plasma membran. Kapitel 6 beskriver 
identifikationen af vævs-transglutaminasen (tTG) som en ny molekylær hæmmer af TRPV5.
tTG er et multifunktionelt Ca2+ afhængigt enzym, der katalyserer den kovalente 
krydsbinding af proteiner. tTG er et intracellulært enzym, med det bliver ogsà udskilt af cellerne, 
hvilket kan betyde at det i nyren kan agere fra den ekstracellulære side, altsà i urinen. Det er 
tidligere blevet vist at tTG regulerere andre TRPV kanaler. I forhold til TRPV5 medieret Ca2+ 
transport sà er det uvist om det Ca2+ aktiverede enzym har nogen effekt pà Ca2+ transporten i 
den distal b0jede del. Vi kunne vise at tTG bliver udskildt i urinen, samt i primære CNT/CCD 
celler isoleret fra kaniner, hvor det bliver udskilt i det apikale medium. Derudover kunne tTG 
reducere aktiviteten af TRPV5 i HEK293 celler og inhibere den transcellulære Ca2+ transport i 
primære CNT/CCD celler. Denne proces sker sandsynligvis ved en kemisk krydsbinding af de 
individuelle TRPV5 monomere til hinanden, som resulterer i en nedsat porest0rrelse af kanalen. 
Den hæmmede effekt af tTG afhænger af N-glycosyleringen af TRPV5, eftersom den 
N-glycosylerinegs deficeint mutant ikke kan modificeres af tTG.
Ca2+ transport i den distal b0jede del spiller en væsentlig rolle i reabsorptionen af den
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totale rn^ngde af Ca2+ i nyren. Dette star klart eftersom mus som mangler TRPV5 genet har en 
0get udskillelse af Ca2+ i urinen. Hypercalciuri kan f0re til dannelsen af nyresten (nephrolithiasis). 
For at fa et bedre indblik i de genetiske faktorer som er vigtig for dannelsen af hypercalciuri og 
dermed nyresten, screenede vi mus som var udsat for det mutagene stof W-ethyl-W-nitrosourea 
(ENU) for hypercalciuri. I Kapitel 7 identificerede vi en muse stamme med autosomal dominant 
hypercaliuri, hvilket viste sig at v ^ re  pa grund af en S682P mutation i TRPV5 genet. M^ngden 
af TRPV5 i nyren hos mus der var heterozygote ( Trpv5682P/+) eller homozygote and ( Trpv5682P/682P) 
var nedsat. I Trpv5682P/+ musene, var ekspressionen af TRPV5 kun nedsat i DCT2, hvorimod 
m ^ngden af TRPV5 var nedsat i bade DCT2 og CNT i Trpv5682P/682P musene. Ydermere var den 
renale expression af calbindin-D28K nedsat i Trpv5682P/682P musene. Mutationen af serine 682 til en 
proline resulterede i et reduceret basalt niveau af intracellulär Ca2+ i HEK293 celler der var 
transfecterede med TRPV5 mutanten, hvilket indikerer en defekt i den TRPV5 afh^ngige Ca2+ 
permeabilitet af cellen.
Det overordnede formal med denne tese var at udrede de m olekyl^re signalveje som 
regulerer elektrolyt transporten i den distal b0jede del. Denne tese lavede detaljerede 
unders0gelser af den m olekyl^re regulering af NCC, TRPM6 og TRPV5. Det er n0dvendigt at 
vedligeholde de systemiske koncentrationer af Na+, Cl-, Ca2+, and Mg2+ indenfor normale rammer, 
fordi «ndringer af disse ioner pavirker mange fysiologiske processer. Den detaljerede 
karakterisation af de m olekyl^re mekanismer som regulerer disse transport systemer kan 
h j^ lp e  til en bredere forstaelse af disse processer. En sadan viden kan derfor ogsa h j^ lp e  til 
behandlingen af sygdomme der f0rer til en « n d re t transport af elektrolytter i den distal b0jede 
del.
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